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Aim: To develop protocols to digest staphylococcal enterotoxins B and C (SEB/SEC), 
toxic shock syndrome toxin 1 (TSST-1) and alpha haemolysin (AH), members of the 
pyrogenic toxin superantigen family (PTSAg). To develop a novel mass spectrometry 
method to analyse and compare urine samples from patients with rheumatoid arthritis 
(RA) and orthopaedic fracture patients for the presence of Staphylococcus aureus. 
Background: RA is a disease of unknown etiology; with a pathogenesis that is due to a 
mixture of genetic, immunological and environmental factors. A T-cell immune response 
to the presence of PTSAgs in the joints of RA patients has previously been described.  
A link has been proposed between pathogenic micro-organisms and the development of 
chronic, autoimmune conditions. Potential pathogenic mechanisms include the hygiene 
hypothesis and molecular mimicry. Due to the widespread prevalence of RA, it has been 
hypothesised that the pathogenesis could involve a common bacterium. In RA, one 
potential bacterial candidate that has been suggested is S.aureus.  
Current published data averages the presence of S.aureus in the general population at 
30% (nasal/nasopharyngeal swabs). However, our unpublished data suggests immune 
complexes containing S.aureus antigens are detectable in urine.  
xii 
Methods: Mid-stream urine samples were collected from the rheumatology and 
orthopaedic departments of the Royal Lancaster Infirmary (RLI), UK. Urine samples 
were analysed by western blot and mass spectrometry. 
Results: 56.4% of RA patients showed the presence of at least one staphylococcal toxin in 
their urine compared with 27.1% of fracture patients. 
Conclusion: Our work demonstrates an increased presence of bacterial toxins in urine 
from RA patients, compared to the fracture controls and the current literature. This study 
is the first to demonstrate the presence of common staphylococcal enterotoxins in RA 
patient urine, raising the question of what role they may have in the disease pathogenesis, 
given that these patients have no active infections.  
This raises questions of whether the bacteria and their toxins are involved in an 
individual’s likelihood of getting RA; are those people with RA more likely to have 
S.aureus infections due to their immunological state? The presence of S.aureus in RA 
patient tissues warrants further investigation to determine if it is causative of, or a result 
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Rheumatoid arthritis (RA) is a chronic and disabling multifactorial autoimmune 
disease of unknown aetiology, affecting approximately 0.5-1% of the world’s 
population, and 690,000 people in the UK alone (Arthritis Research UK, 2012). An 
effective cure has not been developed, primarily because a definite cause of the 
condition is yet to be identified. It has been hypothesised that an environmental factor 
such as pathogenic bacteria could be a trigger for autoimmune disease.  
Numerous pathogens have been researched as a possible cause of RA; however, 
Staphylococcus Aureus, a very common bacterium, seems considerably understudied. 
Furthermore, there is an evident gap in the literature in relation to the complete 
digestion of staphylococcal enterotoxins and the ability to detect very small amounts 
of such toxins in bodily fluids such as urine.   
 
1.2 Aims & Hypothesis 
 
• Hypothesis: patients with RA are more likely to have microbial toxins in their 
urine. 
o Aim 1: To develop a protocol to digest staphylococcal toxins. 
o Aim 2:  develop a protocol using mass spectrometry to detect digested 
staphylococcal enterotoxin fragments/peptides at low levels – in urine. 
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o Aim 3: To perform a case control study, analysing urine from patients 
with RA and control patients, for the presence of staphylococcal 
enterotoxins, using the methodologies developed (as stated above). 
 
1.3 The Immune System 
 
Innate immunity is the body’s initial defence against pathogenic microorganisms, such 
as bacteria and viruses. The innate immune system is generally non-specific and 
includes physical barriers, such as skin, chemicals in the blood, such as cytokines and 
chemokines, and immune cells, primarily neutrophils and macrophages (Flagarone, 
2005). The cells of the innate immune system are activated within hours of the initial 
infection. Neutrophils and macrophages release chemokines that attract more immune 
cells to the site of infection and cytokines that initiate inflammatory processes. 
Cytokines such as tumour necrosis factor alpha (TNFα) and interleukin 1 (IL-1), 
isolated from synovial joints of RA patients, are known to play roles in the 
inflammatory and destructive nature of the disease (Murphy, 2008; Lubberts, 2000; 
Flagarone, 2005). Macrophages are able to phagocytose pathogens, digesting and 
disposing of the proteins. Furthermore, plasma proteins are able to lyse 
microorganisms by way of the complement cascade. Cytokines produced in the 
cascade further contribute to the presence of inflammation. For example, macrophage 
migration inhibitory factor (MIF) is a cytokine that plays a role in fundamental events 
in both innate and adaptive immunity. There is evidence that MIF could play a role in 
RA, amongst other inflammatory diseases; therefore its antagonism may be a potential 
therapeutic option. MIF is abundant in the serum and synovium of patients with RA 
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and is known to induce the expression of pro-inflammatory genes and to be implicated 
in the proliferation and apoptosis of synoviocytes via p53 (Morand, 2005).   
As well as bridging the time gap, the innate immune system contributes to the 
development of adaptive immune responses by increasing the flow of lymph 
containing antigen to the lymphoid tissues. Here, specialised dendritic cells become 
activated antigen presenting cells (APCs) that present the particular antigen to T 
lymphocytes. T cells are able to proliferate and generate highly specific clones that 
detect only the pathogen that induced them. Adaptive immunity is specific and long 
lasting. There are two types of response, antibody response mediated by B 
lymphocytes and cell-mediated responses, governed by T lymphocytes. B cells 
produce antibodies/immunoglobulins that act by binding to antigens, inhibiting their 
binding with host cells. T cells on the other hand can act to the antigen directly by 
killing the host cell whose surface they are presented on or by signalling and 
activating macrophages to destroy the microorganisms that they have phagocytosed 
(Alberts, 2002). 
Strong evidence indicates that autoantigen recognition by specific T cells is crucial to 
the pathophysiology of synovitis in RA. T cells were found to participate in a complex 
network of cell- and mediator-driven events leading to joint destruction. Such T cells 
may be stimulated by an autoantigen - a highly conserved foreign protein cross-
reacting with its human homolog, or a neo-antigen expressed as a result of 
posttranslational events. As well as the direct effects of autoimmunity by effector T 
cells, RA could result from defective homeostatic control of immunity by regulatory T 




1.4 Rheumatoid Arthritis 
 
RA is a chronic, progressive and disabling multifactorial autoimmune disease of 
unknown aetiology. The disease causes chronic systemic inflammation, particularly of 
the joints, and is thought to be sustained by environmental and genetic factors (Bond, 
1996). RA affects approximately 690,000 people in the UK, making it the 2nd most 
common form of arthritis after osteoarthritis (OA), which affects 8.5 million Britons 
(Arthritis Research UK, 2012). The reported financial cost of RA to the UK was 
estimated to be £3.8-4.75 billion per year in 2010; this includes indirect costs and 
work-related disability benefit (NRAS, 2010).  
Common symptoms of RA include: stiffness (particularly morning stiffness), fatigue, 
depression, irritability, anaemia and flu-like symptoms. Less common effects include: 
weight loss, uveitis, rheumatoid nodules and systemic inflammation (Arthritis 
Research UK, 2012). RA does not affect fibrous and cartilaginous joints, only 
synovial joints; most commonly, joints of the hands and feet, knee, elbow, shoulder 
and pelvis are affected (Lubberts, 2000). It is often noted in the diagnosis of RA that 
symmetrical joints are often affected at the same time (NICE, 2009). As RA is a 
systemic inflammatory disease, uncontrolled disease can lead to an increased risk of 
heart attacks and strokes in some patients (NRAS, 2010).  
RA is classed as an autoimmune disease due to the presence of auto-antibodies that 
cause and sustain the chronic inflammation (Shipley, 2009; Firestein, 2003). The 2010 
ACR/EULAR Rheumatoid Arthritis Classification Criteria is the most up to date RA 
criteria, overruling the criteria of 1987 (Arnett, 1988; Aletaha, 2010). To classify a 
patient as having or not having RA the following must be obtained:, a history of 
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symptom duration, a thorough joint evaluation, and at least one serologic test 
(rheumatoid factor [RF] or anti-citrullinated peptide antibodies [ACPA]) and one 
acute-phase response measure (erythrocyte sedimentation rate [ESR] or C-reactive 
protein [CRP]) (Aletaha, 2010). 
The presence and detection of autoantibodies, in particular, RF and ACPA, allows for 
diagnosis up to six years before onset of RA symptoms (Aletaha, 2010; Rantapaa-
Dahlqvist, 2003). ACPA is tested for as anti-cyclic citrullinated peptide (anti-CCP) 
antibodies. Citrullination is a type of post-translational modification that changes the 
amino acid arginine in a protein, for the amino acid citrulline. Enzymes called 
peptidylarginine deaminases (PADs) replace the primary ketamine group (=NH) by a 
ketone group (=O) (Basu, 2011). RF is an auto-antibody directed against the Fc 
fragment of immunoglobulin (Ig). These autoantibodies are thought to arise due to a 
mistake in the response to micro-organisms, switching between Th1 (pro-
inflammatory) and Th2 (anti-inflammatory) responses (Shipley, 2009). 
The disease can progress rapidly after the initial onset of symptoms, causing painful 
swelling of synovial joints due to an excess of synovial fluid produced by inflamed 
synovium. The hyperplastic synovium migrates from the joint margins to the cartilage, 
blocking the normal route between chondrocytes and their nutrition, causing 
irreversible damage to the synovial joint. Direct effects are also exerted by the 
cytokines, such as IL-1 and TNFα, released from the inflammatory cells (Murphy, 
2008; Lubberts, 2000). The normal lining of a synovial joint is very thin and has very 
few blood vessels and no white blood cells. However, a rheumatoid joint lining 
becomes increasingly thick and dense with numerous new blood vessels and an 
infiltration of white blood cells. The inflamed synovial cells excrete chemicals, 
including enzymes, such as collagenase and stromelysin, which reduces the integrity 
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and resilience of the joint cartilage (Lubberts, 2000). Auto reactive T cells are thought 
to play a large role in the immunology of RA by reacting and binding to antigens in 
the joint synovium. This leads to prolonged inflammation, tissue damage and 
subsequent destruction of tissue (Murphy, 2008).  
RA has proved to have been a difficult disease to establish in the past as the 1987 
ACR criteria for diagnosis was not deemed sensitive enough for diagnosis of RA in its 
early disease stages (Aletaha, 2010). Moreover, a number of patients may also have 
been in remission at the time of a prevalence study and will therefore have been 
missed out in the data set. Sometimes, individuals may have been given a differential 
diagnosis like idiopathic RA or polyarthritis, particularly in the very early stages when 
it can be less clear that they are definitely suffering from RA. Currently, the 














1.5.1  Prevalence 
 
Worldwide, RA affects 0.5-1% of the population, with an incidence of around 20–50 
cases per 100,000 annually. The majority of these are women; however the incidence 
of RA seems to be declining overall (Carmona, 2010). Prevalence varies between 
populations and is, for example, high in the Pima Indian population of North America 
and Alaskan Indians, where it can be as high as 7.1% of the whole population (Power, 
1999; Acres, 2012; Bond, 1996) and much lower in black Africans and Chinese 
populations (Shipley, 2009; Gottlieb, 1974). The epidemiological studies conducted in 
Europe have produced data to give intermediate prevalence rates (Aho, 1986; Power, 
1999). The incidence of RA in developing countries is lower than in developed 
countries. For example, it has been reported that China, Indonesia and South Africa all 
show a prevalence of RA lower than the aforementioned 0.5%; whereas developed 
countries have been described as having a prevalence of around 1% (Darmawan, 
1993; Lau, 1993; Silman 1993b, Solomon, 1975). However, the incidence of RA in 
developed countries does appear to be decreasing (Doranb, 2002; Kaipiainen-
Seppanen, 1996; Hochberg, 1990; Symmons, 2002). Doran et al. conducted a 
population cohort study over four decades in Rochester, Minnesota, USA. The 
incidence of RA decreased throughout the study, almost halving over forty years from 
62.1/100,000 in the first decade (1955-1964) to 32.7/100,000 in the last (1985-1994) 
(Doranb, 2002). Furthermore, in Finland it was reported that there was a reduction of 
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approximately 40% (p=0.008) in the number of RF negative RA cases over a single 
decade (1980-1990) (Kaipiainen-Seppanen, 1996).  
 
1.5.2  Morbidity 
 
Extra-articular features of RA include rheumatoid nodules and interstitial lung 
disease, which are seen to occur at a much higher frequency in patients with RA than 
in controls; a clear correlation is shown to the activity and severity of the disease 
(Massardo, 1995; Sany, 2004). Cardiovascular disease (CVD) is considered as major 
co-morbidity, likely due to the systemic inflammatory nature of RA. Other co-
morbidities, known to be significantly raised in patients with RA include congestive 
heart failure, chronic pulmonary disease, dementia, and peptic ulcer disease (Gabriel, 
1999).  Adverse effects due to treatment have more recently been considered as a type 
of comorbidity in RA (Michaud, 2007).  
 
1.5.3  Current Treatment 
 
The first line treatments for early stage and mild RA are analgesic and anti-pyretic 
agents such as low dose corticosteroids and non-steroidal anti-inflammatory drugs 
(NSAIDs), for instance: paracetamol, ibuprofen, aspirin, naproxen and diclofenac 
(Ruderman, 2015). As the disease becomes severe, anti-inflammatory therapy is 
combined with a high dose corticosteroid plus immunosuppressive and cytotoxic 
drugs such as azathioprine, cyclophosphamide and mycophenolate (Murphy, 2008). 
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Long acting corticosteroid injections such as methylprednisolone are usually 
administered into large joints, which are defined as shoulders, elbows, hips, knees and 
ankles (Aletaha, 2010); whereas the use of hydrocortisone injections is the preferred 
option when treating superficial joints and flexor tendon sheaths. Hydrocortisone is a 
weaker preparation and reduces the chance of side effects such as subcutaneous 
inflammation and skin atrophy (Moots, 2004). 
Aside from treating the pain, doctors prescribe disease-modifying anti-rheumatic 
drugs (DMARDs); usually methotrexate is given first. However if methotrexate has 
little or no effect, sulfasalazine (and more recently so, leflunomide) can be given 
(Murphy, 2008). As with the treatment of other complex diseases, such as cancer; it is 
considered that RA is best targeted by combination therapy rather than with a single 
drug (Dale, 2007). ‘Triple therapy’ constitutes the addition of hydroxychloroquine to 
DMARDs methotrexate and sulfasalazine and has been shown to treat severe RA 
better than a single agent alone (Dougados, 2002). The vast majority of current RA 
treatments treat the symptoms of disease rather than the disease itself. The rise of 
DMARDs and new biologics has been paving the way towards more tailored 
treatment. DMARDs have been able to slow disease progression and new biologics 
such as tocilizumab, an anti-IL6 receptor monoclonal antibody, have shown to greatly 
benefit patients and could be a potentially superior treatment option (Choy, 2011). 
However, side effects include a reduction in circulating neutrophils, increased 





1.5.4  Cancer  
 
There has been no overall association found between RA and cancer. A patient with 
RA seems to have the same risk of developing cancer, as the general population; 
however there appears to be an increased incidence of haematopoietic (leukaemia and 
non-Hodgkin’s lymphoma) and lung cancers within the RA population. Predictive 
factors for an increased risk of cancer as a co-morbidity of RA is old age, a male sex, 
chronic disease duration and the use of cytotoxic drugs other than methotrexate 
(Abasolo, 2008; Khurana, 2008). The risk of malignant lymphoma is significantly 
increased in RA (standard incidence ratio (SIR) =2.0) (Askling, 2005) and relates to 
the degree of inflammation (Carmona, 2010; Ekstrom, 2003; Franklin, 2006; 
Zintzaras, 2005). Furthermore, there is also some evidence to suggest that delayed 
exposure to viruses in early life can lead to an increased chance of developing 
childhood acute lymphoblastic leukaemia (cALL) (Brown, 1961). One possible 
mechanism may be due to the fact that lymphocytes are stem cells that can acquire 
somatic mutations as a result of viraemia (Morris, 2012). This links us back to the 
possibility of RA developing as a result of pathogenic invasion. If stem cells can 
mutate as a result of viraemia to cause leukaemia, the defective T cell response 
characteristic of RA may also develop from alterations caused by bacterial or viral 






1.5.5  Mental Health 
 
Many studies have reported an increase of depression and anxiety disorders in patients 
with RA (Covic, 2009; Lok, 2010). Patients who have little social support and who 
rely on social welfare assistance are more prone to developing a psychiatric disorder. 
Conversely, the incidence of schizophrenia is reduced in RA and there is sufficient 
evidence to confirm the negative relationship between both diseases (Gorwood, 2004). 
 
1.5.6  Infection as a Result of RA 
 
The rate of infection, specifically of opportunistic infections, is increased in RA 
compared to that of the general population. For example, tuberculosis (TB) infection 
is increased fourfold (Carmona, 2003) and herpes zoster twofold (Wolfe, 2006). More 
recently it has been documented that the incidence of Pneumocystis jirovecii (formerly 
Pneumocystis carinii) infections in RA patients are on the rise, especially since the use 
of new biologics and they also show a mortality rate higher than that of human 
immunodeficiency virus (HIV)-positive individuals with this fungal pneumonia-
causing infection (Mori, 2012). These increased rates are evidently attributed to the 
amount of systemic inflammation, the immunomodulatory effect of RA and the 
immunosuppressive drugs used in its treatment; e.g. corticosteroids, methotrexate, 
infliximab. The risk of death from infection is ten times higher in individuals with RA 




1.5.7  Mortality 
 
Studies often report an increased mortality rate in RA patients compared to the general 
population. Standard Mortality Ratios (SMRs) can differ dramatically from 0.8 to 3.0; 
however, depending on the exclusion criteria, RA associated SMRs fall between the 
range of 1.5-1.8 (Meune, 2009). In a recent Dutch study, van Nies et al. compared the 
mortality rates of three RA cohorts with that of the general population of the 
Netherlands. The cohorts represented three different time periods: 1993-1995 (mainly 
NSAID use), 1996-1998 (mainly hydroxychloroquine and salazopyrin use) and 1996-
2006 (methotrexate and new biologics). The SMR for the most recent period, when 
treatment was most aggressive, was 0.49. This was significantly reduced from the two 
previous periods which were 1.35 and 1.23 respectively (van Nies, 2010; Carmona, 
2010).  Life expectancy has been calculated to be reduced by 8 years in men and 9 
years in women (Lassere, 2012). 
The risk of CVD is 60% higher in individuals with RA and is the major killer amongst 
the RA population, as it is in the general population, and accounts for 40% of deaths 
in RA patients (Meune, 2009). Other RA-associated causes of death include: cancer 
(17%), infection (14%), musculoskeletal disease (9%), respiratory disease (9%) and 
renal disease (6%) (Meune, 2009). Significant predictors of mortality are older age, 
male sex, a comorbidity and functional status (measured by the Health Assessment 
Questionnaire (HAQ)) (Meune, 2009). Disease evaluation may extend to the 
assessment of socio-economic factors, extra-articular disease and measurements of 








Over the twentieth century, a number of factors have led to a reduction in the amount 
of cross-infection in young families; such as a lower birth rate, a smaller family size, 
higher standard of personal cleanliness and improvement to household sanitation and 
amenities. The idea of a hygiene hypothesis was initially generated by David 
Strachan, who observed an inverse relationship between individuals that suffered from 
hay fever and the number of older siblings that they had. This study involved 17,414 
British children born in the same week in March 1958 (Strachan, 1989).  
The hygiene hypothesis was developed when a decrease in infectious burden in 
urbanised and industrialised countries was associated with an increase in 
autoimmunity and allergic diseases, such as RA, type 1 diabetes (T1D) and multiple 
sclerosis (MS). Criteria for a possible autoimmune disease are: an incidence and/or 
prevalence that is rising in developed countries; a disease more common in females 
than males; a disease more common in higher socio-economic groups and seasonal 
variation (Acres, 2012). According to the hygiene hypothesis, delayed exposure to 
certain pathogens means that the immune system is not able to mature properly; which 
can lead to an inappropriate immune response later in life.  
Infections, bacterial and viral, appear to produce the most severe symptoms, on first 
exposure. Following this exposure, the initial innate immune reaction converts to a 
more specific, acquired immunity. Therefore, subsequent exposure to the same virus 
or bacterium produces only a mild or asymptomatic condition (Morris, 2012). It is 
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thought that delayed exposure to a pathogen often leads to a more severe infection. 
The more severe infection can be the result of two dynamic processes: a decreasing 
exponential curve of the incidence of the primary exposure to a common bacterium 
and increasing deterioration of immune functions in an ageing human body (Morris, 
1987). Morris describes autoimmunity: a decision theory model based on concepts 
from statistical decision theory. The probability of the first exposure to a common 
organism decreases exponentially as we age. For example, 50% of the population are 
initially exposed to the organism in the first year of life, 25% are primarily exposed in 
the second year, 12.5% in the third, 6.25% in the fourth and so on. The resulting curve 
peaks early for more common organisms and later for rarer organisms (Morris, 1987; 
Morris, 2012). Not only is the timing of infection important, but also the dose and 
route of primary infection. It is thought that the preferred exposure, in order to reduce 
the chance of severe disease, is a low dose of the organism via the mucosal route, at 
an early age (Morris, 2012).  
An example of a disease being more severe after delayed exposure is that of paralytic 
poliomyelitis, seen in epidemics of the 19th century. Typically, children would suffer a 
mild infection with little or no paralysis. Yet, as social standards improved and 
technology progressed at the turn of the twentieth century, children began to 
encounter the virus for the first time after infancy. This lead to an increase in the 
incidence of paralysis related to this infection (Nathanson, 1979). Furthermore, the 
incidence of glandular fever is a relevant example, caused by Epstein Barr Virus 
(EBV). This viral infection is very common in Africa and as children contract it at an 
early age, infection is so mild that it is rarely diagnosed as glandular fever. In 
developed countries, lower socio-economic groups are, like the Africans, often 
exposed early; however for individuals in higher socio-economic groups, the initial 
15 
 
encounter is in the teenage years (Heath, 1972). An infection of EBV at this age 
usually results in severe disease, often lasting months and causing severe 
inflammation of a number of organs such as the liver and spleen. 
 
1.6.2 Molecular Mimicry 
 
There are approximately 25,000 human protein-coding genes, resulting in the coding 
of more than 250,000 proteins. The huge amount of proteins, coded for by 10-fold 
fewer genes, is possible due to alternative splicing of messenger RNA (mRNA) and 
post-translational modifications such as phosphorylation, acetylation and citrullination 
(Morris, 2012). Bacteria only have between 3000 and 5000 genes coding for a similar 
number of proteins; viral genomes are considerably smaller still. However, due to the 
huge number of bacterial and viral species, as well as gene conservation throughout 
evolution, there are many genes that share very similar sequences across species 
(Tlaskalova-Hogenova, 2011). This makes it easier for an immature immune system 
to make a mistake and recognise a foreign peptide as self. If a peptide in unable to 
appropriately fit into the groove of the major histocompatibility complex (MHC), 
recognition can be compromised due to impaired molecular presentation (Morris, 
2012). 
It is possible that similar sequences between foreign and self-peptides can be 
sufficient enough to result in the cross-activation of auto-reactive T or B cells (Getts, 
2010). For example, the QKRAA amino acid motif found in human leukocyte antigen 
subunit DRB1*0401 (HLA-DRB1*0401) occurs 37 times in the UniProt database, a 
comprehensive database of protein sequences and functional information. As well as 
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occurring naturally in the human body, the motif has also been found to occur in 
glycoprotein 110 of EBV and in E.Coli (Balandraud, 2004), meaning that a response 
to the QKRAA motif of either of these pathogens could cause the immune system to 
mistake HLA-DRV1*0401 for an invader, initiating autoimmunity. 
The concept of molecular mimicry was initially suggested by Fujinami and Oldstone 
in 1985, when describing 6 consecutive amino acids shared by encephalitogenic site 
of rabbit myelin basic protein (MBP) and Hepatitis B virus polymerase (HBVP) 
(Fujinami, 1985). T cell receptors recognise antigens, both self and foreign, and are 
understood to be degenerate. This allows T cell activation by a number of peptides 
bound to one or numerous MHC molecules. The flexibility of the T cell receptor’s 
(TCR) recognition is thought to be a key characteristic that allows the immune system 
to detect, recognize and react to the vast majority of pathogen-derived peptides. 
However, this apparent degeneracy leaves the mechanism vulnerable to the induction 
of autoimmunity driven by microbial antigens. It has been shown that viral/bacterial 
peptides with a certain degree of homology with self-antigens are able to stimulate 
auto-reactive T cells, in vitro (Wucherpfennig, 1995). Cross-reactive self-antigens are 
known to activate complement pathways that cause tissue damage due to cytotoxic 
products released during the process of inflammation (Wucherpfennig, 1995). 
For example, infection of a group A beta-haemolytic streptococci such as 
streptococcus pyogenes can induce rheumatic fever, a persistent autoimmunity 
following infection (Murphy, 2008). This is thought to occur via the mechanism of 
molecular mimicry, where infected individuals produce autoantibodies to the heart, 
brain, skin and joints (Fujinami, 2006). Monoclonal antibodies from these patients 
cross react with antigens of the bacteria such as the group A carbohydrate antigen and 
the group M protein, as well as, myosin, a superfamily of human motor proteins. It has 
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been shown in murine models of rheumatic heart disease, that cross-reactivity between 
M protein and cardiac myosin can result in autoimmune disease (Fujinami, 2006). It is 
thought that for autoimmunity to occur, the virus must cross-react with a ‘disease-
related’ epitope. This epitope can be presented by MHC class II on APCs such as 
macrophages, dendritic cells and B cells to auto-reactive CD4+ T cells. Induction of 
epitope-sufficient activation of APCs appears to be necessary, as autoimmunity only 
occurs in vivo with the addition of complete Freund’s adjuvant (CFA) or a dose of the 
infection itself (Fujinami, 2006).  
Other examples of instances of molecular mimicry include EBV as a cause for 
Guillain – Barré syndrome (Grose, 1972); and Hepatitis C virus and Herpes Simplex 
Virus (HSV) have been linked to the development of Myasthenia Gravis (Eddy, 1999; 
Schwimmbeck, 1989). Myasthenia Gravis sufferers present with characteristic 
antibodies to the human acetylcholine receptor (HuAChR). The HuAChR α-subunit 
residues 160-167 show ‘specific immunological cross-reactivity’ with a homologous 
domain present as part of HSV glycoprotein D, residues 286-293. It was concluded 
that the cross-reactivity of the ‘self-epitope’ with HSV could suggest a viral role in the 
pathogenesis of Myasthenia Gravis (Schwimmbeck, 1989). 
Mechanisms similar to, but aside from molecular mimicry, include bystander 
activation and persistent viral infection with or without epitope spreading. Such 
mechanisms are not mutually exclusive and are dynamic. It has been difficult to 
establish a causal relationship between RA and a pathogen-derived trigger of human 
autoimmunity. This is due to the problem that symptomatic onset of RA usually 
occurs after a considerable period of subclinical immune responses. After such a long 
time, the initial pathogen is likely to have been cleared by the immune system or 
immune responses will have subsided. This has also been deemed the ‘hit-and-run’ 
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hypothesis (Getts, 2010). Repeated and chronic viral infection can cause damage 
mediated by the immune system. After recovery from acute disease, the infection can 
persist. The virus, its proteins and genome, can be detected throughout life. T cell 
responses promote inflammation. A key example of this is persistent CNS infection of 
Theiler’s murine encephalomyelitis virus in susceptible mice (Fujinami, 2006). 
 
1.6.3 Bystander activation 
 
It has been shown in established murine models, for T1D and MS, that active APCs 
have the ability to activate auto-reactive T cells that are already present in the body. 
Furthermore virus-specific T cells can be activated, which are able to migrate to an 
organ containing infected cells where APCs present viral peptides on MHC class I 
which are recognised by CD8+ T cells. Following this, the CD8+ cytotoxic T cells, 
APCs and already dying infected cells release a deadly cocktail of cytokines such as 
tumour necrosis factor alpha and beta (TNF α and β), nitric oxide (NO), lymphotoxin 
(LT), interferon-gamma (IFN-γ) and interleukins (IL); which consequently kill 
neighbouring, non-infected cells. This results in further inflammation in the infected 
area (Fujinami, 2006). CD4+ T cells recognise peptides presented by MHC class II 






1.6.4  Infection as a cause of RA 
 
There is a good possibility of an infectious cause of RA; therefore its epidemiology is 
being studied alongside the hygiene hypothesis in order to establish if there is any 
association. The surge in incidence of autoimmune diseases, such as asthma, MS and 
Crohn’s disease in developed countries has been linked with the hygiene hypothesis 
(Okada, 2010). Currently, a viral or micro-organism infection is the strongest 
candidate for an environmental RA trigger. Both RF and ACPA have been found in 
individuals who do not suffer from RA after a viral, bacterial or parasitic infection 
(Rashid, 2012). This shows that when these antibodies are found in RA sufferers, they 
could perhaps have originated from an earlier infection which has left their products 
behind, allowing them to play a role in the pathogenesis of RA. Due to the worldwide 
distribution of RA, it has been suggested that it may not be just a single agent that is 
responsible (Silman, 1997). Also, due to the spatial and non -temporal clustering 
nature of the incidence of RA, there is an argument against an acute epidemic 
infection and more towards an endemic agent (Silman, 1997).  
EBV has been suspected as of one the causal agents of RA for the last 35 years, with 
good evidence. EBV-specific suppressor T cell function is known to be defective in 
RA sufferers and patients are shown to have higher serum levels of anti-EBV 
antibodies. The EBV load in peripheral blood lymphocytes of RA patients (median 
8.84 copies/50ng DNA) was found to be considerably increased from that of healthy 
individuals (median 0.6 copies/50ng DNA) (Balandraud, 2004). The virus is highly 
recognised by the immune system; however it is never eliminated and can remain 
latent for long periods of time. EBV has also been associated with the initiation and 
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development of MS and Systemic Lupus Erythromatosus (SLE) via the proposed 
mechanism of molecular mimicry (Getts, 2010). 
A suggested candidate bacterium is Porphyromonas gingivalis, a periodontal pathogen 
that when tested along with numerous other oral bacteria, showed a unique ability to 
citrullinate proteins. Results of a study by Wegner et al. suggest that the citrullination 
mediated by P.gingivalis occurs in both the bacterial proteins and host proteins, thus 
providing a potential molecular mechanism to generate epitopes to which the body has 
no immunologic tolerance (Wegner, 2010).  
Laugisch et al. investigated peptidylarginine deiminase (PAD) and P.gingivalis-
derived enzyme (PPAD) activity in the gingival crevicular fluid (GCF); looking at 
serum levels of antibodies against citrullinated epitopes in RA and periodontitis. 
Citrullination, PAD and PPAD activities were present in similar amounts within the 
RA and non-RA populations. The enzyme activities, derived from both human and 
bacteria, were raised in patients with periodontitis regardless of RA disease (Laugisch, 
2016). PPAD secreted by P. gingivalis residing in epithelial cells may be able to 
citrullinate peptides in distant regions of the periodontium or other distant tissues, 
generating ACPAs after breaching immunotolerance in susceptible individuals. 
Both the presence of foreign (bacterium) citrullinated proteins and the foreign mode of 
proteolytic processing and post-translational modification of host protein, give the 
potential as a causative mechanism from P.gingivalis. 
Another candidate bacterium is Proteus mirabilis, a regular member of commensal gut 
flora that can become pathogenic when given the opportunity to infect a wound or the 
urinary tract. Urinary tract infections (UTI) appear to be much more common in 
patients with RA (Tishler, 1992). Studies have shown that isolation of P.mirabilis in 
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the urine of RA patients can be two-fold higher than controls. Levels of P.mirabilis 
are particularly increased in females (63%) with RA compared with males (50%); and 
even more so than in healthy female (32%) and male (11%) controls (Ebringer, 1996). 
In relation to a genetic link to RA, a study using rabbits injected with HLA-DR4 
positive lymphocytes showed that they produced antibodies to P.mirabilis and none of 
the further eighteen microbes tested for (Ebringer, 1985). Furthermore, such 
antibodies were found to be in higher titres in the sera and urine of RA patients 
compared to controls (Rashid, 2007; Ebringer, 2010). Although the evidence 
regarding P.mirabilis is convincing, it is important to note that the majority of papers 
published are by the same group. 
 
1.7 Staphylococcus Aureus 
 
1.7.1 Staphylococcus Aureus 
 
The polio and EBV examples previously described (Chapter 1.5.1) give reason to 
contemplate S.aureus infection as a possible cause or contributor to the pathogenesis 
of RA in relation to the hygiene hypothesis. As mentioned earlier, S.aureus is a 
common pathogen, often initially encountered early in life. However, delayed 
exposure may lead to an inappropriate immune response to the pathogenic peptides. 
For example, the human T cells may mistake S.aureus peptides for self; as part of the 
phenomenon of molecular mimicry. 
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S.aureus is a very common bacterium, which has evolved to become both a 
component of the commensal flora and a major cause of invasive infection, like 
P.mirabilis (Chapter 1.6.5). S.aureus is not always pathogenic but is known to be a 
common cause of respiratory infections (sinusitis), skin infections (boils, atopic 
dermatitis and staphylococcal scalded skin syndrome (SSSS)) (Curran, 1980) and food 
poisoning. The bacterium can also play a role in or cause life threatening diseases 
such as endocarditis, toxic shock syndrome (TSS) and sepsis. It has been estimated 
that 25-30% of healthy, asymptomatic humans are permanent nasal carriers, with a 
further 30% carrying the bacterium intermittently (Vandenbergh, 1999).  More than 
50% of S.aureus can produce one or more of the SAgs (Kluytmans, 1997). SAgs are 
superior to regular antigens as they do not need to endure processing by APCs and are 
also able to independently induce polyclonal T cell expansion of T cells that contain 
specific Vβ chains in their TCR (Kageyama, 2001; Choi, 1990). 
Staphylococci were first described by Alexander Ogston in 1880, identified in pus 
from a knee joint. The term S.aureus was then coined by Friedrich Julius Rosenbach 
in 1884 (etymologia: staphylococcus, 2013). It took another 50 years however for the 
prevalence of S.aureus to be noted for the first time (Hallman, 1937; Hart, 1937). This 
delay was not due to a lack of recognition of healthy carriers but because the 
numerous staphylococci and micrococci could not be differentiated until the 
development of the coagulase test in 1934 (Chapman, 1934; Cruickshank, 1937).  
Severe respiratory infection due to staphylococci is on the increase. The ability of S. 
aureus to adapt to the environment of the respiratory tract has enabled its persistence 
in the airways, via adaptations such as the expression of surface adhesins (Parker, 
2012). Its metabolic versatility, the ability to scavenge iron, coordinate gene 
expression, and the horizontal acquisition of useful genetic elements have all 
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contributed to its success as a component of the respiratory flora, in both ill and 
healthy hosts (Parker, 2012). 
There are numerous strains of S. aureus, and dependent on type, they are capable of 
secreting a number of enzymes, haemolysins (alpha, beta, delta and gamma) and 
exoproteins. The exoproteins include: leucocidin, exfoliative toxins (EFA and EFB), 
staphylococcal enterotoxins (SEA-E, G-I) and TSST-1. The SEs (A-E, H), TSST-1 
and streptococcal pyrogenic exotoxins (A-C, F-H, J and streptococcal superantigen) 
are also part of a family called the pyrogenic toxin superantigens (PTSAgs) which 
share a number of functional characteristics, as well as, genetic and biochemical 
characteristics. To be included in the group, each of the toxins needs to show a 
number of biological properties, including: superantigenicity, pyrogenicity and the 
capacity to enhance the lethality of endotoxin in rabbits up to 100,000-fold (Bohach, 
1990; Bohach, 1994; Marrack, 1990). 
Mature PTSAgs, cleaved of their precursor proteins, are small, non-glycosylated 
polypeptide molecules with molecular weights between 20 – 30 kDa. They are 
moderately stable and are relatively resistant to denaturation by boiling or enzymatic 
lysis (Dinges, 2000).  An abundance of the TCR β-chain variable regions (Vβ14+) 
have been isolated from T cell populations in synovial fluid taken from the joints of 
patients with RA compared to the peripheral blood, where they are almost absent. 
Results from Paliard et al. suggest that the aetiology of RA may involve the initial 
activation of Vβ 14+ T cells by a Vβ 14-specific superantigen.  This could indicate the 
detrimental presence of PTSAgs (Paliard, 1991). PTSAgs have the ability to activate 
autoreactive T cell clones, meaning that they could induce autoimmune disease in 
humans. However, a definite mechanistic link between autoimmunity and the presence 
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of PTSAgs has not been confirmed. The aforementioned Vβ skewing of T cells is not 
typical in normal infection. 
 
1.7.2  S.aureus toxins 
 
1.7.2.1 Alpha Haemolysin (AH) 
 
AH is the dominant cytotoxic agent secreted by S.aureus bacteria (Bhakdi, 1991). The 
toxin is a water-soluble, monomeric protein and has a pore-forming beta-barrel 
structure; which binds to specific, but unidentified cell surface receptors to create 
heptameric pores that lead to DNA fragmentation and subsequent apoptosis (Tanaka, 
2011). This is due to the rapid loss of vital molecules, such as adenosine triphosphate 
(ATP), dissipation of the membrane potential and ionic gradients and osmosis-induced 
cell wall rupture (Tweten, 1983). 
 At low concentrations, AH induces pro-inflammatory mediators, promoting a breach 
of the epithelial barrier (Frank, 2012). At these low concentrations, AH binds to an as 
yet unidentified receptors that have been reported on the outer cell membranes of a 
number of cells, including human monocytes, platelets and endothelial cells, as well 
as, rabbit erythrocytes, which have been found to be particularly susceptible. Low 
concentrations of 1µg/ml (less than 100nM) can be lethal in this instance (Bhakdi, 
1991). The rabbit erythrocytes are much more susceptible to lysis by AH than other 
cells; at least 100 times more than other mammals and 1000 times more than human 
erythrocytes (Bernheimer, 1963; Bhakdi, 1984). However, at higher concentrations 
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(>1µM), AH binds non-specifically by adhering to the cell membrane and utilises its 
pore-forming ability to disrupt the ion gradients and affect the membrane integrity, 
subsequently leading to direct lysis (Foletti, 2013). 
Although pore formation and cellular lysis appear to be the main consequential 
characteristics of AH secretion, a number of studies have suggested that sub-lytic 
concentrations produce unfavourable cellular responses, particularly by altering the 
cell signalling pathways governing cell proliferation, cytokine secretions and 
inflammatory responses (Bhakdi, 1991). Furthermore, there is evidence that indicates 
that AH induces the rapid processing and secretion of interleukin1β (IL-1β) if there is 
an accumulation of the IL precursor intracellularly. Increased production of IL-1β has 
been linked to the development of a number of autoinflammatory syndromes (Masters, 
2009). 
 
1.7.2.2 Staphylococcal Enterotoxin B (SEB) 
 
SEB is an exotoxin superantigen that is able to regulate the activity of 
immunomodulatory and pro-inflammatory cell types (Li, 2015). SEB is a relatively 
stable toxin that can be resistant to proteolytic enzymes; remaining active after its 
journey through the digestive tract and even once the staphylococcal infection itself 
has been eradicated (Nema, 2007). A study by Argudín et al. indicates that SEB can 
penetrate the intestinal wall, inhibit intestinal absorption of water and electrolytes, and 
trigger a local or systemic immune response (Argudin, 2010). 
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SEB has a strong immuno-regulatory function and plays a vital role in the 
pathogenesis of autoimmune disease either by initiating the autoimmune process or by 
inducing relapse in a person in clinical remission from an autoimmune disease. SEB, 
itself, can directly activate a large number of T lymphocytes without the traditional 
antigen presenting mechanism. Compared with normal antigen-induced immune 
response in which 0.001-0.0001% of the body’s T cells are activated, SEB is capable 
of activating up to 20% of T cells, because it has a unique ability as an SAg to bridge 
the MHC class II on the APCs and the TCRs in both CD4 and CD8 T cells; forming a 
tri-molecular complex (Papageorgiou, 2000; Li, 1998). This bridging effect causes the 
release of massive amounts of cytokines and chemokines, specifically interleukin 2 
(IL-2), TNFα, interferon-γ (IFN-γ) and chemokine (C-X-C motif) ligand 1 (CXCL1) 
(Fujiki, 1999; Ito, 2000; Liu, 2004, Marrack, 1990). The mechanisms described are 























Figure 1.1  Diagram showing two ways in which SEB may be involved in the pathogenesis of RA. 
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SEB has been implicated in the pathogenesis of RA by activating T and B cells in 
combination with Vβ-TCR and activating polyclonal B cells as a bridge between T 
and B cells at the same time. Histological studies of synovium have shown that RA 
patients had increased levels of serum IgM SEB antibody compared with normal 
subjects, and synovial cells could also serve as APCs for SEB and induce further T 
cell activation (Sybre, 2012; Origuchi, 1995). 
Omata et al. studied collagen-induced arthritis (CIA), the experimental disease model 
of human RA. Their results confirmed that SEB in implicated in activating specific 
autoreactive Vβ8+ T cell clones, producing Th1 cytokines, IL-2 and IFN-γ, which are 
all important inflammatory mediators implicated in the joint destruction typical in RA. 
 
1.7.2.3 Staphylococcal Enterotoxin C (SEC) 
 
The SEC SAgs are a group of highly conserved proteins with significant 
immunological cross-reactivity. There are three antigenically distinct SEC subtypes - 
SEC1, SEC2, and SEC3 - distinguishable by their isoelectric point (pI) values: 
approximately 8.6, 7.8, and 8.2, respectively (Reiser, 1984). Amongst the SAgs, SEC 
and SEB are the most homologous and share antibody binding epitopes (Schmidt, 







1.7.2.4 Toxic Shock Syndrome Toxin 1 (TSST-1)  
 
TSST-1 is a SAg known to be produced by 5-25% of S.aureus bacteria (Kageyama, 
2001; Choi, 1990).  
As well as making APCs redundant, SAgs may have other distinctive qualities 
(Kageyama, 2001; Choi, 1990). For example, TSST-1 is unique, in that it has the 
ability to cross mucosal surfaces (Hamad, 1997). This is of particular interest as 
S.aureus often occupies mucosal areas, such as the nasal cavity and this ability means 
that TSST-1 does not need a break in the skin in order to affect the host. Furthermore, 
TSST-1 is the only PTSAg known to reactivate bacterial cell wall-induced arthritis 
(Schwab, 1993) and has been implicated in the pathogenesis of a number of human 
diseases, both acute and chronic (Kotzin, 1993). Examples include TSST-1 being 
found or isolated in 60% of cases with Kawasaki syndrome (Leung, 1993) and in the 
kidneys of 18% of cases of sudden infant death syndrome (SIDS) (Newbould, 1989). 
Higher serum levels of TSST-1 have been reported in RA patients (Tabarya, 1996), 
which was further confounded by an experiment showing an increase in incidence and 
severity of arthritis in mice, compared with control mice lacking TSST-1 (Kageyama, 
2001). However, TSST-1 is not thought to be a causal agent of RA when acting alone, 
it is thought to play a more adjuvant role. For example, bacterial cell walls, exotoxins, 
endotoxins or DNA may heighten the current status of the disease. Experiments 
conducted by Kageyama et al. suggest that products from bacteria could potentially 





1.8 Aetiology  
 
As mentioned earlier, RA is of unknown aetiology, however, a huge number of factors 
are being investigated such as: genetics, socio-economic status (SES), geographical 
location, urbanization, seasonal variation and infectious exposures during childhood. 
The latter of these gives rise to the consideration of the hygiene hypothesis (Section 
1.5). A number of autoimmune diseases have already been linked with the hygiene 
hypothesis such as asthma, T1D, MS and Crohn’s disease (Okada, 2010). It is 
hypothesised that delayed exposure to particular pathogens could increase the risk of 
developing an incorrect immune response in later life. Therefore, this review of 
current literature looks to explore what is already known about the epidemiology of 




People of any age can develop RA, however, epidemiological studies in the UK, USA 
and Norway have described the average age of onset as around 55-64 years in women 
and 65-75 years in men. Over the last half decade the general age of onset has 
increased, while the overall incidence and prevalence of RA has decreased (Symmons, 
2002). It is also important to note, that there are approximately an extra 12,000 
individuals in the UK under the age of 16, suffering from juvenile RA (Arthritis 




1.8.2  Gender 
 
Numerous studies have consistently reported that RA affects many more women, 
specifically premenopausal women, than men (Dorana, 2002; Kaipiainen-Seppanen, 
1996; Symmons, 2002; Bond, 1996; Iikuni, 2007). A study conducted by Doran et al. 
found that the incidence of RA peaked at an earlier age in women than men and even 
claimed that women were three times more likely than men to have RA (73.1% female 
to 26.9% male) (Dorana, 2002; Shipley, 2009). Although incidence and prevalence of 
RA is higher in women than men, it has been shown that RA-related mortality is 
significantly higher in men than women (p<0.001) (Kuo, 2012). It is also important to 
note here that of the general population, men have a 50% greater risk of dying of 
natural causes, at any age. This has been partly linked to the fact that men have at least 
1000 less genes than women due to only having one X chromosome (Morris, 2009). 
Furthermore, the lack of the heterozygous advantage of X leaves them more 
susceptible to, otherwise recessive, genetic disorders. It appears that men are less 
susceptible to disease overall, however women are able to live with disease and 
disability for longer. 
The gender difference has led questions as to whether hormones may play a role in the 
development of RA. A small group of seropositive (IgM-RF positive) women with 
RA were assessed for the concentration of a number of hormones. Normal hormone 
levels were observed in the premenopausal women, however the postmenopausal 
women displayed significantly increased levels of testosterone (p<0.05), 
androstenedione (p<0.05) and dehydroepiandrosterone (DHEAS) (p<0.01) (Cutolo, 
1986). Still, this observation of hypergonadism relative to osteoarthritis (OA) controls 
is not fully explained. Nevertheless, there have also been reports of a reduction in 
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plasma DHEAS in female RA patients (Spector, 1988). Similarly, serum levels of free 
testosterone and plasma androgens were found to be decreased in male RA patients 
compared to OA age matched controls. 
Alternatively, it has been suggested that the difference in incidence between the sexes 
is not down to the direct effects of the sex hormones themselves, but rather it may be 
due to the behavioural and associated differences in exposure to environmental 
pathogens (Bond, 1996).  
 
1.8.3  Birth Order 
 
Believed to be the first study into the association of birth order with the incidence of 
RA; Sayeeduddin et al. studied 115 patients attending a rheumatology clinic in 
Punjagutta, Hyderabad, India. It was reported that being the 1st-3rd child born into a 
family meant that there was an increased likelihood that the individual would develop 
RA. Of the 115 patients studied, 65-70% were the 1st-3rd born and 32.2% of the 
patients with diagnosed RA were the first born child (Sayeeduddin, 1994). 
The Hertfordshire Cohort Study (HCS), assessed each of the 1397 participants 
involved (born between 1930 and 1939) for markers of infectious exposure during 
their childhood, compared with each individual’s RF measurement. They found a 
trend towards a lower birth order (2nd-5th+) as being associated with a lower chance of 




1.8.4  Sharing a bedroom 
 
As part of the HCS, it was also investigated as to whether sharing a bedroom had any 
significant impact on RF positivity in both men and women. They documented that 
sharing a bedroom during early childhood significantly reduced the likelihood of 
being RF positive later in life (Odds Ratio (OR) 0.48, 95% Confidence Interval (CI) 
0.30 to 0.78, p=0.003). This was only the case in women, there was no significance 
amongst the male population studied (Edwards, 2006). 
 
1.8.5  Exposure to animals 
 
Bond et al. carried out a case-control, retrospective study in Adelaide, South Australia 
in order to establish if there was an association between RA and exposure to animals 
in three distinct periods of an individual’s lifetime: the first 5 years from birth, the 5 
year period before puberty and the 5 year period before RA disease onset.  Firstly, 
using questionnaires they looked into the history of each patient from birth to onset of 
rheumatic disease (n=122 RA and 114 controls). It was found that prior exposure to 
cats (OR 3.04 95% CI 1.69-5.50) and budgerigars (OR 1.74 95% CI 0.83-3.66) was 
associated with the occurrence of RA (Bond, 1996). This study follows up from an 
earlier study by Gottlieb et al. that stated that patients with RA appeared to have had 
greater exposure to dogs, cats or birds (combined), dogs alone and sick animals in the 
5-year period before disease onset compared to controls (Gottlieb, 1974).  
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Bond et al. also describe a dose-response effect of a longer extent of prior exposure 
leading to a greater risk of developing RA (OR 3.60 95% CI 2.01-6.47 p=0.0001). 
Furthermore, they investigated the three periods mentioned earlier. There was a 
statistically significant number of RA patients who had been intimately exposed to 
cats during the 5 year period before puberty (OR 3.10 95% CI 1.74-5.55). These data 
may suggest that pets can act as reservoirs for infection that could, after a latency 
period, trigger RA (Bond, 1996). Furthermore, nasal carriage of S.aureus is common 
in dogs and guinea pigs¸ giving support to the hygiene hypothesis (Section 1.2) 
(Morrison, 1961; Freeman, 1956). 
 
1.8.6  Socioeconomic status (SES) 
 
Numerous studies have described a higher prevalence of RA in more affluent and 
highly educated areas compared to poorer and lower social classes. A trend was found 
associating a higher social class with an increased chance of testing RF positive, in 
women only in Hertfordshire, UK (n=1343) (Edwards, 2006). Social class was 
determined however, by the father’s occupation at the time of the child’s birth and 
during early childhood, which may not properly determine the social class of the 
family or the lifestyle that they led. These results were not statistically significant (OR 
0.8 95% CI 0.4401.48). In Karachi, Pakistan a study was undertaken of 4232 adults, 
evenly distributed between a squatter settlement, characterised by poverty and poor 
sanitation; and an affluent district consisting of a large professional population 
(Hameed, 1995). Therefore, it was assumed that the affluent population had a better 
standard of living, better sanitation, a certain level of education and better personal 
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hygiene. The prevalence of RA was determined to be higher in the affluent area 
(1.98/1000) compared to the poorer settlement (0.9/1000). Access to healthcare 
amenities may affect these data as it is assumed that wealthier communities would be 
more willing and have easier access to a doctor in order to express any health 
complaints. 
Education is an established marker of SES (Reckner Olsson, 2001; Pedersen, 2006; 
Bengtsson, 2005; Bergstrom, 2011). Both Olsson et al. (Reckner Olsson, 2001) and 
Pedersen et al. (Pedersen, 2006) carried out studies in Denmark that described an 
association of RA, particularly RF-positive RA, to the level of education. Pederson 
even went on to report a 2-fold lower risk of developing RA in the lowest bracket of 
education compared to those in formal education for the longest duration. It is, 
however, self-criticised by both studies that a higher educational level may affect 
lifestyle and patterns of healthcare use. A Swedish case-control study of 930 cases 
(1126 controls) between 1996 and 2001 found that those with a university degree had 
an increased risk of developing RA compared to those with no degree (Bengtsson, 
2005). Furthermore, it was reported that there was a 20% increased risk of RA in 
manual and intermediate manual workers compared to non-manual (white collar) 
workers. Once again, results were more pronounced for seropositive RA and an 
increased risk linked to women. A much more recent study of 290 cases of RA 
identified in Sweden between 1974 and 1994 further supports the inverse association 
described. Bergström et al. reported that blue collar workers (manual, skilled and 
unskilled) had a significantly greater risk of developing RA compared to individuals 
classed as white collar workers (non-manual workers and professionals) (OR 1.54 




1.8.7  Smoking 
 
Cigarette smoking has been shown to be a major environmental risk factor for RA in 
numerous studies and is often associated with the lower socio-economic classes 
(Sugiyama, 2010). Smoking has been shown to have a causal link to rheumatoid 
vasculitis and extra-articular disease, particularly rheumatoid nodules and pulmonary 
disease (Wolfe, 2000; Albano, 2001). Both past and current smokers are at an 
increased risk of RA; seen in both sexes, particularly men, for whom there is a 
significant linear dose-response relationship with the number of tobacco pack years (p 
<0.005) (Reckner Olsson, 2001; Wolfe, 2000). Here, it is also important to note that as 
the worldwide use of tobacco has reduced, so have RA manifestations (Albano, 2001). 
Quantitative relationships have been established between the extent to which one 
smokes and RF positivity, RF concentration, radiographic progression, nodule 
formation and pulmonary disease; the latter three of which are independent to RF 
positivity and RF concentration (Wolfe, 2000). The increased RF measurement may 
be due to the effect of RF production being able to mediate some of the detrimental 
effects of smoking (Naz, 2007). Furthermore, Hensvold et al. studied genetic and 
environmental factors in the development of ACPAs and ACPA positive RA in twins. 
It was concluded that variability in the ACPA status between twins was mostly 
accounted for by non-shared environmental or stochastic factors rather than shared 
environmental and genetic factors. However, an association was specified 
between smoking, the shared epitope (HLA-DRB1) and the presence of ACPAs. 
Furthermore, twins with ACPA-positive RA were shown to have the shared epitope 




1.8.8  Urbanisation 
 
In the Java, Indonesia study the prevalence of RA was found to significantly differ 
between rural and urban populations (0.2% in rural areas, 0.3% in urbanized areas) .It 
was also found that there was a low prevalence of RA compared to that found in 
developed countries. This could be explained in part by the differing age structures of 
each population and the lower life expectancy of the population in Indonesia as a 
whole (Darmawan, 1993). Further studies conducted in both developed and 
developing countries have reported a higher prevalence of RA in urbanised areas 
(Solomon, 1975; Chou, 1994; Carmona, 2002). In the study of the Norfolk Arthritis 
Register (NOAR), in Norwich, UK between 1990 and 1994 Silman et al. described 
‘clustering in space’. In the northwest area of the region studied the prevalence of RA 
was higher in a market town compared to a local rural village. Migration in this area 
was deemed to be low however there were concerns over the variation of GP 
compliance (Silman, 1997).  
Solomon et al. reported that the prevalence of RA in a black South African 
community in Orlando, a large and long established township in the metropolitan area 
of Johannesburg, was significantly higher than a similar population in rural South 
Africa (p<0.01) (Solomon, 1975). A more detailed study conducted in Taiwan, carried 
out a 2-staged population survey of 8998 people living in rural, suburban, and urban 
areas of the country. The results showed that the prevalence of RA was 0.26 (rural), 
0.78 (suburban) and 0.93 (urban). The prevalence of RA in the rural area was shown 
to be significant compared to that of the suburban and urban areas (p<0.05) (Chous, 
1994). A study of an adult population of Spain reported an increased prevalence of 
RA in cities compared to rural villages. Although not statistically significant, 
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prevalence was shown to be 0.6% in urban areas and 0.2% in rural areas, with a case 
ratio of urban to rural as 4:1. It is considered that many cases of RA go undiagnosed; 
however, the results seen in the Spanish population studied is comparable to other 
Mediterranean countries (Carmona, 2002). 
 
1.8.9  Race and Culture 
 
RA, although a worldwide endemic autoimmune disease, has an uneven distribution 
of prevalence.  A hut-to-hut survey was carried out in Venda, a rural community in 
South Africa that still maintains a traditional way of living. The study received a 
response from 97% of the village population (n=543) and revealed no cases of RA. 
The study also revealed that together, the three major local hospitals had only 
encountered fourteen cases of RA in the population of 520,000 people that they serve. 
This lead to a reported prevalence of just 0.0026% (Brighton, 1988), however, this 
figure needs to be taken with caution as access to healthcare may be limited, allowing 
cases in certain groups to slip up the radar. An earlier study also found that RA was 
rarer in black South Africans compared to their Caucasian counterparts and that the 
overall prevalence of RA in South Africa was lower than that in Europe and North 
America (Solomon, 1975). Consistent with these data, is a more recent study 
comparing RA in Caucasians and people of black Caribbean descent in inner city 
Manchester, UK. The age and sex adjusted results for 1046 black Caribbean’s and 997 
Caucasians showed the prevalence of RA to be 2.9/1000 and 8/1000 respectively 




1.8.10  Seasonal Variation 
 
It is often reported by RA patients that their joints are stiffer and more painful in the 
winter. This is not thought to be related to cold or damp but to a fall in barometric 
pressure (associated with an increase in bad weather) detected by barometric nerves in 
the body that respond to pressure change. This pattern has also been found to occur in 
warmer climates when there is a decrease in barometric pressure (Moots, 2004). 
However, there is conflicting evidence as some studies have observed no association 
between barometric pressure change and RA disease activity (Iikuni, 2007). Similarly, 
no seasonal variation was described in a study by Silman et al. who looked at patients 
who presented as ‘new cases’ on the NOAR between 1990 and 1994. Over the three 
year period studied, no trend was found to associate RA with seasonal variation or 
time within this patient cohort (n=687) (Silman, 1997). 
On the contrary, a study conducted by Doran et al. reported a cyclical pattern in 
annual incidence of RA. Their research is based upon a population-based cohort study 
of the residents of Rochester, Minnesota over a 40 year period (January 1955 to 
December 1994)(n=609) (Doranb, 2002). Additionally, a large observational cohort 
study in Tokyo, Japan, assessed 1665 RA patients and asked them to fill in 
questionnaires bi-annually (Iikuni, 2007). The April/May assessment represented 
spring and the October/November assessment, autumn. Ten criteria were set, collected 
and analysed, for example: CRP, ESR, RF, the physician’s assessment of disease and 
the patient’s assessment of pain. It was reported that there was a statistically 
significant seasonal variation in disease activity (p<0.05 for 9/10 criteria). Disease 




1.8.11  Genetic Influence     
 
Familial genes have been implicated in the increased risk of developing of RA, 
however they are not considered to be causal. Even if an individual with an identical 
twin has RA, their sibling only has a 1 in 5 chance of also developing the disease. 
Disease severity can also vary between identical twins (Arthritis Research UK, 2012). 
Important genetic influences on RA disease susceptibility have been suggested by a 
four times greater monozygotic than dizygotic twin concordance rate (Silman, 1993a). 
A Finnish study conducted of more than 15,000 twins born before 1958, found that the 
age and sex adjusted ratio of observed per expected number of concordant pairs 
(relative risk) was 8.6 for monozygotic twins and 3.4 for dizygotic twins (Aho, 1986). 
Furthermore, inheritability of RA has been estimated at about 60%, based on current 
published studies (MacGregor, 2000). Genome Wide Association Studies (GWAS) 
have identified a number genes contributing to a genetic predisposition to RA 
(Perricone et al., 2011), where the strongest association was found with a gene 
polymorphism in the MHC region of the genome (Spector, 1988). Within this region, 
the strongest association for RA susceptibility is with the alleles of the HLA-DRB1 
locus, with the QK/RRAA or RRRAA motifs in the third hyper variable region 
(HVR3) (Balandraud, 2004). HLAs of the DR subtype encode the beta chain of MHC 
class II. These alleles have been found to share a common sequence of amino acids, 
encoding HLA-DR4, also known as, ‘the shared epitope’, where the polymorphism 
codes for a specific part of the peptide binding groove. Individuals presenting with the 
shared epitope have a higher risk of developing RA (Cutolo, 1986).  
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A study to determine the specificity of the HLA-DR4 shared epitope for antibodies to 
citrullinated proteins was conducted in a Dutch population cohort containing 408 RA 
patients. A statistically significant association was reported, between possessing the 
shared epitope and the risk of developing RA (OR 4.37, p<0.0001). Furthermore, a 
dose effect was described, where the possession of more than one shared epitope allele 
led to an even further increased risk of RA (OR (2 copies) 11.79, p<0.0001). There is 
evidence that anti-CCP antibodies primarily mediate association of the shared epitope 
with joint damage and disease persistence (Cutolo, 1986). Both RF and ACPA display 
a positive correlation to the increase in virus/bacteria specific antibodies and the HLA-
DR4 shared epitope (Rashid, 2012). 
The association of RA with HLA-DR1, -DR4 and -DR10 alleles in different 
populations has further encouraged the shared epitope hypothesis (Hameed, 1995; 
Fujinami, 1985). In northern European populations, HLA-DR4 subtypes, DW14 and 
DW4, show a very strong association to RA and these alleles, along with double 
alleles of the shared epitope are shown to be good severity markers for clinical RA 
(Massardo, 1995). Stastry et al. were able to show an increase in the presence of 
HLA- D subtype DW4 in RA patients (70%) compared to healthy controls (28%) 
(Spector et al., 1988). It has been shown that HLA-DRB1 alleles can be segregated 
into three groups: Susceptible – e.g. DR1 and DR4 (except DRB*0402 and *0403); 
Neutral (positive charge in P4 pocket) – DR3, DR15; Protective (negative/neutral 
charge) – D7, D8 and DRB1*0403 (Fujinami, 2006). 
In the past, autoimmune diseases linked to the hygiene hypothesis have often been 
shown to be associated with MHC polymorphisms (Wucherpfennig, 1995). This 
highlights the importance of MHC molecules when trying to establish a suitable 
response from the immune system.  
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Even though the shared epitope it seen to be increased in 90% of patients with RA, 
such a high association with genetic haplotypes cannot explain the comparatively low 
incidence of the disease. Genes appear to only play a limited part in disease 
development, exhibited by the 15% concordance rate between monozygotic twins. 
This gives an indication that an exogenous entity is playing a vital causal role that is 




The possible link between the hygiene hypothesis, late microbial /bacterial /viral 
infection in childhood and the onset of autoimmune disease in later life has been well 
documented; and over the last half a century, the theory has become widely accepted. 
A huge number of papers and studies back EBV as a good candidate for the initiation 
of autoimmune disease, and many others show substantial links with bacterial 
infections of Porphyromonas gingivalis, Proteus mirabilis and Staphylococcus 
aureus.  
Currently, there is little published literature discussing any possible link between 
S.aureus toxins and RA. Due to this apparent gap in the literature we will analyse 
patient samples of urine in order to establish if SEB, SEC, AH and TSST-1, are 
present. TSST-1, SEB and SEC are the most abundant enterotoxins (respectively)  
secreted by the bacterium  and AH is produced by all S.aureus strains (Kohler, 2012). 
Additionally, it would be interesting to create a patient questionnaire that includes 
questions linking to the epidemiological areas discussed in this chapter. The data will 
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be used to identify an association between lifestyle, the hygiene hypothesis and RA. 
Although this is not part of the initial project, it would be a wasted opportunity to have 
access to a large number of patients and to not gain some extra information to describe 




Chapter 2       MATERIALS  
 
2.1    Chemicals & Reagents 
 
Antibodies bought from Abcam 
αSEB (ab15919), αSEC (ab), αTSST-1(SLT1101), αAH (ab50536) (ab15948), goat 
anti-rabbit HRP conjugate, rabbit anti-sheep HRP conjugate. 
Chemicals bought from Fisher Scientific 
Pierce ECL western blotting substrate (10005943), Pierce ECL Plus western blotting 
substrate (11557910), Protogel acrylamide 30% (12381469), Film CL-Xposure 
180mmx240mm (10465145), Sodium dodecyl sulphate (SDS) (10090490). 
Chemicals bought from GE Healthcare 
Calibration kit low molecular weight (SDS) for electrophoresis (10606515). 
Reagents bought from Geneflow 
SDS PAGE Tris-Glycine 10x tank buffer (B9-0032). 
 





Chemicals bought from Lyreco 
Lyreco A4 plain write-on transparency film. 
Chemicals bought from Merck Millipore 
Immobilon PVDF 0.45UM 26.5 X 3.75M roll (P2938). 
Chemicals and reagents bought from Scientific Lab Supplies 
Tween 20 (CHE3852), whatman 3mm chromatography paper 580 x 680 nm 
(CHR1134), glacial acetic acid (CHE1012), coomassie brilliant blue (27815-100g-F), 
ammonium bicarbonate (09830), Eppendorf Protein LoBind tubes 1.5ml PCR clean 
(100pk) (E0030108116), Acetonitrile for HPLC gradient grade (00683-2), Water lc-
ms chromasolv (39253-1L-R). 
Chemicals and enzymes bought from Sigma Aldrich (Dorset, UK) 
Bovine Serum Albumin (A7906), N,N,N,N, - Tetramethylethylenediamine (T9281), 
GBX developer/replenisher (P7042), GBX fixer/replenisher (P7167), Ammonium 
persulfate (A3678), 1-butanol (B7906), Extravidin, peroxidase conjugate (E2886), 
Fish gelatin (G7765), Carbonate buffer (C3041), Trypsin singles kit (T7575),  trypsin 
from bovine pancreas (T8658), Pepsin from porcine gastric mucosa (P7000), Papain 
from papaya latex (P3125), α-chymotrypsin from bovine pancreas (P6423), 
trifluoroacetic acid (TFA) (T6508), endoproteinase lysine c from lysobacter 
enzymogens (P3428). 
Reagents bought from Toxin Technology (Florida, USA) 
Alpha haemolysin (AH), staphylococcal enterotoxin B (SEB), staphylococcal 
enterotoxin C1 (SEC1), toxic shock syndrome toxin 1 (TSST-1).  
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Chemicals bought from Total Lab Systems 
Glycine (G0709), Tris (B2005).  
Equipment bought from Web Scientific 
1.5mm gel spacers (SHS08-150), Alumina Plates 8.3cmx10.2cm (10 plates) (AHS-
0810-10). 
 
2.1.1    Toxins 
 
All toxins were reconstituted to 1mg/ml in distilled water and stored as 100µl aliquots 
at -20oC until use, as described in the manufacturer’s instructions. 
• Staphylococcal enterotoxin B (SEB) 
• Staphylococcal enterotoxin C (SEC) 
• Toxic Shock Syndrome Toxin-1 (TSST-1) 









2.1.2   Antibodies 
 
Antibodies were divided into 50µl aliquots to reduce freeze-thaw cycles. 
 
Antibody Conc Specificity Animal  Dilution 
Primary 
 
Anti-AH IgG antibody  











Anti-SEB IgG antibody  1mg/ml Monoclonal Rabbit 1:2000 
 
Anti-SEB IgG antibody  1mg/ml Polyclonal Sheep 1:2000 
 
Anti-SEC IgG antibody  1mg/ml Monoclonal Rabbit 1:2000 
 
Anti-SEC IgG antibody  1mg/ml Monoclonal Sheep 1:2000 
 
Anti-TSST-1 IgG antibody  1mg/ml Monoclonal Rabbit 1:2000 
  
 
   Secondary Anti-rabbit HRP conjugate 1mg/ml Polyclonal  Goat 1:4000 
 
Anti-sheep HRP conjugate 2mg/ml Polyclonal  Rabbit 1:8000 
 
2.1.3   Enzymes 
 
All enzymes were purchased from Sigma-Aldrich and prepared and stored as 
instructed by the manufacturers (Section 2.3). 
• Trypsin Profile IGD (T7575-1kt) kit and trypsin from bovine pancreas 
(T8658).  
• Pepsin from porcine gastric mucosa (P7000).  
• Papain from papaya latex (P3125).  




2.1.4   Buffers 
 
Phosphate buffered saline (PBS)  
PBS was made up as a 10x solution in the laboratory and stored at room temperature 
(8g sodium chloride, 0.2g potassium chloride, 1.44g sodium phosphate dibasic, 0.24g 
potassium phosphate monobasic, 1L distilled water, pH adjusted to 7.4 using 1M 
hydrochloric acid.). A working solution of 1x PBS was made by making a 1 in 10 
dilution with distilled water. 
PBS-Tween20 (0.1%) (PBST) 
PBST was made with 1ml Tween (Sigma Aldrich CHE3852) in 1L of 1x PBS. 
SDS-PAGE buffers 
Resolving buffer 
To make the resolving gel: 1.5M tris HCl pH8.8 (72.6g tris, 400ml dH2O).  
Stacking buffer 
To make the stacking gel: 1M tris HCl pH6.8 (24g tris, 400ml dH2O). 
Running buffer (for gel electrophoresis)  
100ml tris glycine buffer (Sigma Aldrich 93015-10L-F) and 900ml dH2O. 
Transfer buffer  





PBS-Tween (0.05%)  
500µl Tween in 1L 1x PBS. 
Carbonate buffer 
Empty 1 carbonate capsule (Sigma Aldrich C304)1 into 100ml dH2O. 
Blocking buffer 
Dissolve 2.5ml fish gelatin (Sigma Aldrich G7765) in 100ml dH2O. 
Stop solution 
40ml 10% H2SO4 and 200ml dH2O. 
 
2.1.5  Gels 
 
All recipes for both resolving and stacking gels are enough to make two 1.5mm thick 
gels. 
Stacking gel 
7.66ml dH2O, 1.26ml stacking buffer, 1ml 30% acrylamide (Thermo Scientific, 
Hemel Hempstead, UK), 100µl 10% SDS (w/v), 0.5ml 0.15% ammonium persulfate 
(Sigma Aldrich A3678) (w/v), and 10µl TEMED (Sigma Aldrich T9281). 
12.5% acrylamide resolving gel  
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6.3 ml dH2O, 5ml resolving buffer, 8.3ml 30% acrylamide, 200µl 10% (w/v) SDS, 
200µl 0.15%(w/v) ammonium persulfate and 20µl TEMED. 
17% acrylamide resolving gel 
1.48g sucrose, 5.56ml resolving buffer, 8.4ml 30% acrylamide, 148µl 10% (w/v) 
SDS, 880µl 0.15%(w/v) ammonium persulfate and 12µl TEMED. 
20% acrylamide resolving gel 
1.48g sucrose, 10ml 30% acrylamide, 148µl 10% (w/v) SDS, 880µl 0.15%(w/v) 
ammonium persulfate and 12µl TEMED. 
 
2.1.6  Reduction & Alkylation 
 
Dithiothreitol (DTT) was made up: 
• In-gel: 10mM DTT (from a 1M stock) in 100mM ammonium bicarbonate. 
• In-solution: 15mM DTT in dH2O used 1:3 to result in a 5mM DTT solution. 
Iodoacetamide (IAA) was made up (fresh each time): 
• In-gel: 55mM iodoacetamide in 100mM ammonium bicarbonate. 






2.1.7  Mass Spectrometry Sample Preparation 
 
Bovine serum albumin (BSA) bought as lyophilised powder (Sigma Aldrich) was 
made up at 2mg/ml in dH2O and stored in the freezer (-20oC). 
Ammonium bicarbonate (ABC) was made up as 100mM solution in dH2O. This was 
always made on the day of use and discarded. 
Dithiothreitol (DTT) was made up at 10mM DTT (from a 1M stock, dH2O) in 
100mM ammonium bicarbonate immediately prior to use. 
Iodoacetamide (IAA) was made up as 55mM Iodoacetamide in 100mM ammonium 
bicarbonate immediately prior to use. 
 
2.1.8  Mass Spectrometry  
 
Lyophilised samples for mass spectrometry analysis were re-suspended in 0.1% TFA 
(Sigma Aldrich). 
HPLC-MS materials 
Liquid chromatography (LC) was carried out using a Dionex Ultimate 3000. 
Subsequent electrospray ionisation mass spectrometry (ESI-MS) used a Bruker HCT 
ultra mass spectrometer. 
LC Buffers: 5% MeCN, 95% MeCN , 5% Formic acid 
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Software to control the LC-MS includes Hystar, esquireControl, Bruker daltonics and 
Chromeleon Xpress. Subsequent MS data analysis was carried out using Biotools and 
MASCOT. 
LCMS-IT-TOF materials 
MS analysis was performed using an LCMS-IT-TOF mass spectrometer (Shimadzu, 
Kyoto) coupled to a NexeraX2 HPLC system (Shimadzu, Kyoto Japan). 
Chromatographic separation was performed using a Shim Pack XR-ODS 2.2 µm (3.0 
x 50 mm) analytical column with mobile phase conditions of solution A; ultrapure 
water + 0.1% formic acid (v/v), and solution B; acetonitrile + 0.1% formic acid (v/v).  
A total flow rate of 0.5 mL/min was used during the analytical segment of the 
instrument method, with gradient LC conditions, (see Table 7.6). 
HPLC gradient grade acetonitrile (Fisher), ultrapure water (Milli-Q purification) and 











2.2  Sample Population 
 
The RA sample population was derived from rheumatology clinics at Medical Unit 2, 
Royal Lancaster Infirmary, under the supervision of consultant, Dr Marwan Bukhari. 
When choosing a control population for the case/control comparison, we needed a 
cohort of individuals without a diagnosis of RA. Patients presenting with closed 
fractures attending the fracture clinic in the orthopaedic department of the same 
hospital were chosen as good candidates. Clinical supervision was provided by Mr 
Paul Marshall and Mr Shyam Kumar.  
As both the RA and fracture patients were attending the RLI as outpatients, it could be 
assumed that their exposure to hospital pathogens was similar. Furthermore, both 
populations were in a clinical setting and the collection of urine and personal data 
could be carried out under the supervision of the appropriate consultant(s). 
 
2.2.1  Sample Size Calculation 
 
The sample size issue for unmatched case control studies having dichotomous 
exposures, dichotomous disease status and no stratification, is as follows: you need to 
determine the number of cases and controls necessary to have 100 x (1-β)% 
confidence of identifying a Relative Risk (exposure odds ratio) of R or larger at the 
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100x(1-α)% level of statistical significance, if the rate of exposure in the controls is 
equal to p0. 
It can be shown that the exposure rate, p1, among many cases would then be equal to: 
 
 
Therefore, the following equation is necessary for the cases and controls (corresponds 
to PEPI results without continuity correction factor):  
 
 
For 95% significance, two tailed, Zα = 1.96 
For 80% power, Zβ = 0.84 
There is no published data that reports the prevalence of S.aureus in urine, to 
determine the exposure to the general population. The current literature was searched 
and an average prevalence of 30% determined for individuals testing positive for 
S.aureus by nasal or nasopharyngeal swab: 
P0 = 0.3 
R = OR = 2 
The calculation resulted in a number of ~142 subjects per population for statistical 




2.2.2  Inclusion/Exclusion Criteria 
 
 
Table 2.1  Inclusion criteria 
RA Fracture 
Rheumatology clinic, 
Medical Unit 2, RLI 
Fracture clinic, 
Centenary Building, RLI 
RA diagnosis No RA diagnosis 
>30 years old 
No infection 
- Closed fracture 
Able to read and understand the patient information 
Able to give consent 
Able to give a urine sample 
 
2.2.3  Risks/Benefits 
 
Taking part in the study should not involve any risk to the health of the participants. 
There were no further risks other than those already associated with the patients’ 
scheduled appointment and subsequent assessments and/or procedures. 
There was no intended immediate clinical benefit to the participants. By taking part in 
the study individuals were helping us to gather valuable information that will allow us 




2.2.4  Questionnaire Design 
 
Based on the epidemiological studies discussed in Chapter 1, a patient questionnaire 
was designed to generate data about our study populations. These results can be 
extensively compared to each patient’s positive or negative result for S.aureus 
presence. An example of each questionnaire (RA and Fracture) can be seen in 















2.2.5  Study Design 
 
This project will be a case-control study, looking at the case population of RA patients 



















Patient information given 
prior to appointment 
Approach patients prior to appointment 
(wearing visible identification) 
Urine sample collection 
Urine sample labelled,       
aliquoted and frozen 
Toxin digestion 
Western Blot 




Written consent obtained  Exclude unsuitable patients 
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2.3  Anonymisation 
 
Study participants were assigned a unique study number – e.g. LR001 or LF001 - 
which was used to label the urine sample given, and to identify the subsequent data.  
 
2.4  Sample Collection and Storage 
 
Mid-stream urine samples were obtained and immediately stored in a refrigerated 
environment. Samples were consequently transported on ice to the university 
laboratories. There, they were aliquoted into 1.5ml eppendorfs and stored at -20oC in a 
locked freezer. 
 
2.5   Enzyme Digestion 
 
All lyophilized enzymes were reconstituted in a fume cupboard, in line with health 






2.5.1   Trypsin  
 
2.5.1.1  Trypsin Singles, proteomics grade  
 
‘Trypsin singles’- pre-prepared trypsin kit, stored at 4oC, contains the required 
reagents and instructions.  
 
In-solution digestion 
 To each 1µg vial, 1µl of Trypsin Solubilisation Reagent was added. Next, 50µl of 
protein sample was added and the vial was vortexed to mix. 49µl of prepared Trypsin 
Reaction Buffer was then added to each vial. The final NH4HCO3 buffer 
concentration was ~20mM. The sample can be incubated at 37oC for 2-18 hours to 
digest the target protein(s). 
 
In-gel digestion 
To each 1µg vial, 5µl of Trypsin Solubilisation Reagent was added and vortexed to 
ensure all of the trypsin had been dissolved. Next, 45µl of the Trypsin Reaction Buffer 
was added and vortexed; the final trypsin concentration was 20µg/ml. 25µl (0.4µg of 
trypsin) of the trypsin single is added to each Protein LoBind Eppendorf containing 
the dried gel sample. Following the rehydration of the gel sample, a further 30µl of the 
prepared Trypsin Reaction Buffer was added to each vial. The sample was incubated 
at 37oC for 18 hours/overnight to digest the target protein(s). 
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2.5.1.2  Trypsin  
 
The lyophilised trypsin (T8658) was soluble in 1 mM HCl (1 mg/ml) (pH3), yielding 
a clear solution. Before and after reconstitution in HCl, the trypsin was stored at -
20oC. For trypsin digestion of peptides, use of a ratio (w/w) of 1:100 to 1:20 for 
trypsin: peptide is desired. 
 
Solutions in 1 mM HCl (pH 3) are stable for approximately 1 year when aliquoted and 
stored at -20°C. The presence of Ca2+ (20 mM) reduced trypsin's ability to autolyse 
and therefore maintained the stability of the trypsin in solution (Sipos, 1970; Walsh, 
1970). 
 
2.5.2  Pepsin  
 
Pepsin was made up at a concentration of 1%. Ratio of substrate: pepsin was 1:100. 
Pepsin (1%) dissolved easily in 3M guanidine hydrochloride (GuHCl) (Sigma Aldrich 
G3272). 3M GuHCl was mixed at 30oC for 30 minutes. Pepsin can also be dissolved 
in distilled water, as it is soluble in water at 1% (10mg/ml). 
Pepsin, in its powdered form, is stable at room temperature; however, pepsin made up 
in solution is best stored at -20oC. 
The enzyme solution used was kept between pH 2.0-3.0, as literature has described 
this pH range as the optimum for experimental peptide digestion (Bohak, 1969). 
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Pepsin solutions are stable at pH 6-7, however, if the pH is increased to between 8 and 
11 at room temperature, the pepsin will be irreversibly inactivated (Ryle, 1970). 
 
2.5.3  Papain  
 
The papain was supplied as a buffered aqueous suspension of 2x crystallized papain 
purified from papaya latex in 0.05M sodium acetate, pH 4.5, containing 0.01% 
thymol. It was stored at 2-8oC. Immediately prior to use, the papain was diluted in 
buffer containing ~5mM L-cysteine (Sigma Aldrich W326305). A stock solution of 
10mM L-cysteine was made and used 1:1 with the papain (21mg/ml). Control toxin 
(1mg/ml) was added to the enzyme solution at a ratio of 1:100 and incubated at 25oC 
for 1-18 hours. 
 
2.5.4   Chymotrypsin  
 
Chymotrypsin is supplied as a lyophilised powder that is reconstituted in 1ml of 
distilled water and stored at 2-8oC until needed. Chymotrypsin was made up to a 
working solution immediately prior to use: 10µl stock chymotrypsin, 10µl 1mg/ml 
substrate protein, 40µl Tris HCl (0.2M) and 40µl calcium chloride (20mM). The 




2.5.5   Lysine C & Trypsin  
 
Lysine C was supplied as a lyophilised powder and stored in the fridge. When needed, 
the powder was reconstituted in 100µl dH2O and stored at -20oC. Lysine C was used 
at approximately 1:100 with the target peptide and incubated at 37oC. Following this, 
the sample(s) was further incubated with trypsin, as described in 2.5.1.1. 
 
2.6   Western Blot for Detection of Staphylococcal 
Toxins 
 
12.5% acrylamide resolving gels (1.5mm) were poured and allowed to set for thirty 
minutes at room temperature with a layer of isobutanol-saturated water on top to 
prevent air bubbles.  Once set, a stacking gel and comb were added and allowed to set 
at room temperature for a further thirty minutes.  
Samples were prepared by dilution with dissociation buffer (3.5g 1M Tris pH 6.8, 
2.5g SDS, 0.3085g DTT, 5ml glycerol, 0.05g bromophenol blue in 25ml total volume 
with dH2O) to achieve  a solution containing two thirds sample, one third dissociation 
buffer.  These samples were heated at 98O C using a dry heat block for three minutes. 
A low molecular weight standard (GE Healthcare, Buckinghamshire, UK) was diluted 
1/4 in dissociation buffer.  
20µl of the low molecular weight ladder mixture was added to the first lane then 28µl 
of each sample to the remaining lanes. The gels were electrophoresed using running 
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buffer (Tris-Glycine- SDS PAGE buffer, Geneflow, Staffordshire, UK) at 
60mA/300V for approximately one hour.  
After electrophoresis, the proteins were transferred to a PVDF membrane (Immobilion 
P, Millipore, UK) using a transfer tank containing Towbin Buffer ( 20mM Tris, 
150mM Glycine and 20% methanol) for one hour at 700mA/115V. After transfer, the 
membrane was washed with PBS for 5 minutes then blocked in 20 ml milk or BSA 
(5% (w/v) skimmed milk powder or BSA in PBST (0.1%)) for one hour at room 
temperature on a rotary agitator. After blocking, the membrane was again washed with 
PBS before incubation overnight at 4OC on a rotary agitator, in the appropriate 
antibody diluted in 2% (w/v) BSA ( Sigma-Aldrich, Dorset, UK)  in PBST (0.1%). 
Anti-SEB and anti-SEC primary antibodies were used at 1:2000; anti-TSST-1 and 
anti-AH primary antibodies were used at 1:1000. 
The following morning, each membrane was washed in PBST (0.1%) once for 1 
minute and twice for 15 minutes.  The secondary antibody was diluted at 1:4000 
(GαR) or 1:8000 (RαS) in 2% (w/v) BSA in PBST (0.1%). The membrane was 
incubated in 20ml of antibody at room temperature for 1h. Finally, each membrane 
was washed with PBS, once for 1 minute and twice for 15 minutes.   
Imaging the membrane 
To enable visualisation of the protein(s), 2ml electrochemiluminescence (ECL) 
substrate (Thermo Scientific, Hemel Hempstead, UK) was pipetted over each 
membrane, at room temperature, for 2 minutes. The membranes were sandwiched 
between two sheets of acetate and any bubbles squeezed out. Two different imaging 




Using the X-ray film: In a dark room, X-ray film was placed over the membrane for 
sufficient time to gain exposure (2 minutes for SEB and SEC, 4-5 minutes for TSST-
1). The X-ray film was developed manually using developer and fixer.  
Using the Chemidoc: membranes were exposed for up to 3 minutes in the Chemidoc. 
Protein bands were usually visible within seconds. 
Staining the membrane 
Each membrane was stained with amido black stain (250ml H2O, 200ml methanol, 
50ml acetic acid and 0.1% (w/v) amido black) for five minutes and then rinsed with 
distilled water. 
 
2.7  ELISA for Detection of Staphylococcal Toxins 
 
Blocking buffer: (2.5% (v/v) fish gelatin in phosphate buffered saline-0.05% (v/v) 
Tween 20. 
Microwell plates (Nunc-Immuno F96 Maxisorp, Thermo Scientific, Hemel 
Hempstead, UK) were coated using 100µl/well of solution containing 0.5µg/ml of 
capture antibody in coating buffer (0.1 M Na2CO3, pH 9.6). Plates were incubated 
overnight at 4oC. 
The following morning plates were washed four times using a multi-channel pipette 
with 200µl of wash buffer (Phosphate buffered saline (PBS) 0.05% (v/v) Tween20). 
Once all wells were filled, the plates were inverted sharply over a sink and tapped on 
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paper to ensure all remaining wash buffer was removed. After the washing, 200µl of 
blocking buffer (PBS-0.05% (v/v) Tween20 with 2.5% (v/v) cold water fish gelatin) 
was added and plates incubated at 37OC for one hour. Next, TSST-1 samples digested 
by pepsin were added at 100µl/ well. Standards containing known concentrations of 
the toxin to be detected were treated in the same way. Any blank wells were filled 
with blocking buffer. After a 45 minute incubation at 37OC the wash step as described 
previously was repeated.  
100µl of biotinylated anti-toxin antibody in blocking buffer was added to each well. 
For TSST, the biotinylated antibody was diluted to 0.5µg/ml. After a further 45 
minute incubation a third wash step was performed. ExtrAvidin®−Peroxidase (Sigma-
Aldrich) diluted 1:2000 in blocking buffer was added at 100µl/well and incubated at 
37OC for 30 minutes.  
After a final wash stage, 100µl/well of substrate (TMB Microwell Peroxidase, (KPL, 
Gaithersburg, MD) was added and colour allowed to develop for 10-15 minutes. The 
reaction was stopped with 100µl/well stop solution (0.3M H2SO4).  
Absorbance was read at 450nm for one second using a Wallac Victor2 Plate Reader 
(Perkin Elmer, Buckinghamshire, UK). 
 
2.8   Mass Spectrometry Sample Preparation 
 
Gels were made, as the western blot method describes: 1.5mm12.5% resolving gels 
were poured and allowed to set for thirty minutes at room temperature with a layer of 
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isobutanol-saturated water on top to prevent air bubbles.  Once set, the stacking gel 
and comb were added and allowed to set at room temperature for thirty minutes.  
Samples were prepared by dilution with dissociation buffer (3.5g 1M Tris pH 6.8, 
2.5g SDS, 0.3085g DTT, 5ml glycerol, 0.05g bromophenol blue in 25ml total volume 
with dH2O) to achieve  a solution containing two thirds sample.  These samples were 
heated at 98O C using a dry heat block for three minutes. A low molecular weight 
standard (GE Healthcare, Buckinghamshire, UK) was diluted 1/4 in dissociation 
buffer.  
30µl of low molecular weight ladder was added to the first lane then 30µl of sample to 
remaining lanes. The gels were electrophoresed using running buffer (Tris-Glycine- 
SDS PAGE buffer, Geneflow, Staffordshire, UK) at 60mA/300V for approximately 
70 minutes. 
The gels were transferred to a petri dish and incubated for 1 hour at room temperature 
with Coomassie brilliant blue (2g coomassie brilliant blue in 500ml - 50% methanol, 
40% dH2O, 10% acetic acid). Following this, they were incubated with destain (50% 
dH2O, 40% methanol, 10% glacial acetic acid) until the background of the gels 
became clear. They were left overnight in dH2O to rehydrate. 
 The bands of interest were excised using a sterile scalpel. Each band was diced into 
1mm cubes. The gel pieces were transferred into Protein LoBind microcentrifuge 
Eppendorfs and spun down in a bench-top microcentrifuge. 100mM ammonium 
bicarbonate (ABC) was made up immediately prior to use. The gel pieces were 
destained using 100µl of destain solution, comprising 100mM ABC/acetonitrile 
(ACN) (1:1, v/v) and incubate with occasional vortexing for 60 minutes. This can take 
longer, depending on staining intensity. 
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500µl ACN was added and the samples were incubated at room temperature with 
occasional vortexing, until gel pieces become white and shrink. The ACN was 
removed. The dithiothreitol (DTT) solution (1:100 in 100mM ammonium bicarbonate) 
was made up immediately prior to use. 50µl of the DTT solution was added to each of 
the dehydrated gel pieces (to completely cover) and incubated for 30 minutes at 56oC 
in an air thermostat. 
Samples were left to cool down to room temperature, all liquid was removed and 
500µl ACN was added. They were incubated at room temperature for 10 minutes, 
until dehydrated. The 55mM iodoacetamide solution was made up immediately prior 
to use. All liquid was removed and 50µl of the iodoacetamide solution was added and 
the samples were incubated for 20 minutes at room temperature, in the dark. Again, all 
liquid was removed and 500µl ACN was added to the gel pieces until white and 
shrunken.  
Trypsin digestion, using trypsin singles kit (Sigma), was carried out according to the 
manufacturer’s instructions. 5µl of trypsin solubilisation reagent (1mM) was added to 
each vial and vortexed. 45µl of trypsin reaction buffer was added and mixed (final 
trypsin concentration of 20µg/ml). 25µl (0.5µg trypsin) of the prepared mixture was 
added to each sample. All samples were incubated at 4oC for 30 minutes. Following 
hydration of the gel pieces, a further 30µl trypsin reaction buffer was added to 
completely cover the gel pieces. Samples were incubated at 37oC overnight in an air 
thermostat. 
All of the remaining liquid was removed and 110µl of extraction buffer (1:2, (v/v) 5% 
formic acid/acetonitrile) was added to each eppendorf and incubated for 15 minutes at 
37oC in a shaker. For samples with much larger (or smaller) volume of gel matrix, the 
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extraction buffer should be added such that the approximate ratio 1:2 between 
volumes of the digest and extraction is achieved. The supernatants were transferred 
into fresh Protein LoBind eppendorfs and the lid pierced 3-4 times. The samples were 
frozen in a freeze-dryer and left to dry overnight. 
Each sample was re-suspended in 20µl 0.1% trifluoroacetic acid (TFA), ensuring that 
the dry matter was completely re-suspended and mixed. The samples were incubated 
in an ultra-sonic water bath for 5 minutes. The samples were spun down in a table-top 
microcentrifuge to ensure the entire sample was at the bottom. The 20µl of each 
sample was transferred into sterilised micro-volume sample vials.  
Each sample was inserted into the automated high performance liquid chromatography 
(HPLC) machine and in the position defined in esquireControl, the system used to 
control the HPLC/MS.  
 
2.9  mMass  
 
The accession number for each toxin needs was found using the European 
Bioinformatics Institute (EBI), part of the European Molecular Biology Laboratory 
(EMBL) (http://www.ebi.ac.uk/). The accession number was input into a BLAST 
search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the UniProt database chosen. The 
BLAST search came with an abundance of results and the relevant toxin was chosen. 
The amino acid code of the toxin was then copied into mMass – an open source mass 
spectrometry tool (http://www.mmass.org/ ). From here, the digest button was clicked 
and the relevant enzyme chosen. mMass then gave an output of expected peptides; 
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their amino acid code, length and mass:charge ratio (m/z). When clicking on an 
individual peptide, a separate window opened to show what the expected peaks would 
actually look like in the MS. 
 
2.10   Mass Spectrometry 
 
2.10.1  HPLC-ESI-MS 
 
In the initial experiments, MS sample solutions were made up of 50µl acetonitrile, 
45µl 0.1% formic acid and 5µl of the digested protein sample. The sample was then 
taken up by a syringe and fitted into an automatic injector that fed the sample into the 
MS at a constant rate. 
Biotools was used to process the raw data from the MS by finding the compounds 
(AutoMS(n)), de-convoluting the subsequent mass spectra and exporting as an .mgf 
file. The .mgf produced was run through the MASCOT database to identify the 
proteomic composition of the sample. 
The defined method used as involved the following settings:  
Scan mode: standard enhanced; divert valve: to source; range: 5-3000m/z; speed: 
8100m/z/sec; polarity: positive; Trap: ICC (smart target = 200000; max accumulation 




2.10.2  LCMS-IT-TOF 
 
Following the protocol for mass spectrometry preparation (2.1.7), the freeze-dried 
samples were diluted with 20µl of mobile phase A (ultrapure water + 0.1% formic 
acid) to provide sufficient sample for accurate collection from the autosampler. An 
estimated concentration of 50ng/ml was hypothesised prior to analysis. 
MSn analysis was performed using electrospray ionisation (ESI) using an LCMS-IT-
TOF mass spectrometer (Shimadzu, Kyoto) coupled to a NexeraX2 HPLC system 
(Shimadzu, Kyoto Japan).  Mobile phase consisted of solution A; ultrapure water + 
0.1% formic acid (v/v), and solution B; acetonitrile + 0.1% formic acid (v/v).  LC 
conditions are described in Table 7.6. 
Electrospray ionisation was employed with probe voltages of 4.5 kV, curve 
desolvation line temperature 200°C, heater block temperature 200°C, nebuliser gas 
flow 1.5 L/min.  Collision energies were not optimised for each transition or 
fragmentation experiment; therefore, fragmentation efficiencies were a product of the 
instrument default settings; collision energy set at 50%, collision gas set at 50%, q 
value 45.0 kHz.  Ion accumulation times were consistent in all MS1 and MS2 scans 
set at 10 milliseconds and 200 milliseconds respectively. A full description of the 
instrument method parameters is reported in Table 7.6. 
UniProt Knowledgebase (UniProtKB, Magrane and the UniProt consortium) was 
searched for SEB, SEC1, TSST1, AH and BSA amino acid sequences.  Protein 
sequences were digested in silico using PeptideMass (ExPASy) with trypsin digestion 
enzyme, cysteines treated with iodoacetamide and up to 2 missed cleavages allowed.  
Monoisotopic peptide masses were reported, and data searched for the masses of the 
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resultant peptide sequences.  Peptides observed in analysis of standard compounds 
were checked for uniqueness using NCBI protein BLAST online tool to check if 
targets are proteotypic, peptides that are unique to the target protein (Kuster 2001). An 
online tool (FragmentIonCalculator) was used to generate fragment ions of the 
targeted peptides, generating monoisotopic masses of y/b fragment ions in the 1+, 2+ 
and 3+ charged states. 
The standard compounds of SEB, SEC1 and TSST-1 were combined in the same 
standard sample having undergone the sample preparation procedure proposed for the 
patient samples, reported in section 2.1.7.  Each toxin was added to the sample 
preparation procedure as 20 µL of 10 µg/mL; the reclaimed sample band from the 
SDS-Page gel was assumed as 100% recovery as tryptic peptide material.  Stock 
solutions containing all three toxins were diluted with mobile phase A (ultrapure water 
+ 0.1% formic acid) to achieve an external serial dilution standards used to generate 
the calibration curve.  All solutions were frozen when not in use and once defrosted 
kept at 4°C using the chilled sample compartment of the instrument autosampler until 
injection. 
Injection volume of 10µl was used throughout.  Periodic blank and standard analytical 
runs were performed every 5 analytical injections confirming no effects from 
carryover or loss of instrument sensitivity.  However, anecdotal evidence of sample 
degradation was observed from analyses performed over the entire course of method 
development; the impact of which was not investigated, but may have had an effect on 
the quantitation values or toxin detection in cases where concentration levels were 




2.11  Statistical Analysis 
 
Initially patients with RA will be compared to fracture controls using the students T 
test for continuous variables and chi squared test for categorical variables. 
A logistic model will be fitted to determine the odds of positivity in the RA group.  
In the RA group, we will investigate whether patients with higher disease activity 
(using either DAS >5.2 or DAS >2.6) had a higher prevalence of positivity.  
 
2.12  Ethical Approval 
 
This study was given a favourable opinion on 17th February 2015 by Northwest 


































Chapter 3     TOXIN DIGESTION 
 
3.1  Staphylococcal Toxins 
 
Staphylococcal enterotoxins SEB, SEC, TSST-1 and AH needed to be digested by 
enzymes in order to be analysed by mass spectrometry. Western blot and ELISA were 









Figure 3.1 shows each of the four staphylococcal toxins analysed and their molecular 
weights relative to a low molecular weight ladder. The molecular weights of the toxins 
(according to the manufacturers) are: 
Figure 3.1  Coomassie stain of ladder (kDa), 
AH, SEB, SEC and TSST-1 (125ug/ml). 1.5mm 
12.5% acrylamide gel. 
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 AH = 33kDa  
 SEB = 28kDa 
 SEC = 30kDa 
 TSST-1= 24kDa 
 









As part of the aim of the project was to develop a mass spectrometry technique of 
superior sensitivity to current detection methods, it was important to show the 
sensitivity of the current method. The western blot membranes above (Figure 3.2-3.4) 
show two-fold serial dilutions of SEB, SEC and AH. The first band in each blot is 
carbonic anhydrase, the 30kDa band of the low molecular weight ladder used. The 
concentration of each toxin band (shown in corresponding lane) is as follows: 5µg/ml 
(1), 2.5µg/ml (2), 1.25µg/ml (3), 625ng/ml (4), 312.5ng/ml (5), 156.25ng/ml (6), 
78.1ng/ml (7), 39ng/ml (8). Although faint, all bands from 5µg/ml to 39ng/ml (100ng-
78fg in 20µl load) can be seen for each of the 3 toxins. 
Figure 3.2  Western blot of SEB. 
Ladder (L) (30kDa) and two-fold serial 
dilution from 5µg/ml - 39ng/ml. 
Figure 3.3  Western blot of SEC. 
Ladder (L) (30kDa) and two-fold serial 
dilution from 5µg/ml - 39ng/ml. 
Figure 3.4  Western blot of AH. 
Ladder (L) (30kDa) and two-fold serial 
dilution from 5µg/ml - 39ng/ml. 









3.3  Sensitivity of Electrochemiluminescence (ECL) 
Substrate 
 
From the beginning of the project, the standard ECL from Fisher Scientific (Pierce 
ECL western blotting substrate 10005943) was used in order to develop the 
membranes. The sensitivity of this product has proved suitable for SEB, SEC and AH 
toxins, however, TSST-1 proved difficult to develop, even if it was left to expose for 
15 minutes or more. This was a problem when developing on film and when using the 
BioRad ChemiDoc. Therefore, a more sensitive ECL substrate. ECL 2 (Pierce ECL 
Plus western blotting substrate 11557910) from Fisher Scientific was purchased. 
For ECL1: The ratio of substrate 1 (stable peroxidase solution): substrate 2 (luminal 
solution) is recommended at 1:1, therefore, 1ml of each solution was combined to 
develop the membrane. When using film, exposures upwards of 15 minutes were 
needed to visualise TSST-1. A long exposure time and a long duration in the 
developer risks making the film dark, thus making bands harder to see. The Chemidoc 
was used to overcome the need to develop film, however a similar exposure time was 
needed and any bands were still faint.  
For ECL2: The ratio of substrate 1 (stable peroxidase solution): substrate 2 (luminal 
solution) is recommended at 40:1, therefore, 2ml of solution 1 and 50µl of solution 2 
was combined to develop the membrane. 
In order to see the bands in Figure 3.5, an exposure of over 10 minutes is needed. 















Figure 3.6, shows a repeat of the membrane in Figure 3.5, however, on this occasion 
ECL 2 has been used to develop the membrane, with just a 1 minute exposure.  
The image is much clearer and the bands are easier to see, even with the exposure 







Figure 3.7 shows the sensitivity capabilities of ECL 2 when developing blots of 
TSST-1. Concentrations of 500-125ng/ml [1-3] can be seen easily, with the possibility 
L Tw 0.5 
L 1 3 2 4 5 7 6 8 9 Figure 3.7  Serial (1:1) dilution 
of TSST-1. (1) 500, (2) 250, (3) 125, 
(4) 62.5, (5) 31.25, (6) 15.6, (7) 7.8, 
(8) 3.9, (9) 1.9ng/ml. Exposed for 240 
seconds. ECL2. 
30.0 
ECL2 3 4 5 6 Figure 3.6  Western 
blot of TSST-1 (250ng/ml), 
60 second exposure. Lanes 
contain ladder (L), 
undigested TSST-1 and 
samples incubated with 
pepsin for 0.5-6 hours. 
ECL2. 
30.0 
0.5 1 2 TSST-1 L 
ECL1 L 0.5 1 3 2 4 5 TSST-1 Figure 3.5  Western 
blot of TSST-1 (250ng/ml), 
600 second exposure. Lanes 
contain ladder (L), 
undigested TSST-1 and 
samples incubated with 





of detecting concentrations as low as 31.25ng/ml [5]. To achieve this, a longer 
exposure time would be necessary (i.e. longer than 4 minutes). 
 
3.4  Digestion of SEB 
 










The product information sheet recommended an incubation of between 2-18 hours. 
Therefore, the initial digestion experiments using trypsin included an incubation time 























Figure 3.8  Western blot 
of SEB (1µg/ml). Exposure = 5 
seconds. Lanes contain low 
molecular weight ladder, 
undigested SEB and two 
samples of SEB incubated with 
trypsin 18 hours at 37
o
C; the 
second of which has been 
reduced and alkylated (R&A). 
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The membrane shows a 30kDa band in the ladder and a 28kDa band in the lane 
containing whole SEB. There is no band at 28kDa in the lanes containing SEB 
incubated with trypsin. However, there is a band at around 22kDa, in the ‘No R&A’ 
(no reduction and alkylation) lane, meaning there is still a rather large peptide 
fragment present. Following reduction, alkylation and 18h incubation with trypsin 
(37
o
C), SEB has been completely digested.  
 
3.5   Digestion of SEC 
 









The membrane shows a 30kDa band in the ladder and a 30kDa band in the lane 























Figure 3.9  Western blot of 
SEC (1µg/ml). Exposure = 5 
seconds. Lanes contain low 
molecular weight ladder, 
undigested SEC and two samples 
of SEC incubated with trypsin 18 
hours at 37
o
C; the second of 




level of 30kDa. The membrane shows no 30kDa band in the lanes containing SEC 
incubated with trypsin. However, as with SEB, there is still a large molecular weight 
protein in the ‘No R&A’ lane, where the SEC has not been reduced or alkylated prior 
to enzymatic digestion. Such a band is not present in the ‘R&A’ lane, showing that 





3.6   Digestion of TSST-1 
 







As shown in Figure 3.10, there is still a strong band present at 24kDa in the ‘No 
R&A’ lane containing TSST-1 incubated with trypsin. However, following reduction, 
alkylation and 18h incubation (37
o
C), TSST-1 is sufficiently digested. Complete 























Figure 3.10  Western blot of 
TSST (1µg/ml). Exposure = 10 
seconds. Lanes contain low 
molecular weight ladder, 
undigested TSST-1 and two 
samples of TSST-1 incubated with 
trypsin 18 hours at 37
o
C;  the 
second of which has been reduced 
and alkylated (R&A). 
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‘R&A’ lane. Although not completely digested, sufficient unique peptide fragments 
have been generated for MS analysis. 
 




TSST-1 was also digested by pepsin. Figure 3.11 shows a western blot membrane of  
TSST-1 incubated with pepsin. Bands of TSST-1 are seen at 24kDa after 0.5 and 1 
hour of incubation. Bands are no longer visible after 2 hours of incubation with 
pepsin. From this, it can be concluded that TSST-1 is completely digested after 2 









L TSST-1 0.5 1 3 2 4 5 6 
Figure 3.11  Western blot of TSST-1 (250ng/ml) incubated with pepsin 
for 0.5-6 hours at 37
o
C. Exposure = 180 seconds. Lanes contain ladder (L), 
whole TSST-1 and samples incubated with pepsin for ‘n’ hours. 
[a] 
[b] 
Figure 3.12  ELISA of TSST-1 incubated with pepsin. Wells contain blanks (B), incubation 
intervals (columns 1-5) and repeats (A-C), and undigested TSST-1 of concentrations 100, 10, 1, 
0.1ng/ml (columns 9-12 respectively) and repeats (A-C). [a] the sample is in each well. [b] the 









Figure 3.13  Western blot of AH 
(5µg/ml) incubated with trypsin for 
0.5-5 hours at 37
o
C. Exposure = 20 
seconds. Lanes contain ladder (L), 
undigested AH and AH incubated 
with trypsin (0.5-5 hours). 
The ELISA (Figure 3.12) has a sensitivity of 0.2 A
450nm
, therefore it is assumed that 
anything below that threshold of detection is negative. The ELISA confirms the 
results of the western blot – TSST-1 has been digested by pepsin. 
 
3.7   Digestion of AH 
 






In Figure 3.13, bands of AH are consistently present at ~36kDa, even after 5 hours of 










AH was incubated with pepsin. Bands of AH are present throughout at ~36kDa, after 
incubation with pepsin. Although the bands in lanes containing samples incubated for 
0.5-2 hours are considerably stronger, there are also faint bands in the lanes of the 3-5 
hour samples. Pepsin does not appear to completely digest AH.  
Therefore, the search for an enzyme to digest AH continues. The enzymes 
chymotrypsin and papain were chosen to be tested next as they are both enzymes 
found naturally in the human body.  
 
3.7.3   Chymotrypsin Digestion of AH 
 
AH was incubated with chymotrypsin for up to 24 hours (Figure 3.15). Bands of AH 
are present consistently at 36kDa, even after 24 hours of incubation with 
chymotrypsin. The bands are faint in this instance but it is clear to see that the AH 
toxin has not been digested. It can be concluded that chymotrypsin does not digest AH 
either. 




Figure 3.14  Western blot of AH 
(250ng/ml) incubated with pepsin for 
0.5-5 hours at 37
o
C. Exposure = 20 
seconds. Lanes contain ladder (L), 
undigested AH (Aw) and samples 














After discovering that trypsin, pepsin and chymotrypsin do not digest AH, papain was 
the next proteolytic enzyme chosen. As shown in Figure 3.16, bands of AH are 
present at ~36kDa, up until ~5 hours of incubation with papain. The bands are very 
faint on this membrane but it can be seen that the AH toxin has not been digested in 
lanes containing AH incubated for 1-4 hours. It can be concluded that papain does 
digest completely digest AH after 6 hours. 




Figure 3.16  Western 
blot of AH (250ng/ml) 
incubated with papain for 1-
18 hours at 30
o
C. Exposure 
= 30 seconds. Lanes contain 
ladder (L), undigested AH 
and samples incubated with 
papain (hours). 




Figure 3.15  Western 
blot of AH (250ng/ml) 
incubated with 
chymotrypsin for 0.5-24 
hours at 25
o
C. Exposure = 
30 seconds. Lanes contain 
ladder (L), undigested AH 

















In Figure 3.17, AH was firstly incubated for 2, 4, 6 and 18 hours with lysine c only. 
These samples are shown under the ‘Lys-C (h) only’ bracket. These samples were 
then all incubated with trypsin for 18h following their incubation with lysine c for 2, 
4, 6 or 18 hours. These samples are shown under the ‘Lys-C (h) + Trypsin (18h)’ 
bracket. 
Following staining with coomassie brilliant blue, bands of AH can be seen in all lanes 
after incubation with lysine c only; although the bands appear fainter over time. After 
the subsequent trypsin incubation, there is still a band present in the AH sample that 
had a 2 hour incubation and 18 hour trypsin incubation. However, there are no bands 
Figure 3.17  Coomassie stain of AH (62.5ug/ml), initially incubated with Lysine C 
only for 2-18 hours (37
o
C); followed by incubation with trypsin for18 hours (37
o
C). Lanes 
contain ladder (L), undigested AH (AH) and AH incubated with lysine C only followed by 
the same samples incubated with trypsin. 
Lys-C (h) only Lys-C (h) + Trypsin (18h) 



















Figure 3.18 shows a comparison of AH digested with and without R&A prior to 
incubation with lysine c and trypsin. Both of the images are of the same samples. 
















































Figure 3.18  Western blot (x2) of AH (1µg/ml). Exposure = 10 seconds. Lanes contain 
low molecular weight ladder, undigested AH (AH) and two samples of AH incubated 
with lysine c for 4 hours and trypsin for a further 18 hours at 37
o
C; the second sample of 
which has been reduced and alkylated. 
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So far, all toxin samples have been in buffer, which would not have any adverse 
effects on the western blotting process. As the patient samples will be bodily fluids, 
samples in a solution more complex than buffer needed to be tested. Therefore, urine 
of a healthy male was collected and spiked with the toxins (SEB, SEC, TSST-1 and 
AH), in order to establish the effects of urine on the detection process.  As Figure 3.20 
shows, the whole toxins are clearly visible in all of the lanes. The uncentrifuged urine 
(x) and centrifuged urine (y) do not appear to show any differences. 
 










Figure 3.19  Western blots of:  
[a] SEB (100ng/ml). Exposure = 60 
seconds. [b] SEC (100ng/ml). 
Exposure = 80 seconds. [c] AH 
(250ng/ml). Exposure = 30 seconds. 
[d] TSST-1 (250ng/ml). Exposure = 
20 seconds. Lanes contain ladder 










3.9  Discussion 
 
3.9.1  The Toxins 
 
Each of the toxins – AH, SEB, SEC, TSST-1 – are said to be of a particular molecular 
weight, according to each datasheet. As shown in Figure 3.1, the proteins do not 
always appear to be the exact weight described. This discrepancy can be caused by the 
type of gel used and the parameters used in the running of it. When comparing each 
toxin to the low molecular weight ladder SEB, SEC and TSST-1 appear to be 
approximately the same weight as described on the data sheets; 28kDa, 30kDa and 
24kDa, respectively. However, AH appears at approximately 40kDa, rather than 
33kDa. AH has also been described as 36kDa (Parimon et al., 2013). This may be due 
to a precursor or additional protein binding with the main protein, making it heavier 
and appear as a band higher up the 12.5% acrylamide gel. 
 
3.9.2  WB sensitivity 
 
Following the serial dilution of each toxin, bands were seen in lanes containing 
39ng/ml toxin. The sensitivity of this western blot protocol is good, showing albeit 
faint bands of a total 780pg protein load. Bands of SEB and SEC appeared stronger 
than the bands of AH throughout, this may be due to differences in the binding affinity 
of the antibodies used for each. For TSST-1 however, the technique was not so 
sensitive, as shown in Figure 3.7. A more sensitive ECL (ECL2) was used and strong 
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bands were seen to 250ng/ml (5ng protein load) and very faint bands down to 
31.25ng/ml sample (625pg protein load). 
 
3.9.3  Toxin Digestion 
 
A number of proteolytic enzymes were trialled in the digestion of the four 
staphylococcal toxins, including trypsin, pepsin, chymotrypsin, papain and a lysine c - 
trypsin combination. Trypsin is currently the most commonly used enzyme in 
proteomics and provides a reliable method for effective and accurate protein digestion. 
For this reason, trypsin was used first. Initially unaltered (not reduced or alkylated) 
toxin samples of SEB and SEC were sufficiently digested and AH and TSST-1 were 
not. Subsequently, pepsin was used to digest AH and TSST-1. Pepsin dissolves well in 
an acid, such a GuHCl, but only at very low concentrations in water. It was found that 
the samples dissolved in acid did not stay in the wells during the western blot. 
Therefore, after running the gel, there were no bands in any of the samples containing 
GuHCl. Gels were run using the 3M pepsin that we had tried to dissolve in water 
(heating, vortexing) and they did give some results; however it was impossible to 
know what the actual concentration of pepsin in the sample was. It was therefore 
concluded that pepsin was not the best enzyme to be used. Chymotrypsin and papain 
were each incubated with AH and gave similar results. Both partially digested AH 
however, a faint band remained in most of the lanes at the MW of AH. With AH 
proving difficult to successfully digest, a combination of lysine c and trypsin was 
eventually used. This dual enzyme incubation proved to be very successful as AH was 
completely digested. Lysine c appears to open up the tertiary protein structure of AH, 
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allowing the trypsin more access to completely digest the toxin. The 293 amino acid 
long mature protein of AH is preceded by a 26 residue signal sequence that is cleaved 
during secretion (Gray, 1984). The signal peptide contains 2 amino-terminal charged 
residues, followed by 16 neutral, hydrophobic amino acids, a helix-bending proline 
and a further four neutral residues (Gray, 1984).   
For trypsin to be most effective, the protein needs to be completely denatured and 
contain a sufficient number of arginine and lysine residues (Shah, 2010). Once this 
was realised, all of the staphylococcal toxins were reduced and alkylated prior to 
incubation with trypsin (prior to lysine c for AH) and compared to toxin incubated 
with trypsin only. The results proved how vital reduction and alkylation was the 
digestion of these toxins using trypsin. Although SEB and SEC had no band at 28kDa 
and 30kDa, respectively, there was a strong band in each of a lower molecular weight. 
TSST-1 remained seemingly untouched by trypsin. The AH results were inconclusive 
due to very faint bands, even for the whole control toxin. Following reduction and 
alkylation, SEB and SEC showed no bands remaining and TSST-1 only showed a very 
faint band at 24kDa and none elsewhere, allowing us to conclude that all three toxins 
were completely or sufficiently digested, suitable for mass spectrometry. 
Reduction and alkylation in more detail: 
DTT (C4H10O2S2) is a small molecule, strong reducing agent. Once oxidised, a stable 
6-membered ring forms, with an internal disulphide bond. The reduction of a typical 
disulphide bond proceeds be two sequential thiol-disulfide exchange reactions, 
















Iodoacetamide (C2H4INO) binds covalently with the thiol group of cysteine so that the 




Figure 3.20  Chemical structure of dithiothreitol 
(DTT) (Lukesh, 2012).  
Figure 3.21  Mechanism of action of DTT (Minikel, 2015). 




The thiol group is the functional unit of cysteine, which plays a role in protein folding. 
Oxidation generates a cysteine unit containing a disulfide bond. When the cysteines 
are within the same peptide, the tertiary structure is affected; when cysteines are in 
different peptides, quaternary structure is affected (strong covalent bonds). 
Iodoacetamide binds to the thiol group, inhibiting such bonds, preventing reformation 




Chapter 4  MASS SPECTROMETRY: TOXIN 
DIGESTION 
 
4.1  Introduction 
 
The work in this chapter was carried out using the HPLC-ESI-MS method. The 
result(s) of mass spectrometry (MS) were determined using the MASCOT server. The 
raw data generated by the LC-MS is opened into ‘Esquire’. There, the compounds are 
found using ‘Find – Compounds AutoMSn’. The resultant mass spectrum is 
subsequently de-convoluted and the compounds are exported and saved as an ‘.mgf’ 
file. Such ‘.mgf’ files can be opened in ‘Biotools’ – the software used to run the data 
through the MASCOT database. 
The MASCOT database can be discriminatory and we chose to only search for 
staphylococcal peptides, so as not to detect proteins that could have implications for 
the participants taking part in the study. 
MASCOT scores are generated for each peptide detected. A threshold of 50 has been 
set and any score over this value is considered a correct and confident identification. 
The higher the score, the more confident the identification. 
The one letter amino acid abbreviations used are explained in appendix A. 




4.2  Toxin Alignments 
 
Using EMBOSS Pairwise Alignment software, each toxin was run against one another 
to determine the similarity of their amino acid sequences. Similarity within their 
amino acid sequences could result in similar tertiary protein structures which  may 
lead to cross-reactivity. 
  
4.2.1  Comparison of SEB and SEC1 
 
SEB    1   MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMEN   50 
           |.|..|||.||||||||||:.||||||||||||.||||||:||||||||| 
SEC1   1   MNKSRFISCVILIFALILVLFTPNVLAESQPDPTPDELHKASKFTGLMEN   50 
 
SEB    51  MKVLYDDNHVSAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDL  100 
           |||||||::|||..|||:|:||..||||:|.|.||.|||.|:.|..|:.| 
SEC1   51  MKVLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEGL  100 
 
SEB    101 ADKYKDKYVDVFGANYYYQCYFSKKTNDINSHQTDKRKTCMYGGVTEHNG  150 
           |.||||:.|||:|:|||..||||.|.|   ..:....|||||||:|:|.| 
SEC1   101 AKKYKDEVVDVYGSNYYVNCYFSSKDN---VGKVTGGKTCMYGGITKHEG  147 
 
SEB    151 NQLDK--YRSITVRVFEDGKNLLSFDVQTNKKKVTAQELDYLTRHYLVKN  198 
           |..|.  .:::.:||:|:.:|.:||:|||:||.|||||||...|::|:.. 
SEC1   148 NHFDNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINK  197 
 
SEB    199 KKLYEFNNSPYETGYIKFIENE-NSFWYDMMPAPGDKFDQSKYLMMYNDN  247 
           |.|||||:|||||||||||||. |:||||||||||||||||||||||||| 
SEC1   198 KNLYEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDN  247 
 
SEB    248 KMVDSKDVKIEVYLTTKKK  266 
           |.||||.|||||:||||.. 
SEC1   248 KTVDSKSVKIEVHLTTKNG  266 
 
Identity:     182/269 (67.7%) 
Similarity:   213/269 (79.2%) 




4.2.2  Comparison of SEB and TSST-1 
 
SEB    1   MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMEN   50 
           |.|:|.::..|:         :|.:||.:..|..|..|..:.    :::. 
TSST-1 1   MNKKLLMNFFIV---------SPLLLATTATDFTPVPLSSNQ----IIKT   37 
 
SEB    51  MKVLYDDNHVSAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDL  100 
           .|...:||....::..|.....:.:.  .:.|..||:     :..||.|. 
TSST-1 38  AKASTNDNIKDLLDWYSSGSDTFTNS--EVLDNSLGS-----MRIKNTDG   80 
 
SEB    101 ADKYKDKYVDVFGANYYYQCYFSKKTNDINSHQTDKRKTCMYG-------  143 
           :..     :.:|.:.||...:...:..|:|:.:|.|.:....|        
TSST-1 81  SIS-----LIIFPSPYYSPAFTKGEKVDLNTKRTKKSQHTSEGTYIHFQI  125 
 
SEB    144 -GVTEHNGNQLDKYRSITVRVFEDGKNL-LSFDVQTNKKKVTAQELDYLT  191 
            |||  |..:|.....:.::|...||:. |.:..:.:||::....||:.. 
TSST-1 126 SGVT--NTEKLPTPIELPLKVKVHGKDSPLKYGPKFDKKQLAISTLDFEI  173 
 
SEB    192 RHYLVKNKKLYEFNNSPYETGYIKFIENENSFWYDMMPAPGDKFDQSKYL  241 
           ||.|.:...||.  :|....||.|...|:.|.:..         |.||.. 
TSST-1 174 RHQLTQIHGLYR--SSDKTGGYWKITMNDGSTYQS---------DLSKKF  212 
 
SEB    242 MMYNDNKMVDSKDVKIEVYLTTKKK  266 
           ....:...::..::|.   :..:.. 
TSST-1 213 EYNTEKPPINIDEIKT---IEAEIN  234 
 
Identity:      56/275 (20.4%) 
Similarity:   107/275 (38.9%) 
Gaps:          50/275 (18.2%) 
 
4.2.3  Comparison of SEB and AH 
 
SEB    1   MYKRLFISHVILIFALILVISTPNV-LAESQPDPKPDELHKSSKFTGLME   49 
           |..|: :|.|.....|..::..|.. .|:|..:.|.......|..|.... 
AH     1   MKTRI-VSSVTTTLLLGSILMNPVAGAADSDINIKTGTTDIGSNTTVKTG   49 
 
SEB    50  NMKVLYDDNH-------VSAINVKSIDQFLYFDLIYSIKDTKLGNYDNVR   92 
           :: |.||..:       .|.|:.|:.::.|   |:...|.|..|.|.... 
AH     50  DL-VTYDKENGMHKKVFYSFIDDKNHNKKL---LVIRTKGTIAGQYRVYS   95 
 
SEB    93  VEFKNKD-------------LADKYKDKYVDVFGANYY-YQCYFSKKTND  128 
           .|..||.             |.|....:..|.:..|.. .:.|.|..|.. 




SEB    129 INSHQTDKRKTCMYGGVTEHN---GNQLDKYRSITVRVFEDGKNL-----  170 
           .|.:.|.. .|...||:...|   |:.|...:.....:.|...:.      
AH     146 FNGNVTGD-DTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWK  194 
 
SEB    171 LSFDVQTNKK----------KVTAQELDYLTRHYLVKN-------KKLYE  203 
           :.|:...|:.          .|...:|...||:..:|.       .|... 
AH     195 VIFNNMVNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASS  244 
 
SEB    204 FNNSPYETGYIKFI--ENENSFWYDMMPAPGDKFDQSKYLMMYNDN-KMV  250 
           ..:|.:...:...|  :.:.|.....:....::......|...:.| |.. 
AH     245 LLSSGFSPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGT  294 
 
SEB    251 DSKD---------VKIEVYLTTKKK  266 
           ::||         .||:........ 
AH     295 NTKDKWTDRSSERYKIDWEKEEMTN  319 
 
 
Identity:      60/325 (18.5%) 
Similarity:   101/325 (31.1%) 
Gaps:          65/325 (20.0%) 
 
4.2.4   Comparison of SEC1 and TSST-1 
 
SEC1   1 MNKSRFISCVILIFALILVLFTPNVLAESQPDP-TPDELHKASKFTGLME     49 
         |||.     :::.|.::..|.......:..|.| :.:::.|.:| ....: 
TSST-1 1 MNKK-----LLMNFFIVSPLLLATTATDFTPVPLSSNQIIKTAK-ASTND     44 
 
SEC1   50 NMKVLYDDHYVSATKVKSVDKFLAHDLIYN-ISDKKLKNYDKVKTELLNE    98 
          |:|.|.| .|.|.:     |.|...:::.| :...::||.|...:.::   
TSST-1 45 NIKDLLD-WYSSGS-----DTFTNSEVLDNSLGSMRIKNTDGSISLII--    86 
 
SEC1   99 GLAKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGN   148 
           ....|..... ..|....:|...:.|...............|:|..|   
TSST-1 87 -FPSPYYSPAF-TKGEKVDLNTKRTKKSQHTSEGTYIHFQISGVTNTE--   132 
 
SEC1   149 HFDNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKK  198 
           .........:.::|: .|.:.:.:..:.|||.:....||.:.|:.|.... 
TSST-1 133 KLPTPIELPLKVKVH-GKDSPLKYGPKFDKKQLAISTLDFEIRHQLTQIH  181 
 
SEC1   199 NLYEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNK  248 
           .||  .||....||.|...|:|:|:..|:    ..||:.:......|.:: 
TSST-1 182 GLY--RSSDKTGGYWKITMNDGSTYQSDL----SKKFEYNTEKPPINIDE  225 
 
SEC1   249 TVDSKSVKIEVHLTTKNG  266 
           .   |:::.|::       




Identity:      53/268 (19.8%) 
Similarity:   103/268 (38.4%) 
Gaps:          36/268 (13.4%) 
 
4.2.5  Comparison of SEC1 and AH 
 
SEC1   1   MNKSRFISCVILIFALILVLFTPNVLAESQPD-----PTPDELHKASKFT   45 
           | |:|.:|.|.....|..:|..| |...:..|     .|.|.....:..| 
AH     1   M-KTRIVSSVTTTLLLGSILMNP-VAGAADSDINIKTGTTDIGSNTTVKT   48 
 
SEC1   46  GLM-----EN---MKVLY---DD--HYVSATKVKSVDKFLAHDLIY----   78 
           |.:     ||   .||.|   ||  |......:::.........:|     
AH     49  GDLVTYDKENGMHKKVFYSFIDDKNHNKKLLVIRTKGTIAGQYRVYSEEG   98 
 
SEC1   79  -NISDKKLKNYDKVKTELLNEGLAK---KYKDEVVDVYGSNYYVNCYFSS  124 
            |.|.....:..||:.:|.:..:|:   .|....:|.......:...|:. 
AH     99  ANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMSTLTYGFNG  148 
 
SEC1   125 K---DNVGKVTG--GKTCMYGGITKHEGNHF----DNGNLQNVLIRV-YE  164 
           .   |:.||:.|  |.....|...|:....|    ::...:.|..:| :. 
AH     149 NVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFN  198 
 
SEC1   165 NKRNTISFEVQTDK-KSVTAQELDIKARNFLINKK-NLYEFN------SS  206 
           |..|........|. ..|...:|.:|.||..:... |..:.|      || 
AH     199 NMVNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASSLLSS  248 
 
SEC1   207 PYETGYIKFI---------ENNGNTFWYDMMPAPGDKFDQSKYLMMYNDN  247 
           .:...:...|         :.|.:..:..:.......:..:.:......: 
AH     249 GFSPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKD  298 
 
SEC1   248 KTVD--SKSVKIEVHLTTKNG  266 
           |..|  |:..||:........ 
AH     299 KWTDRSSERYKIDWEKEEMTN  319 
 
Identity:      61/321 (19.0%) 
Similarity:   104/321 (32.4%) 




4.2.6   Comparison of TSST-1 and AH  
 
TSST-1   1 MNKK--------LLMNFFIVSPLLLATTAT---DFTPVPLSSNQIIKTAK  39 
           |..:        ||:...:::|:..|..:.   ......:.||..:||.. 
AH       1 MKTRIVSSVTTTLLLGSILMNPVAGAADSDINIKTGTTDIGSNTTVKTGD  50 
 
TSST-1  40 ASTNDNIKDLLD--WYSSGSDTFTNSEVL-----DNSLGSMRIKNTDGSI  82 
           ..|.|....:..  :||...|...|.::|     ....|..|:.:.:|:. 
AH      51 LVTYDKENGMHKKVFYSFIDDKNHNKKLLVIRTKGTIAGQYRVYSEEGAN  100 
 
TSST-1  83 -SLIIFPSPY-YSPAFTKGEKVDLNTKRTKKSQHTSEG----TY-IHFQI  125 
            |.:.:||.: ........|...::....:.|..|.|.    || .:..: 
AH     101 KSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMSTLTYGFNGNV  150 
 
TSST-1 126 SG---------------VTNTEKLPTP-----IELPLKVKV---------  146 
           :|               :.:|.|...|     :|.|...||          
AH     151 TGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNM  200 
 
TSST-1 147 -------HGKDS--PLKYGPKFDKKQ------------------------  163 
                  :.:||  |:.....|.|.:                         
AH     201 VNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASSLLSSGF  250 
 
TSST-1 164 ----LAISTLDFEIRHQLTQIHGLY-RSSDKTGGYWKITMNDGSTYQSDL  208 
               ..:.|:|.:...|.|.|..:| |..|....:|..|...|:..:.   
AH     251 SPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKD--  298 
 
 
TSST-1 209 SKKFEYNTEKPPINIDEIKTIEAEIN  234 
            |..:.::|:..|:.::    |...| 
AH     299 -KWTDRSSERYKIDWEK----EEMTN  319 
 
Identity:      57/326 (17.5%) 
Similarity:   104/326 (31.9%) 
Gaps:          99/326 (30.4%) 
Table 4.1  The similarity of each toxin - AH, SEB, SEC1, TSST - as determined by 
EMBOSS pairwise alignment. 
 SEB SEC1 TSST-1 AH 
SEB  79.2 % 38.9% 31.1% 
SEC1   38.4% 32.4% 
TSST-1    31.9% 




4.3  ExPASy: Expected Peptide Fragments 
 
Using the gi number of each toxin, a theoretical enzymatic digestion was carried out 
using ExPASy enzyme cutter. 
The amino acids highlighted in blue (Section 4.4.1 – 4.4.4) are amino acids that have 
been identified successfully by the MS. The detection may have been of the exact 
peptide shown or a combination of 2 or more. 
Table 4.3 shows the gi number of each toxin and the enzyme(s) used to digest each 
one. The enzyme choice for the digestion of each toxin was explained previously in 
Chapter 3. Amino acids that were identified by the MS and matched to a peptide in the 
‘expected’ peptides list generated by ExPASy were counted and totalled up. The % of 






Table 4.2 The toxins used (gi number) and the enzyme(s) used to digest each one. Total number 
of amino acids in each toxin and the number of amino acids detected by the MS. 
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4.3.1  AH & Lysine C/Trypsin 
 











































4.3.2  SEB & Trypsin 
 


































181-181     K 
200-200     K 
265-265     K 




4.3.3  SEC1 & Trypsin 
 
Position Peptide Cleavage 
106-125 DEVVDVYGSNYYVNCYFSSK  






































4.3.4  TSST-1 & Trypsin 
 
Position Peptide Cleavage 
5-36 LLMNFFIVSPLLLATTATDF TPVPLSSNQIIK 
48-74 DLLDWYSSGSDTFTNSEVLD NSLGSMR 
112-133 SQHTSEGTYIHFQISGVTNT EK 































4.4  Initial Mass Spectrometry 
 
Mass spectrometry has never been used to detect these staphylococcal enterotoxins in 
urine before, but it has been used to analyse urine and toxins separately (Callahan, 
2006; Andjelkovic, 2016; Storer, 2011). 
 
4.4.1   MS of Bovine Serum Albumin 
 
In order to analyse patient samples for the presence of staphylococcal enterotoxins, a 
highly sensitive and robust method needs to be developed. Currently, ELISA and 
western blot methods are able to detect the toxins at ng/ml levels. Mass spectrometry 
has the potential to detect proteins of picomolar concentration. 
Firstly, a protocol needed to be established to run the samples through the MS and to 
be able to identify the peaks that could be peptide fragments of a staphylococcal 
enterotoxin. To do this, bovine serum albumin (BSA) was used as a standard; as it is 
an inexpensive protein that has been extensively used in MS, meaning that well-







Figure 4.1  Resolved spectra of BSA. 
(Bruker Daltonics).) 
 









Results of this showed that milli-, nano- and picomolar concentrations can be 
observed. Although the spectra are not the same, some of the expected peaks have 
been seen in the spectra of BSA (Figure 4.2). 
 
4.4.2    Initial MS of Staphylococcal Toxins 
 
Figures 4.3-4.5 show the spectra of SEB (1ng/ml), SEC1 (1pg/ml) and TSST-1 
(1pg/ml), digested with trypsin for 18 hours at 37oC. The list of numbers to the right 
of each figure, are the expected m/z (mass to charge) values of the resultant peptides, 
according to mMass. The numbers coloured purple are where the expected peak has 






Figure 4.3  MS spectra of SEB (1µg/ml) and expected m/z peaks according to 




Figure 4.4  MS spectra of SEC (1µg/ml) and expected m/z peaks according to 























































































Figure 4.5  MS spectra of TSST-1 (1µg/ml) and expected m/z peaks 
according to mMass. Samples were digested with trypsin at 37oC for 18h then 




























The MS spectra of the trypsinised toxins did not prove as successful as expected. 
These samples were not reduced and alkylated and these data were generated before 
the importance of reduction and alkylation in these tryptic digests was realised. As 
shown in Chapter 3, western blots compared the trypsinised toxins with and without 
prior reduction and alkylation. 
 
4.5  MS of BSA and Staphylococcal Toxins in Water 
 
BSA is used as a standard in the protocol for enzymatic digestion using trypsin and 
the subsequent LC-MS spectra are well established and defined. The table below 
summarises the identifications of each protein and the highest score produced. A score 
of <50 means that the MASCOT database is quite certain of the identification; the 
higher the score, the higher the certainty. 
 
The mascot identifications stated in the table above are the gi numbers that have the 
highest score, most often. However, sometimes, slightly different gi numbers are 
given for a similar peptide; i.e. a precursor or smaller derivative. 
Other gi numbers included: 
Table 4.3 Each sample, concentration, proteolytic enzyme(s) used and MASCOT identification 
based on MS raw data.  
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• BSA (ALB protein [Bos Taurus] gi|74267962, Albumin gi|164318) 
• SEC (Enterotoxin C3 precursor gi| 153004) 
 
4.6  MS of Urine 
 
Samples of urine – from a healthy individual - were analysed by mass spectrometry in 
order to understand what proteins exist and can be detected in ‘normal’ urine. The 
urine was centrifuged for 10 minutes at 5000 x g; no other ‘clean-up’ steps were 





4.7  MS of Spiked Urine 
 
Following the results of the MS of urine and of each protein in dH2O, urine was 
spiked with individual staphylococcal toxins. 




Table 4.5 MS results of urine spiked with BSA or toxin, including the identification (gi 
number) and MASCOT score. 
 
4.8  MS Repeatability 
 
To analyse the repeatability of the HPLC-MS method, BSA was diluted to 200ng/ml 
in dH2O. Three identical vials were made up, treated identically and run consecutively 
in the LC-MS. As shown in Table 4.7, the BSA samples were constistantly identified 
as BSA, with a very high MASCOT score. 
 
The exact same three BSA samples shown in Table 4.7 were run through the LC-MS 
again, once the first cycle had finished. The results are shown in Table 4.8. Again, 
BSA was correctly and strongly identified by the MASCOT database.  
 
  
Table 4.6  MS repeatability of BSA (200ng), first analysis cycle. MASCOT identification and 
score >50. 





Further to the repeatability results of BSA, repeatability was further tested using one 
of the toxins. SEC1 was diluted to 10µg/ml with dH2O. Three samples were made, 
treated identically and run consecutively in the LC-MS. 
 
Two of the three samples have been identified as SEC3 precursor. This is most likely 
due to the homology within the SEC family. The scores recorded are similar to one 
another and considerably more than the >50 threshold. It has been concluded that the 
LC-MS method shows good repeatability. 
 
4.9  MS Sensitivity 
 
To test the sensitivity of the HPLC-MS method, SEC1 was diluted from 1mg/ml in 
dH2O, reduced and alkylated then trypsinised (37oC, 18 hours).  
 





SEC (gi|162648) was correctly identified at concentrations of 5µg/ml to 500ng/ml. 
There was no detection of SEC in the 100ng/ml and less samples. 
 
4.10  SEC1-3 
 
There is strong sequence homology within the SEC family (Reiser, 1984). The toxin 
used was SEC1, however it is important to include information about SEC2 and SEC3 
due to their similarity. The amino acid sequences of SEC2 and SEC are available in 
Appendix B (5-6). SEC1-3 were compared for similarity by alignment and the results 
are shown below: 
 
4.10.1  Comparison of SEC1 and SEC2 
 
 
SEC1     1 MNKSRFISCVILIFALILVLFTPNVLAESQPDPTPDELHKASKFTGLMEN  50 
           ||||||||||||||||||||||||||||||||||||||||:|:|||.|.| 
SEC2     1 MNKSRFISCVILIFALILVLFTPNVLAESQPDPTPDELHKSSEFTGTMGN  50 
 
SEC1    51 MKVLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEGL 100 
           ||.||||||||||||.||||||||||||||||||||||||||||||||.| 
SEC2    51 MKYLYDDHYVSATKVMSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEDL 100 
 





SEC1   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC2   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
 
SEC1   151 DNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC2   151 DNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
 
SEC1   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC2   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
 
SEC1   251 DSKSVKIEVHLTTKNG 266 
             |||||||||||||||| 
SEC2   251 DSKSVKIEVHLTTKNG 266 
 
Identity:     259/266 (97.4%) 
Similarity:   261/266 (98.1%) 
Gaps:           0/266 ( 0.0%) 
 
4.10.2  Comparison of SEC1 and SEC3 
 
 
SEC1     1 MNKSRFISCVILIFALILVLFTPNVLAESQPDPTPDELHKASKFTGLMEN  50 
           |.|..|||.||||||||||:.||||||||||||.||:|||:|:|||.|.| 
SEC3     1 MYKRLFISRVILIFALILVISTPNVLAESQPDPMPDDLHKSSEFTGTMGN  50 
 
SEC1    51 MKVLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEGL 100 
           ||.|||||||||||||||||||||||||||||||||||||||||||||.| 
SEC3    51 MKYLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEDL 100 
 
SEC1   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC3   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
 
SEC1   151 DNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
           |||||||||:|||||||||||||||||||||||||||||||||||||||| 
SEC3   151 DNGNLQNVLVRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
 
SEC1   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC3   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
 
SEC1   251 DSKSVKIEVHLTTKNG 266 
           |||||||||||||||| 





Identity:     251/266 (94.4%) 
Similarity:   256/266 (96.2%) 
Gaps:           0/266 ( 0.0%) 
 
4.10.3  Comparison of SEC2 and SEC3 
 
 
SEC2     1 MNKSRFISCVILIFALILVLFTPNVLAESQPDPTPDELHKSSEFTGTMGN  50 
           |.|..|||.||||||||||:.||||||||||||.||:||||||||||||| 
SEC3     1 MYKRLFISRVILIFALILVISTPNVLAESQPDPMPDDLHKSSEFTGTMGN  50 
 
SEC2    51 MKYLYDDHYVSATKVMSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEDL 100 
           |||||||||||||||.|||||||||||||||||||||||||||||||||| 
SEC3    51 MKYLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEDL 100 
 
SEC2   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC3   101 AKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHF 150 
 
SEC2   151 DNGNLQNVLIRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
           |||||||||:|||||||||||||||||||||||||||||||||||||||| 
SEC3   151 DNGNLQNVLVRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNL 200 
 
SEC2   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
SEC3   201 YEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTV 250 
 
SEC2   251 DSKSVKIEVHLTTKNG 266 
           |||||||||||||||| 
SEC3   251 DSKSVKIEVHLTTKNG 266 
 
Identity:     256/266 (96.2%) 
Similarity:   259/266 (97.4%) 





Table 4.10 Comparison of the similarities of the amino acid structures of SEC1, SEC2 and 
SEC3. 
 SEC1 SEC2 SEC3 
SEC1  98.1% 96.2% 
SEC2   97.4% 




4.11  Comparison of Bovine Serum Albumin and 
Human Albumin 
 
Finally, the amino acid make-up of BSA and human albumin (HA) were compared to 
see if they held much similarity to one another. BSA has been used as a standard 
protein and it is possible to see HA in human urine.  The amino acid sequences for 
BSA and HA are available in Appendix B (7-8). The theoretical tryptic digest peptides 







4.11.1  Comparison of BSA and HA  
 
 
BSA   1  MKWVTFISLLLLFSSAYSRGVFRRDTHKSEIAHRFKDLGEEHFKGLVLIA  50 
         ||||||||||.||||||||||||||.||||:||||||||||:||.||||| 
HA    1  MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA  50 
 
BSA  51  FSQYLQQCPFDEHVKLVNELTEFAKTCVADESHAGCEKSLHTLFGDELCK 100 
         |:||||||||::|||||||:||||||||||||...|:|||||||||:||. 
HA   51  FAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCT 100 
 
BSA 101 VASLRETYGDMADCCEKQEPERNECFLSHKDDSPDLPKL-KPDPNTLCDE  149 
        ||:||||||:|||||.|||||||||||.||||:|:||:| :|:.:.:|.. 
HA  101 VATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTA  150 
 
BSA 150 FKADEKKFWGKYLYEIARRHPYFYAPELLYYANKYNGVFQECCQAEDKGA  199 
        |..:|:.|..|||||||||||||||||||::|.:|...|.|||||.||.| 
HA  151 FHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAA  200 
 
BSA 200 CLLPKIETMREKVLASSARQRLRCASIQKFGERALKAWSVARLSQKFPKA  249 
        |||||::.:|::..||||:|||:|||:|||||||.|||:||||||:|||| 
HA  201 CLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKA  250 
 
BSA 250 EFVEVTKLVTDLTKVHKECCHGDLLECADDRADLAKYICDNQDTISSKLK  299 
        ||.||:||||||||||.||||||||||||||||||||||:|||:|||||| 
HA  251 EFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK  300 
 
BSA 300 ECCDKPLLEKSHCIAEVEKDAIPENLPPLTADFAEDKDVCKNYQEAKDAF  349 
         |||:||||||||||||||.|.:|.:||.|.|||.|.|||||||.||||.| 
HA  301 ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVF  350 
 
BSA 350 LGSFLYEYSRRHPEYAVSVLLRLAKEYEATLEECCAKDDPHACYSTVFDK  399 
        ||.|||||:||||:|:|.:||||||.||.|||:|||..|||.||:.|||: 
HA  351 LGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDE  400 
 
BSA 400 LKHLVDEPQNLIKQNCDQFEKLGEYGFQNALIVRYTRKVPQVSTPTLVEV  449 
        .|.||:||||||||||:.||:||||.|||||:||||:||||||||||||| 
H   401 FKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEV  450 
 
BSA 450 SRSLGKVGTRCCTKPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKC  499 
        ||:|||||::||..||::||||.|||||::||:|||||||||||::|||| 
HA  451 SRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKC  500 
 
BSA 500 CTESLVNRRPCFSALTPDETYVPKAFDEKLFTFHADICTLPDTEKQIKKQ  549 
         |||||||||||||||..|||||||.|:.:.||||||||||.:.|:||||| 
HA  501 CTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQ  550 
 
 BSA 550 TALVELLKHKPKATEEQLKTVMENFVAFVDKCCAADDKEACFAVEGPKLV  599 
        ||||||:|||||||:||||.||::|.|||:|||.|||||.|||.||.||| 
HA  551 TALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV  600 
 
BSA 600 VSTQTALA-  607 
        .::|.||.  




Identity:      465/609 (76.4%) 
Similarity:   536/609 (88.0%) 
Gaps:          2/609 (0.3%) 
 
4.12   Summary 
 
4.12.1  Amino Acid Sequences 
 
All of the toxins share some degree of similarity (31.1-38.9%); however the similarity 
between SEB and SEC1 is clearly very high (79.2%).  Amongst the SAgs, SEC and 
SEB are the most homologous and share antibody binding epitopes (Schmidt, 1983; 
Spero et al., 1978), which lead to antibody cross-reactivity. The SEC1 family showed 
similarity of 96.2-98.1%, often leaving them indistinguishable. BSA and HA were 
also found to be very similar (88%). 
 
4.12.2  MS Detection 
 
MS analysis of each toxin detected 40-55% of the amino acids within the derived 
peptides. Each protein was successfully identified, in both LCMS grade water and 
healthy urine, with scores well over the MASCOT threshold of 50. The scores for the 
toxins in spiked urine were considerably lower than those in water but more than 50. 
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This may have been due to the toxins in urine being half as concentrated; although this 
should not really affect the score too much as MS is a sensitive method that is 
detecting the presence of specific peptides. As shown in Section 4.7, there is a number 
of other protein components in urine and these may hinder the detection of the specific 
peptides that we are looking for.  Overall, the number of resultant m/z peaks identified 
was disappointing and is likely due to the fact that these samples were not reduced and 
alkylated. The importance of this step was eventually realised (Chapter 3.9.3).  For 
trypsin work most effectively, the protein needs to be completely denatured (Shah, 
2010). 
 
4.12.3  MS Repeatability & Sensitivity 
 
As shown in Table 4.7 the LC-MS method showed good repeatability. The results 
shown in Table 4.7 are re-runs of Table 4.8. Two of the BSA scores are slightly lower 
than in the first round of running cycles. This may be due to the fact that they have 
been in the HPLC autosampler (10oC) for up to 6 hours. This may allow the sample 
time to degrade or evaporate as the first round of analysis will have punctured a hole 
in the vial lid.  
Similarly, SEC1 repeatability results shown in Table 4.9 agree with the repeatability 
results for BSA. SEC1 was also used to test the sensitivity of the method. The toxin 
was only detected down to 500ng/ml, whereas the MS is capable of detecting much 




CHAPTER 5   SUBJECT POPULATION  
5.1  Introduction 
 
Following the initial research carried out in the literature review (Chapter 1), a 
questionnaire was designed to be completed by each study participant. The 
information collected would also describe each of the populations that we have 
sampled. Additionally, some of these data could be compared to current literature that 
has explored the pathogenesis of RA and factors that could contribute to its 
development. 
The risk of developing RA is increased by an average age (of onset) of 55-64 (Chapter 
1.8.1), being female (Chapter 1.8.2) and of Caucasian ethnicity (Chapter 1.8.9). A 
higher birth order (1st – 3rd) (Chapter 1.8.3), not sharing a bedroom (Chapter 1.8.4) 
and exposure to animals (Chapter 1.8.5.), particularly birds, cats and sick animals, are 
also linked with an increased chance of RA. Socioeconomic status (SES) (Chapter 
1.8.6), smoking (Chapter 1.8.7) and urbanisation (Chapter 1.8.8) also seem to 
influence the chance of developing RA. Genetics appear to predispose individuals to 
RA (Chapter 1.8.11) and seasonal variation of disease severity has also been discussed 
(Chapter 1.8.10). 
A 3 page questionnaire was completed by each participant. The study populations are 




5.2  Age & Gender  
 
Table 5.1 Table to show the age and gender of participants. Age was recorded in age 







The average age of the RA patients fell within the 65-74 years bracket. The fracture 









Female (%) 110 (73.8) 52 (74.3) 
Age 25-34 years (%) 4 (2.7) 10 (14.3) 
Age 35-44 years (%) 5 (3.4) 3 (4.3) 
Age 45-54 years (%) 21 (14.1) 20 (28.6) 
Age 55-64 years (%) 42 (28.2) 7 (10.0) 
Age 65-74 years (%) 49 (32.9) 14 (20.0) 
Age 75-84 years (%) 24 (16.1) 12 (17.1) 
Age 85-94 years (%) 4 (2.7) 2 (2.9) 
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5.3  Ethnicity 
 
Of the total RA population sampled (n=149), 146 (98%) described themselves as 




Figure 5.1  Pie chart to show the ethnicity of the RA patient cohort. 
 
 
The fracture patient cohort (n=70) all identified themselves as white; 68 (97.1%) as 









Figure 5.2  Pie chart to show the ethnicity of the fracture patient cohort. 
 
5.4  Smoking Status 
 
Of the 149 participants 64 (43.0%) had never smoked and 58 (39.0%) had smoked in 
the past. Of the participants that still smoke (n=27(18.1%)), 14 (9.4%) smoked less 
than 10 cigarettes per day, 10 (6.7%) smoked 10-20 per day, 2 (1.3%) smoke 20-30 








Figure 5.3  Pie chart to show the proportion of the rheumatology cohort who have never 
smoked, have smoked in the past or currently smoke (number of cigarettes/day). 
 
Of the 70 participants from the fracture cohort, 41 (58.6%) had never smoked and 22 
(31.4%) had smoked in the past. Of the participants that still smoke (n=7(10.0%)), 4 
(5.7%o of total) smoked less than 10 cigarettes per day and 3 (4.3%) smoked 10-20 
per day. No patients said that they currently smoked more than 20 cigarettes per day.  
 
Figure 5.4  Pie chart to show the proportion of the fracture patient cohort who have never 













5.5  Genetics 
 
Of the 149 participants surveyed, 72 (48.3%) people said that there was or had been a 
case of RA in their blood-related family. 74 (49.7%) people said that there were no 
cases in their family or, at least, any that they knew of. The remaining 3 (2%) people 
were adopted, fostered or did not answer the question. Participants were able to 
identify as many relations as they wanted to/could. The relatives identified are shown 
below: 
 
Table 5.2 Family members identified as having RA; number, percentage of the total 












Family Member Number 
% of ‘Yes’ 
(n=72) 
% of Total 
(n=149) 
Great Grandmother 1 1.4% 0.7% 
Great Aunt 3 4.2% 2.0% 
Grandmother 18 25.0% 12.1% 
Grandfather 5 6.9% 3.4% 
Mother 25 34.7% 16.8% 
Father 16 22.2% 10.7% 
Aunt 9 12.5% 6.0% 
Uncle 1 1.4% 0.7% 
Sister 8 11.1% 5.4% 
Half Sister 1 1.4% 0.7% 
Brother 7 9.7% 4.7% 
Cousin 3 4.2% 2.0% 
Daughter 4 5.6% 2.7% 
Son 1 1.4% 0.7% 
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Of the participants that answered ‘Yes’ (n=72), 102 family members were indicated to 
have/have had RA. 70.6% of those indicated were female and 29.4% male, much like 
the gender ratio of the sample cohort.  ‘Mother’ made up a third of the answers and 
‘Grandmother’, a quarter. This was followed closely by ‘Father’.  
 
Of the participants that answered ‘Yes’ (n=12) in the fracture patient cohort, 13 family 
members were indicated to have/have had RA. 92.3% of those indicated were female 
and 7.7% male.  As with the rheumatology cohort, ‘Mother’ and ‘Grandmother’ made 
up the majority of the answers.  
 
Table 5.3 Family members identified as having RA; number, percentage of the total 









Family Member Number 
% of ‘Yes’ 
(n=12) 
% of Total 
(n=70) 
Grandmother 5 41.7% 7.1% 
Grandfather 1 8.3% 1.4% 
Mother 5 41.7% 7.1% 
Sister 1 8.3% 1.4% 
Daughter 1 8.3% 1.4% 
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5.6  Birthplace 
 
Participants were asked in what region of the UK they were born, the results from the 
RA patients (Table 4.4) and fracture patients (Table 4.5) are shown below. 
Table 5.4 Birthplace (by region) of each RA patient; number and percentage of the total 
RA population. 
 
Birthplace (UK Region) Number (n=149) % of Total (n=149) 
Scotland 7 4.7% 
North West 102 68.5% 
North East 4 2.7% 
Yorkshire 14 9.4% 
West Midlands 6 4.0% 
East Midlands 2 1.3% 
South West 3 2.0% 
South East 7 4.7% 
Norther Ireland 2 1.3% 







Table 5.5 Birthplace (by region) of each fracture patient; number and percentage of the 
total fracture population. 
 
Birthplace (UK Region) Number (n=70) % of Total (n=70) 
Scotland 1 1.4% 
North West 49 70.0% 
North East 3 4.3% 
Yorkshire 6 8.6% 
West Midlands 2 2.9% 
East Midlands 1 1.4% 
South West 1 1.4% 
South East 4 5.7% 
Northern Ireland 1 1.4% 
Outside of the UK 2 2.9% 
 
5.7  Birth Order 
 
Participants were asked, amongst their siblings, where in the birth order were they 
born. Only children were considered as 1st born. Participants who had had a sibling 
before them in the birth order, who had died at birth were not to include them in this 






















1st Born 63 41.6% 28 40.0% 
2nd Born 33 22.1% 22 31.4% 
3rd Born 31 20.8% 10 14.3% 
4th Born 13 9.4% 5 7.1% 
5th Born 8 5.4% 5 7.1% 
Twin 1 0.7% 0 0.0% 
 
5.8  Sharing a bedroom 
 
RA N Minimum Maximum Mean 
Std. 
Deviation 
Bedroom Age 83 0 10 2.54 3.005 
Bedroom Years 83 3 23 10.89 5.097 
Bedroom Total People 83 2 10 2.51 1.162 
      
 
Table 5.7  The age at which the RA patient started sharing a bedroom, for how many years 







Fracture N Minimum Maximum Mean 
Std. 
Deviation 
Bedroom Age 40 0 12 2.03 2.759 
Bedroom Years 40 2 18 9.85 4.860 
Bedroom Total People 40 1 4 2.20 .516 
      
 
Table 5.8  The mean age at which fracture patients started to share a bedroom, the mean 
duration and mean number of total people in the bedroom. 
 
In the RA population 83 of 149 (55.7%) participants shared a bedroom, compared to 
40 of 70 (57.1%) of the fracture patient cohort.  
 
5.9  Parent’s Occupation during childhood 
 
Participants were asked to state the occupations of their mother and father during their 
early childhood. Occupations were divided into three divisions: white, blue and pink 
collar. A white collar worker is “a person engaged in non-manual work, esp. in office 
work of an administrative, managerial, or clerical nature; an office worker” (Oed.com, 
2016). Blue collar workers are defines as “A manual worker, esp. one employed in 
industry” (Oed.com, 1968). Pink collar work is defined as “relating to employment 
traditionally associated with women (as nursing, hairdressing, secretarial work, etc.), 
or workers engaged in such employment” (Dictionary.com, 2016). This could also be 
extended to when a person’s labour is related to customer interaction, entertainment, 




Table 5.9 The occupation type of each patient’s father; divided into white collar, pink 
collar or blue collar or absent. 
 
 White Collar Pink Collar Blue Collar Absent 
RA 19.5% 3.4% 71.8% 5.4% 
Fracture 24.3% 4.3% 64.3% 7.1% 
 
5.10  Area/Farm 
 
Participants were asked to state the type of area they lived during their early childhood 
and the type of area that they currently live in.  
 
Table 5.10 Respondents’ ‘Yes’ or ‘No’ answers to the type of area they lived in during their 




Table 5.11 Respondents’ ‘Yes’ or ‘No’ answers to spending time on a farm during their 










‘Yes’ 34 22.8% 24 34.3% 
‘No’ 115 77.2% 46 65.7% 
 
CHILDHOOD RA Fracture CURRENT RA Fracture 
Urban 36.9% 25.7% Urban 22.8% 32.9% 
Suburban 27.5% 18.6% Suburban 38.2% 22.9% 
Rural 35.6% 55.7% Rural 37.5% 44.3% 
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5.11  Pets 
 
The majority of RA participants had pets during their early childhood (n=123; 82.6%). 
Similarly, the majority of fracture participants had pets during their early childhood 
(n=60; 85.7%). Many participants lived with a combination of pets.   
Table 5.12 Pet ownership during childhood. 








Dog(s) 86 69.9% 45 64.2% 
Cat(s) 65 52.8% 28 40.0% 
Rabbit(s) 33 26.8% 15 21.4% 
Guinea pig(s) 6 4.9% 6 8.6% 
Bird(s) 28 22.8% 15 21.4% 
Total 123 82.6% 60 85.7% 
 
5.12   DAS28 
 




Table 5.13  The mean and range of the DAS28 scores for the RA patients. 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
DAS28 149 1.11 7.73 3.6134 1.32178 


















Figure 5.5  Pie chart to show the proportion of RA patients in each disease category based 
on DAS28 score. Remission (<2.6); Low (2.6-3.2); Moderate (3.2-5.1); High (>5.1). 
 
5.13  Duration of RA 
 
RA patients were asked at what age their symptoms began, at what age they were 
diagnosed with RA and how many years it had been since diagnosis. 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
Symptom Age 149 15 85 49.46 15.032 
Diagnosis Age 149 16 85 51.12 14.526 
RA Duration (years) 149 0 52 13.09 11.598 
      
 
Table 5.14  The age at which RA symptoms started, the age of RA diagnosis and the number 




Winter Autumn Spring Summer 
48 10 6 1 
9 
1 
5.14  Season 
 
52 (34.9%) of RA participants said that they felt that their RA symptoms were more 
severe in one or more seasons. 
 
Figure 5.6 The number of RA patients that said that their symptoms appeared to be worse 










CHAPTER 6  RESULTS: PATIENT SAMPLES 



















Figure 6.1  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure 6.2  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 
(Lane 2-4) and neat samples of urine from patients LR0046-054 (28µl) (Lane 5-13). 
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Figure 6.1 is an example of a western blot membrane of urine from RA patients, 
analysed using a sheep αAH primary antibody and a rabbit anti-sheep HRP-
conjugated secondary antibody. The low molecular weight protein ladder shows bands 
at 20.1, 30.0, 45.0, 66.0 and 97.0 kDa. There is a band visible in the AH lane, between 
the 30.0 and 45.0 kDa bands in the ladder. AH is approximately 33 kDa, however the 
band of control AH was often seen higher (heavier) than this in our blots. There are no 
bands seen in the lanes of control SEB and SEC as the αAH has little specificity to 
these toxins. The blot in Figure 6.1 does not seem to have run perfectly even and runs 
down to the right. There are bands at approximately 30 kDa in lanes LR082, LR083, 
LR086, LR088 and LR090. Heavier proteins are detected in the lanes containing 
urine, except LR087 and LR089.  
Figure 6.2 is a western blot membrane of urine from RA patients, analysed using a 
sheep αSEC primary antibody and a rabbit anti-sheep HRP-conjugated secondary 
antibody. There is a band visible in the both control lanes of SEB and SEC; the toxins 
are approximately 30 and 28 kDa, respectively. It is no surprise that both toxins were 
detected by αSEC, as there is cross-reactivity between the toxins and corresponding 
antibodies due to the structural similarities of SEB and SEC (see Table 4.1). There is 
no band seen in the lane of control AH as the αSEC has no specificity to AH. There 
are bands at approximately 30 kDa in lanes LR050, LR052 and LR053. As seen in 
Figure 6.1, Figure 6.2 shows heavier proteins that have been detected in all of the 




















Figure 6.3  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure 6.4  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 








Figure 6.3 is an example of a western blot membrane of urine from fracture patients, 
analysed using a sheep αAH primary antibody and a rabbit anti-sheep HRP-
conjugated secondary antibody. As for the RA urine western blots, the low molecular 
weight protein ladder shows bands at 20.1, 30.0, 45.0, 66.0 and 97.0 kDa. Again, there 
is a band visible in the AH lane, between the 30.0 and 45.0 kDa bands in the ladder. 
AH is approximately 33kDa, however the band of control AH was often seen higher 
(heavier) than this in our blots. There are no bands seen in the lanes of control SEB 
and SEC. As in Figure 6.1, the blot in Figure 6.3 runs down to the right. There are 
bands at approximately 30 kDa in lanes LF028, LF029, LF030 and LF031. Each of 
the bands does appear to be at a different level but all are within the range of the 
molecular weight of AH.  As in the RA blots, heavier proteins are detected in the lanes 
containing urine, except in LF033. 
Figure 6.4 is a western blot membrane of urine from fracture patients analysed using a 
sheep αSEC primary antibody and a rabbit anti-sheep HRP-conjugated secondary 
antibody. There is a strong band visible in the control lane SEC. There are bands at 
approximately 30 kDa in lanes LF052 and LF054. As in all of the blots shown, 








6.3 Western Blot Summary 
 
6.3.1 RA Patient Samples 
 
Table 6.1 RA patient results showing whether samples LR001-152 were positive or 
negative for each toxin: AH, SEB, SEC and TSST-1.  
Patient Sample AH SEB SEC TSST-1 
LR001 - - - - 
LR002 - - - - 
LR003 + - + - 
LR004 + + + - 
LR005 - - - - 
LR006 - - - - 
LR007 + - + - 
LR008 + + + - 
LR009 - - - - 
LR010 - - - - 
LR011 + - + - 
LR012 - - - - 
LR013 - + + - 
LR014 + - + - 
LR015 + + + - 
LR016 + + + - 
LR017 - - - - 
LR018 - - - - 
LR019 - - - - 
LR020 - - + - 
LR021 + - + - 
LR022 + - + - 
LR023 - - - - 
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LR024 - - - - 
LR025 + - - - 
LR026 + - - - 
LR027 + - + - 
LR028 + - + - 
LR029 - - + - 
LR030 + + + - 
LR031 - - - - 
LR032 - - - - 
LR033 - - - - 
LR034 + - - - 
LR035 + - - - 
LR036 - - - - 
LR037 - - - - 
LR038 + + + - 
LR039 + - - - 
LR040 + + + - 
LR041 - - - - 
LR042 + + + - 
LR044 - - - - 
LR045 + - - - 
LR046 - - - - 
LR047 + - - - 
LR048 + - - - 
LR049 - - - - 
LR050 + + + - 
LR051 + - - - 
LR052 + + + - 
LR053 + + + - 
LR054 + - - - 
LR055 + - + - 
LR056 - - - - 
LR057 + - + - 
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LR058 + - + - 
LR059 - - - - 
LR060 - - - - 
LR061 + + + - 
LR062 - + - - 
LR063 - - - - 
LR064 - - - - 
LR065 - - - - 
LR066 - - - - 
LR067 + + + - 
LR068 - - - - 
LR069 - - - - 
LR070 + + + - 
LR071 + - - - 
LR072 + - - - 
LR073 + + + - 
LR074 - - - - 
LR075 - - - - 
LR076 - - - - 
LR077 - - - - 
LR078 + - + - 
LR079 + + + - 
LR080 + + + - 
LR081 + + - - 
LR082 - - - - 
LR083 + - + - 
LR084 + - - - 
LR085 - - - - 
LR086 + + + - 
LR087 - - - - 
LR088 + - - - 
LR089 - - - - 
LR090 + - - - 
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LR091 - + - - 
LR092 - - - - 
LR094 - - + - 
LR095 + + + - 
LR096 + - - - 
LR097 + + - - 
LR098 - - - - 
LR099 - - - - 
LR100 - - + - 
LR101 - - - - 
LR102 - - - - 
LR103 - - - - 
LR104 - - - - 
LR105 - - - - 
LR106 - - - - 
LR107 + + - - 
LR108 - - - - 
LR109 + - + - 
LR110 + - + - 
LR111 + - + - 
LR112 - - + - 
LR113 + - + - 
LR114 - - - - 
LR115 - + + - 
LR116 - + + - 
LR118 - - - - 
LR119 - - - - 
LR120 + + + - 
LR121 - - - - 
LR122 - - - - 
LR123 - - - - 
LR124 + + - - 
LR125 - - - - 
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LR126 - - - - 
LR127 + + + - 
LR128 + - + - 
LR129 - + + - 
LR130 + - + - 
LR131 - - + - 
LR132 + - + - 
LR133 - - + - 
LR134 - + + - 
LR135 - - + - 
LR136 - - - - 
LR137 + + + - 
LR138 - - - - 
LR139 - - - - 
LR140 - - - - 
LR141 + + - - 
LR142 + + + - 
LR143 + + - - 
LR144 - - - - 
LR145 + + + - 
LR146 - - - - 
LR147 + + - - 
LR148 + + - - 
LR149 - - - - 
LR150 - - - - 
LR151 + + - - 





Figure 6.5  Pie chart to show the percentage of RA patients testing positive and negative for 
one or more of the staphylococcal toxins. 
 
Overall, the presence of at least one staphylococcal toxin was found in 84 of the 149 
samples (56.4%). 
69 urine samples obtained from patients with RA were positive for AH. This accounts 
for 82.1% of the total positive samples (n= 84) and 46.3% of the whole patient cohort 
(n=149). 
40 urine samples obtained from patients with RA were positive for SEB. This 
accounts for 47.6% of the total positive samples (n= 84) and 26.8% of the whole 
patient cohort (n=149). 
57 urine samples obtained from patients with RA were positive for SEC. This 
accounts for 67.9% of the total positive samples (n= 84) and 38.3% of the whole 
patient cohort (n=149). 
0 of 149 urine samples obtained from patients with RA were positive for TSST-1.  
In total, 26 urine samples tested positive for 1 toxin only [AH] [SEB] [SEC]; 31% of 






34 urine samples tested positive for 2 toxins in the following combinations: 9 [AH, 
SEB], 20 [AH, SEC], 5 [SEB, SEC]; 40.5% of the total positive samples (n=84) and 
22.8% of the whole patient cohort (n=149). 
24 urine samples tested positive for 3 toxins [AH, SEB, SEC]; 28.6% of the total 
positive samples (n=84) and 16.1% of the whole patient cohort (n=149). 
 
6.3.2  Fracture Patient Samples 
 
Table 6.2 Fracture patient results showing whether samples LF001-070 were positive or 
negative for each toxin: AH, SEB, SEC and TSST-1.  
Patient Sample AH SEB SEC TSST 
LF001 - - - - 
LF002 - - - - 
LF003 - - - - 
LF004 - - - - 
LF005 - - - - 
LF006 - - - - 
LF007 - - - - 
LF008 - + + - 
LF009 - + - - 
LF010 - - + - 
LF011 - - + - 
LF012 - - - - 
LF013 - - - - 
LF014 - - - - 
LF015 - - - - 
LF016 - - - - 
LF017 - - - - 
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LF018 - - - - 
LF019 - - - - 
LF020 - + + - 
LF021 - - - - 
LF022 - + + - 
LF023 - + + - 
LF024 - - - - 
LF025 - - - - 
LF026 - - - - 
LF027 - - - - 
LF028 - - - - 
LF029 - + + - 
LF030 - + + - 
LF031 + + + - 
LF032 - - - - 
LF033 - - + - 
LF034 - - - - 
LF035 - - + - 
LF036 - - - - 
LF037 - - - - 
LF038 + + + - 
LF039 - - - - 
LF040 - - - - 
LF041 - - - - 
LF042 - - - - 
LF043 - - - - 
LF044 - - - - 
LF045 - - - - 
LF046 - - - - 
LF047 - - - - 
LF048 - - - - 
LF049 - - - - 
LF050 - - - - 
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LF051 - - - - 
LF052 - + + - 
LF053 - - - - 
LF054 + + + - 
LF055 - + - - 
LF056 - + - - 
LF057 - - - - 
LF058 - - - - 
LF059 - - - - 
LF060 - - - - 
LF061 - - - - 
LF062 - - - - 
LF063 - - - - 
LF064 - + - - 
LF065 - - - - 
LF066 + - - - 
LF067 - - - - 
LF068 - - - - 
LF069 - - - - 



















Figure 6.6  Pie chart to show the percentage of fracture patients testing positive and 
negative for one or more of the staphylococcal toxins. 
 
Overall, the presence of at least one staphylococcal toxin was found in 19 of the 70 
samples (27.1%). 
4 urine samples obtained from fracture patients were positive for AH. This accounts 
for 21.1% of the total positive samples (n= 19) and 5.7% of the whole patient cohort 
(n=70). 
14 urine samples obtained from fracture patients were positive for SEB. This accounts 
for 73.7% of the total positive samples (n= 19) and 20.0% of the whole patient cohort 
(n=70). 
14 urine samples obtained from fracture patients were positive for SEC. This accounts 
for 73.7% of the total positive samples (n= 19) and 20.0% of the whole patient cohort 
(n=70). 
0 of 70 urine samples obtained from fracture patients were positive for TSST-1.  
In total, 9 urine samples tested positive for 1 toxin only [AH] [SEB] [SEC]; 42.9% of 
the total positive samples (n=19) and 12.9% of the whole patient cohort (n=70). 
7 urine samples tested positive for 2 toxins appearing in the following combination:  




3 urine samples tested positive for 3 toxins [AH, SEB, SEC]; 15.8% of the total 
positive samples (n=19) and 4.3% of the whole patient cohort (n=70). 
 
6.4  Questionnaire Data 
 
6.4.1  Age 































25-34 4 4 4.8% 2.7% 
35-44 2 5 2.4% 3.4% 
45-54 8 21 9.5% 14.1% 
55-64 21 42 25.0% 28.2% 
65-74 34 49 40.5% 32.9% 
75-84 14 24 16.7% 16.1% 
85-94 1 4 1.2% 2.7% 
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Table 6.4 The number of fracture patients in each age category; of the positive population 







6.4.2  Birth Order 
 
Participants were asked, amongst their siblings, where in the birth order did they 
come. Only children were considered as 1st born. Participants who had had a sibling 
before them in the birth order, who had died at birth were not to include them in this 
















% of  
Total 
(n=70) 
25-34 3 10 14.3% 14.3% 
35-44 0 3 0.0% 4.3% 
45-54 4 20 19.1% 28.6% 
55-64 2 7 9.5% 10.0% 
65-74 2 14 9.5% 20.0% 
75-84 7 12 33.3% 17.1% 
85-94 1 2 4.8% 2.9% 
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Table 6.5  Where each RA patient appeared in the birth order amongst their siblings; 
number and percentage of positive RA samples and number and percentage of the total RA 
population. 
 












1st Born 36 63 42.9% 41.6% 
2nd Born 21 33 25.0% 22.1% 
3rd Born 15 31 17.9% 20.8% 
4th Born 7 13 8.3% 9.4% 
5th + Born 4 8 4.8% 5.4% 







Table 6.6  Where each fracture patient appeared in the birth order amongst their siblings; 
number and percentage of positive fracture samples and number and percentage of the total 
fracture population. 
 












1st Born 9 28 42.9% 40.0% 
2nd Born 9 22 38.1% 31.4% 
3rd Born 1 10 0.0% 14.3% 
4th Born 1 5 5.8% 7.1% 




6.4.3  Sharing a bedroom 
 
The comparison of ‘Yes’ and ‘No’ answers versus positivity/negativity for S.aureus 
are shown below: 
 
Table 6.7  RA patients that responded ‘Yes’ or ‘No’ to sharing a bedroom as a child 





Table 6.8  Fracture patients that responded ‘Yes’ or ‘No’ to sharing a bedroom as a child compared 




In the RA population 83 of 149 (55.7%) participants shared a bedroom, compared to 
41 of 70 (58.6%) of the fracture patient cohort. After looking in more detail, the 
percentage of RA patients positive for S.aureus is similar if they shared a bedroom or 
not. However there is a notable difference in the fracture patient cohort where 45.7% 
of the respondents had said that they did not share a bedroom but were positive for 
S.aureus. This is compared to just 15.7% of whom were positive but did share a 
bedroom during their childhood. 
 
RA Positive Negative 
‘Yes’ 29.5% 26.2% 
‘No’ 26.8% 17.4% 
FRACTURE Positive Negative 
‘Yes’ 14.3% 14.3% 
‘No’ 45.7% 27.7% 
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6.4.4  Parent’s Occupation During Childhood 
 
 Table 6.9 The occupation type of each RA patient’s father; divided into white collar, pink 
collar or blue collar or absent and compared to S.aureus positivity. 
 
Table 6.10 The occupation type of each fracture patient’s father; divided into white collar, 
pink collar or blue collar or absent and compared to S.aureus positivity. 
 
Fracture White Collar Pink Collar Blue Collar Absent 
Positive 5.1% 0.0% 18.6% 2.9% 
Negative 18.6% 4.3% 45.7% 4.3% 
Total 24.3% 4.3% 64.3% 7.1% 
 
6.4.5  Area/Farm 
 
Participants were asked to state the type of area they lived during their early childhood 
and the type of area that they currently live in.  
RA White Collar Pink Collar Blue Collar Absent 
Positive 8.1% 0.7% 43.6% 4.0% 
Negative 11.4% 2.7% 28.2% 1.3% 







Table 6.11  The area of residence during childhood and currently, compared to S.aureus 
positivity/negativity – of the RA cohort. 
 
Of the rheumatology patient cohort, 34 of the 149 participants lived on or spent a lot 
of time on a farm during their early childhood. Of these, 61.8% were positive for 
S.aureus. Of the patients that responded ‘No’, 54.8% tested positive. 
Table 6.12 RA respondents’ ‘Yes’ or ‘No’ answers to spending time on a farm during their 
childhood, compared to S.aureus positivity; number and percentage of total positive samples and 





% of positive 
(n=84) 
% of total 
(n=149) 
‘Yes’ 21 34 25% 22.8% 
‘No’ 63 115 75% 77.2% 
 
Table 6.13  The area of residence during childhood and currently, compared to S.aureus 
positivity/negativity – of the fracture cohort. 
CHILDHOOD Positive Negative CURRENT Positive Negative 
Urban 20.1% 16.8% Urban 16.1% 6.7% 
Suburban 16.8% 10.7% Suburban 22.8% 15.4% 
Rural 19.5% 16.1% Rural 17.4% 20.1% 
CHILDHOOD Positive  Negative CURRENT Positive Negative 
Urban 8.6% 17.1% Urban 10.0% 22.9% 
Suburban 4.3% 14.3% Suburban 4.3% 18.6% 
Rural 14.3% 41.4% Rural 12.9% 31.4% 
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One third (34.4%) of the fracture patients said that they had lived on or spent a lot of 
time on a farm during their early childhood. Of the 24 patients that answered ‘Yes’, 
29.2% were positive for S.aureus. Of the patients that responded ‘No’, 30.4% tested 
positive. 
Table 6.14  Fracture respondents’ ‘Yes’ or ‘No’ answers to spending time on a farm during 
their childhood, compared to S.aureus positivity; number and percentage of total positive 






% of positive 
(n=19) 
% of total 
(n=70) 
‘Yes’ 6 24 28.6% 34.3% 
‘No’ 13 46 61.9% 65.7% 
 
Table 6.15 Summary of RA and fracture patients, positive for S.aureus, compared with 
time spent on a farm during childhood. 

















6.4.6  Pets 
 
Table 6.16 The number and percentage of positive RA samples divided by pet ownership 
during childhood. 
RA N positive of pet 
total 
% positive of pet 
total 




52 59.8% 61.9% 
Cat(s) 
(n=65) 
34 52.3% 40.5% 
Rabbit(s) 
(n=33) 
16 48.5% 19.0% 
Guinea pig(s) 
(n=6) 
3 50.0% 3.6% 
Bird(s) 
(n=28) 
18 64.3% 21.4% 
 
Table 6.17 The number and percentage of positive fracture samples divided by pet 
ownership during childhood. 
FRACTURE N positive of 
each pet total  
% positive of each pet 
total  




14 31.1% 73.7% 
Cat(s) 
(n=28) 
9 32.1% 47.4% 
Rabbit(s) 
(n=15) 
4 26.7% 21.1% 
Guinea pig(s) 
(n=6) 
1 16.7% 5.3% 
Bird(s) 
(n=15) 




6.4.7  DAS28 
Table 6.18  The proportion of RA patients testing positive or negative for S.aureus, divided 
by disease category. Remission (<2.6); Low (2.6-3.2); Moderate (3.2-5.1); High (>5.1). OR Table 
6.18 The proportion of RA patients testing positive or negative for S.aureus, divided by disease 
category. Remission (<2.6); Low (2.6-3.2); Moderate (3.2-5.1); High (>5.1). 
 Positive Negative 
Remission (DAS<2.6) 14.1% 11.4% 
Low (DAS 2.6-3.2) 10.7% 5.4% 
Moderate (DAS 3.2-5.1) 23.5% 20.1% 
High (DAS>5.1) 8.1% 6.7% 
 
As shown in Figure 6.18, the distribution of DAS28 category, within the positive and 
negative results are very similar. DAS28 does not seem to correlate with any increased 









6.5  Statistical Analysis  
 
Table 6.19  Descriptive characteristics of the population(s). 








Female (%) 162 (74.0) 110 (73.8) 52 (74.3) - 
Mean Age (SD) 62.1 (14.3) 63.9 (12.4) 58.1 (17.1) <0.0045 
Positive AH (%) 73 (33.3%) 69 (46.3%) 4 (5.7%) <0.001 
Positive SEB (%) 54 (24.7%) 40 (26.9%) 14 (20%) 0.27 
Positive SEC (%) 71 (32.4%) 57 (38.23%) 14 (20%) 0.007 
Positive TSST (%) 0 (0) 0 (0) 0 (0) - 
Any Toxin (%) 103 (47.0%) 84 (56.4%) 19 (27.1%) - 
Mean DAS (SD) - 3.6 (1.3) - - 
*p value obtained by chi squared test. 
No date of birth was obtained from the participants. Instead, participants indicated 
their age based on 10 year age brackets. It was assumed that there was an even spread 
of age within each bracket. The ages halfway through each age bracket were used in a 






Table 6.20  Odds ratio of S.aureus positivity in RA. 
Odds of positivity OR 95% CI P value* 
Unadjusted 3.47 1.87 6.44 0.000 
Adjusted for age 3.25 1.74 6.09 0.000 
Adjusted for age and gender 3.38 1.78 6.43 0.000 
Adjusted for age, gender and smoking 3.56 1.87 6.76 0.000 
*p value obtained by chi squared test. 
 
In patients with RA, is disease activity associated with toxin positivity? Initially a t-
test was carried out to calculate the mean DAS score of the positive and negative RA 
samples: 
Mean DAS (positive) = 3.6 (1.36) 
Mean DAS (negative) = 3.61 (1.30) 
Furthermore, a logistic model was used to see if the DAS score can explain positivity. 
This result was not significant (OR 1.00; CI 0.78, 1.28). We can conclude that DAS 
has no bearing on the likelihood of a patient tasting positive for a staphylococcal 
enterotoxin. 
 
Table 6. 21 Number of positive samples divided by disease activity status. 
DAS score Total n Positive n (%) 
<2.6 43 24 (55.8) 
2.6 – 5.19 87 50 (57.5) 




Table 6.22  Odds ratio of S.aureus positivity by toxin. 
Positive Toxin OR 95% CI P value* 
AH Unadjusted 14.23 4.93 41.05 0.000 
 Adjusted for age 13.65 4.71 39.60 0.000 
 Adjusted for age and gender 15.33 5.15 45.68 0.000 
 Adjusted for age, gender and smoking 16.63 5.52 50.10 0.000 
SEB Unadjusted 1.47 0.74 2.92 0.275 
 Adjusted for age 1.34 0.66 2.71 0.414 
 Adjusted for age and gender 1.34 0.65 2.76 0.423 
 Adjusted for age, gender and smoking 1.42 0.69 2.94 0.346 
SEC Unadjusted 2.48 1.27 4.85 0.008 
 Adjusted for age 2.41 1.22 4.78 0.012 
 Adjusted for age and gender 2.48 1.23 4.95 0.011 
 Adjusted for age, gender and smoking 2.62 1.29 5.31 0.008 
*p value obtained by chi squared test. 
 
6.6  Questionnaire Results Discussion 
 
6.6.1  Age and Gender 
 
The mean age group of both populations was similar; the average age was 65-74 years 
in the RA cohort and 55-64 years in the fracture cohort. 
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Each patient population is made up of a similar ratio of females: males; 3:1. It has 
been consistently reported that women are three times more likely than men to have 
RA (73.1% female to 26.9% male) (Doran, 2002; Shipley, 2009). Our results, in Table 
6.19, support this with the gender split being 73.8% female to 26.2% male in the RA 
population. However, the gender distribution is also very similar in the fracture cohort 
(74.3% female to 25.7%). According to the most recent census (ONS, 2011), 
Lancaster’s population was 52% female, therefore the high number of subject females 
cannot simply be explained by the proportion in the general population. The gender 
distribution of both populations sampled may be explained in a couple of ways. There 
may just have been more female patients within each hospital department; this could 
have been at random or because women are more likely to have RA or sustain 
fractures. As the average age of the fracture population was 55-64 years old, it can be 
assumed that most of the women were post-menopausal and more prone to suffering 
from osteoporosis (Cawthon, 2011).  Men also suffer from osteoporosis and low bone 
mass in old age but at a much lower rate; women are more susceptible at a rate of 3:1 
(NOF, 2002).The second option is that female adherence to the study was better in 
each population; women may be more inclined to take part.  
 
6.6.2  Ethnicity 
 
According to the 2011 census, Lancaster had a population of 138,375, of which 95.6% 
identified as white. The high percentage of white people in both sample populations- 
98.7% in RA and 100% in fracture – is similar to the demographic of the general 
population in Lancaster. 
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6.6.3  Smoking 
Overall, the rheumatology cohort consisted of fewer people who had never smoked, 
more people who had smoked in the past, and of the individuals who still smoked, 
they smoked more cigarettes per day. This may agree with previous findings, that 
smoking plays a role in the development of RA (Sugiyama, 2010). Smoking is linked 
to infection, which may explain why S.aureus was detected in more of the patients 
with RA (Stampfli, 2009). 
 
6.6.4  Genetics 
 
GWAS have identified a number of genes that contribute to a genetic predisposition to 
RA and inheritability of RA is estimated at 60% (MacGregor, 2000; Perricone, 2011). 
Of the RA respondents, 72 (48.3%) individuals indicated that 102 of their blood-
relatives have/had RA, whereas only 12 (17.1%) of the fracture patients said that 13 of 
their relatives have/had RA. Coupled with the literature, these data infer that genetics 
may play a role in the development of RA. 
 
6.6.5  Birthplace 
 
The information gathered on the region that each patient was born in shows us that, in 
both populations, people were born all over the UK, however the vast majority (68-
70%) were born in, and have remained in the North West. 
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6.6.6  Birth order 
 
It has been hypothesised that being 1st-3rd born in a family increases the chances of 
developing RA. This is based on the hygiene hypothesis and the assumption that 
having more older siblings means that an individual will be introduced to pathogens 
earlier in life (Strachan, 1989). In both populations, the majority (40-42%) of 
participants were 1st born, followed by 2nd born, 3rd born, 4th born and 5th+ born. Of 
these, similar percentages were positive for S.aureus within each category. 
Sayeeduddin et al. reported that of their rheumatology cohort (n=115), 65-70% were 
1st-3rd born children, with 32.2% 1st born. In comparison, our rheumatology cohort is 
85.2% 1st-3rd born, with 41.6% (Sayeeduddin, 1994). On the face of it, there seems to 
be an association with an early birth order and the chance of developing RA. 
However, if we also compare these data to our fracture cohort, the results are very 
similar, with 85.7% 1st-3rd born; 40.0% 1st born. According to these data, birth order 
does not seem to show any difference in the S.aureus positivity between the two 
populations. 
 
6.6.7  Sharing a bedroom 
 
In the literature, it has been described that women who shared a bedroom as a child, 
were less likely to be RF-positive (Edwards, 2006). It would be expected that those 
who shared a bedroom during their childhood would have more opportunity to come 
into contact with pathogens. In both the RA and fracture populations, if the 
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participants answered “Yes” to sharing a bedroom, roughly similar percentages of the 
total of each population were positive or negative for S.aureus toxins. However, of all 
the participants that said “No”, the vast majority, tested positive for S.aureus. The 
presence of the bacterium may be because they encountered S.aureus later on in life, 
when they weren’t able to mount the correct immune response to clear it. If they had 
shared a bedroom, they would have been more likely to have been ‘infected’ at a 
younger age (Strachan, 1989). 
 
6.6.8  Fathers’ occupation 
 
Fathers’ occupation has been used as a measure of SES (Edwards, 2006). It has been 
said that children of fathers with a white collar job, who were considered to have a 
higher SES, were more likely to be RF positive (in women only) (Edwards, 2006). 
The majority of the fathers’ occupations were classed as “blue collar”. This also 
reflects the average age of the sample populations, which are 55-74 collectively. 
These patients would have been born between the 1930s and 1960s; decades where 
there were a lot of manual jobs. There seems to be little difference between the RA 
and fracture patient populations with regards to the influence of father’s occupation on 
producing a urine sample positive for S.aureus. The use of the father’s occupation as a 
marker for SES is controversial. The status of a father’s job does not always determine 





6.6.9  Area 
 
Studies have shown that people living in urban areas are more likely to develop an RA 
than individuals in rural areas (Soloman, 1975; Chou, 1994; Carmona, 2002). The 
questionnaire data collected, seems to show that the type of area lived in as a child or 
currently as an adult, does not influence whether an individual will be positive for 
S.aureus or develop RA.  
 
6.6.10  Farm 
 
In summary, the percentage of fracture patients who answered “Yes” or “No” and who 
were positive for S.aureus, were very similar. However, the percentage of 
rheumatology patients testing positive for S.aureus, regardless of their answer, was 
nearly double. Also, within this cohort, patients answering “Yes” were 7% more likely 
to have S.aureus in their urine. 
 
6.6.11  Pets 
 
On comparison of each population, there is little difference between the proportions of 
the animals within each household during the participants’ early childhoods. There is 
no particular pet that stands out as contributing to an increased chance in S.aureus 
positivity or to the development of RA. 
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6.6.12  RA population  
 
The DAS28 value did not, in this case, show any correlation to the presence of 
S.aureus in the urine of the RA patients. 
On average, patients start to develop symptoms at 49 years of age, gaining a formal 
diagnosis of RA at the age of 51. Diagnosis within this population occurred at a 
slightly younger age than on average (Symmons, 2002). In the sample population, 
patients had had their RA diagnosis for 0-52 years, 13 years on average. 
The vast majority of the RA respondents named winter as the/a season where they felt 
that their RA was worse. This could be due to the low temperatures endured during a 
UK winter, which make even a healthy individual’s joint more stiff and immobile. 
Additionally, some patients felt that their RA symptoms were worse when there was a 








6.7  Discussion 
 
6.7.1   Toxins 
 
The odds ratio for each individual toxin, unadjusted, adjusted for age, adjusted for age 
and gender and adjusted for age, gender and smoking status, are shown in Table 6.22. 
TSST-1 is not shown in the table as the western blot analysis didn’t show any protein 
bands at the level of TSST-1 (24kDa). The odds ratio for the presence of both AH and 
SEC were significant (p value <0.05), and there was little difference once results were 
adjusted for age, gender and smoking status.  
AH is a 33kDa pore forming toxin that is secreted by the majority of S. aureus strains 
and is active against a wide range of mammalian cells (Bhakdi, 1991; Gray, 1984). 
AH also induces the release of cytokines and chemokines such as IL-6, IL-1β, IL-1α, 
IL-8, TNF-α, KC and MIP-2 (Bhakdi, 1989; Dragneva, 2001; Hruz, 2009); many of 
which are strongly implicated in RA (Brenner, 2015). Along with pro-inflammatory 
cytokines such as TNF-α and IL-6, large amounts of IL-1β released from macrophages 
and monocytes in response to AH (in cultured cells) (Bhakdi, 1989). Such mediators 
are shown to cause joint damage; directly by activating osteoclasts or indirectly by 
stimulating synovial macrophages to produce further inflammatory cytokines. 
Increased production of IL-1β has even been linked to the development of a number of 
autoinflammatory syndromes (Masters, 2009). TNF-α and IL-1 are considered to work 
synergistically to induce the body into a shock-like state (Ikejima, 1988). However, 
human leukocytes, although originally considered to have high resistance to 
endotoxins, have shown to be particularly vulnerable to the effects of AH (Bhakdi, 
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1989). It is also understood that AH promotes the adherence of neutrophils to 
endothelial cells (Fast, 1988), an important step in the early inflammatory reaction.  
AH is secreted as a monomeric protein and has a pore-forming beta-barrel structure; 
which binds to specific, but unidentified cell surface receptors to create heptameric 
pores that lead to DNA fragmentation and subsequent apoptosis (Tanaka, 2011). AH 
is particularly defined by its ability to kill healthy cells by apoptosis. Once the pore 
inserts itself in the membrane, rapid loss of vital molecules occurs; there is dissipation 
of the membrane potential and ionic gradients and osmosis-induced cell wall rupture 
(Tweten, 1983). 
AH is encoded by the hla gene and is an important virulence factor for S. aureus, 
which can lead to ailments such as sepsis and septic arthritis (Nilsson, 1999). For 
example, Nilsson et al. inoculated mice with AH and describe inflammation, joint 
damage and weight loss as a consequence (Nilsson, 1999). Furthermore, Fast et al. 
have suggested that strains of staphylococci that produce exotoxin, such as TSST-1, 
are able to inhibit the migration of polymorphonuclear neutrophils (PMN) to sites of 
infection by the production of TNF (Fast, 1988). 
AH induces colloid osmotic lysis in erythrocytes (Bhakdi, 1984) and necrosis or 
apoptosis in nucleated cells (Essmann, 2003; Jonas, 1994). Pore formation does not 
always lead to cell death and studies have shown that cells can survive and recover 
from a limited number of small pore formations (Thelestam, 1983; Walev, 1994; 
Valeva, 2000). S.aureus AH pores are relatively small and are calcium impermeable 
and can therefore not be repaired by the wounded membrane response (Walev, 1994). 
Conversely, streptolysin O inflicts mechanical lesions and large pores that rely on the 
rapid calcium-dependent replacement of ions in the attacked cell (McNeil, 2005; 
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Idone, 2008). The latter repair mechanism is faster than that for the AH pores and both 
differ at a molecular level, particularly in the role played by p38 (Husmann, 2006).  
Compared to AH, there is much less in the literature about SEC and its possible link to 
autoimmune development. Our results have shown a significant presence of SEC in 
the urine of patients with RA or closed fractures; although the OR for SEC is 
considerably lower than AH. The pathological roles of SEC in relation to 
inflammation have been discussed by Kuroishi et al. in relation to bovine 
staphylococcal mastitis (Kuroishi, 2003). Strains isolated from cases of bovine 
staphylococcal mastitis were shown to produce SEs, the main one of which was SEC. 
Results concluded that SEC stimulates mononuclear cells to activate PMNs that 
migrate to the mammary glands, causing inflammation. Previous cases have shown 
staphylococci to cause subclinical and/or chronic mastitis because of persistent 
infection in the mammary gland (Sutra, 1994). It has been proposed that the chronic 
nature of bovine staphylococcal mastitis suggests that S.aureus or (part of) its 
products, in particular the SAgs, could interfere with the proper development of a 
protective immune system (Ferens, 1998). This appears to show that staphylococcal 
enterotoxins are able cause subclinical inflammation and remain in the body, exerting 
their effects, for a long period of time. 
 
6.7.2  Inflammation 
 
The literature suggests that up to 20% of the general population are permanent, 
asymptomatic carriers of S.aureus, 60% are intermittent carriers and 20% never carry 
S.aureus; based on results from nasal and nasopharyngeal swabs (Kluytmans, 1997; 
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Ansari, 2016). A number of studies were compared and a mean of 30% of the general 
population were positive for the presence of S.aureus (Fall, 2014; Treesirichod, 2014; 
Lucia Preoţescu, 2013; Kuehnert, 2006; Weidenmaier, 2012; Graham, 2006, den 
Heijer, 2013; Ateba Ngoa, 2012). 
The presence of the bacterium in the nasal passage is not unexpected as S.aureus is a 
commensal bacterium of the normal flora found on the moist squamous epithelium of 
the anterior nares (Ansari, 2016; Williams, 1963). The nasal flora of the upper 
respiratory tract is made up of nearly 200 species of bacteria and is established within 
48 hours of birth. The normal flora is influenced by an individual’s age, sex, race, 
genetics, diet, nutrition and stress levels. Staphylococci are generally non-pathogenic 
and produce fatty acids to prevent the growth of fungi and yeast on the skin (Todar, 
2012). The lower respiratory tract does not have commensal bacteria however, as it is 
virtually pathogen free. This is due to the action of the ciliated epithelium that lines 
the tract. Any microbes that manage to reach the lower respiratory tract are swept 
upwards by the action of the mucociliary blanket that lines the bronchi (Todar, 2012). 
Consequently, in a healthy individual, the lungs are pathogen-free. Defective host 
immunity and the ability of staphylococci to evade host innate immunity results in the 
ability of the nasal passages to harbour pathogenic S.aureus that may see it’s 
opportunity to infect (Ansari, 2016; Quinn, 2007). This reservoir promotes the 
multiplication and spread of the bacterium.  
Further to the figure of 30% positivity in the general population, unpublished data has 
suggested that S.aureus toxins can only be detected in the urine of 18% of the general 
population (Bull, 2014). Compared with our result of 56.4% S.aureus positivity in RA 
patients, there is a substantial difference when compared with either base figure. As 
the unpublished figure, of 18%, was generated when detecting the same four 
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staphylococcal toxins in urine, it is perhaps a better comparison. This would make the 
presence of S.aureus three times higher in the urine of the RA patients than the 
general population. 
The urine from patients with closed fractures has demonstrated the presence of at least 
one staphylococcal enterotoxin in 27.1% of the samples. This is similar to the figures 
for the general population, according to the data associated with nasopharyngeal 
carriage (Fall, 2014; Treesirichod, 2014; Lucia Preoţescu, 2013; Kuehnert, 2006; 
Weidenmaier, 2012; Graham, 2006, den Heijer, 2013; Ateba Ngoa, 2012). However, 
these figures are not comparable due to the differing route and conditions that the 
bacterium and/or toxins have gone through. Treatment of a fracture requires frequent 
visits back to the hospital for outpatient appointments. It is well known that the 
S.aureus carrier rates of hospital personnel and patients can be high, approximately 
50% (Millian, 1960; Kluytmans, 1997; Rongpharpi, 2013). Furthermore, in the study 
conducted by Rongpharpi et al., the orthopaedic department had the highest S.aureus 
presence in the hospital (Rongpharpi, 2013). This added exposure could contribute to 
the increased prevalence of S.aureus toxins in the urine of patients with closed 
fractures. 
It is not known exactly why the presence of S.aureus in urine is so much higher in 
patients with RA. Due to the fact that all of the patients recruited already had RA, we 
can only speculate whether the S.aureus presence could be a cause or an effect of the 
disease. It may be that individuals were infected with a strain of S.aureus at some 
point earlier in life, since which time, the bacteria have remained in the body, 
avoiding clearance by the immune system by hiding in immune privileged sites. The 
evasion of bacteria/pathogens from the immune system is not a new concept (Finlay, 
2006). This phenomenon has been described in relation to viruses, bacteria and 
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parasites; for example, Ebola, HIV, TB and malaria (Morens, 2004; Fauci, 2005; 
Audet, 2015). Pathogens can evade the immune system using a number of strategies, 
such as antigenic hyper variability, subverting or killing immune cells/phagocytes or 
inhibiting complement; to name but a few (Finlay, 2006).  Bacterial pathogens have 
also shown an ability to alter downstream inflammatory cytokines, however, the 
molecular mechanisms by which this is achieved is not known in most cases due to 
the complexity of bacteria and the diverse array of effectors and other immune 
modulators produced by these organisms (Tato, 2002). However, S.aureus is an 
example of a pathogen that can specifically target a cytokine pathway to enhance 
pathogenesis. The bacterium produces protein A which is able to bind directly to the 
TNFα receptor, TNFR1, on respiratory epithelium, which then potentiates a 
chemokine and cytokine cascade and subsequent disease (Gomez, 2004). TNFα is 
known to play a major role in RA pathogenesis (Brenner, 2015). 
As an exact molecular cause of RA is unknown, part of the S.aureus bacterium or the 
toxins that it produces could perhaps be an antigen that stimulates the immune system 
into eliciting the inappropriate immune response, stimulating the production of the 
autoantibodies that attack the synovial joints (Cusick, 2012). Autoantibodies cause the 
chronic and systemic inflammation characteristic of RA. SEB in particular has been 
implicated in the disease pathogenesis of RA and other autoimmune diseases (Li, 
2015). 
Typically, small proteins (<70kDa) can be filtered through the glomeruli of the 
kidneys and are found in the urine of a healthy individual (Wartiovaara, 2004; 
Pavenstadt, 2003; Akilesh, 2008). Some of the toxins are small enough to be filtered 
through into the urine; however, their amino acid structure may have been altered 
whilst in the body and/or they may become part of a larger protein complex. As shown 
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in Chapter 3, the toxins are susceptible to degradation by proteolytic enzymes such as 
trypsin and pepsin. Both of these enzymes are naturally present in the human body as 
part of the gastric and pancreatic juices of the digestive system (Boundless Biology, 
2016). Assuming that at least some of the bacterial toxins pass through the digestive 
system, it is likely that these activated enzymes could alter the amino acid makeup of 
the proteins. Alternatively, the kidneys can become leaky, allowing large proteins and 
larger protein complexes into the urine (Chamberlain, 2003). This can happen when 
an individual’s body is under stress, such as chronic inflammation. Diabetes, SLE, RA 
and infection have all been described as being able to cause damage to glomeruli, 
resulting in nephrotic syndrome (leaky kidneys) (Hull, 2008; Kodner, 2009). It can 
also occur as a side-effect of medicines and treatments, as well as a consequence of 
various poisons or toxins. Nephrotic syndrome is characterised by proteinuria that was 
described by Richard Bright’s series of descriptions of “albuminous urine” (Hull, 
2008; Cameron, 2002). In our western blots, strong bands were seen in many of the 
lanes at the level of albumin, approximately 66.5kDa (Sigma Aldrich – Human 
Albumin). This supports a claim that many of the patients sampled were perhaps 
suffering from nephrotic syndrome, possibly caused by inflammation, which was 
allowing the filtration of staphylococcal toxin complexes through the kidney and into 
the urine.   
Alternatively, the inability to clear S.aureus from individuals with RA may be due to 
the fact that such patients already have a lot of demand on their immune system, 
which is both attacking and trying to defend itself. The white blood cells (WBCs) may 
not be present in the quantities necessary to kill and phagocytose enough of the 
bacteria and toxin products. Neutrophils circulate in the blood for approximately 10 
hours, during which time all of an individual’s blood passes through the capillary 
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venules of the lungs numerous times. Here, the neutrophils move more slowly than the 
red blood cells (RBCs), meaning that an estimated 50% of all neutrophils are present 
in the lung at any one time; which is a very effective mechanism for clearing the lungs 
of pathogens (Morris, 2007). During inflammation or fever, neutrophils and RBCs 
appear to flow through the venules at the same speed, thus reducing the concentration 
of WBCs in the lung, leaving the lungs more vulnerable to invasion by pathogens 
(Morris, 2007). 
Similarly, the treatment of RA often involves the prescription of a combination of 
drugs that suppress the immune system.   Severe RA is treated with high dose 
corticosteroids alongside immunosuppressive and cytotoxic drugs such as 
azathioprine, cyclophosphamide and mycophenolate (Murphy, 2008). The drug 
combinations are used to suppress the immune system, reducing the symptoms rather 
than treating the cause. The use of glucocorticoids (GCs) as an immunosuppressant 
have been shown to increase the risk of infection 4-fold (in a dose dependent manner) 
(Listing, 2013). The use of DMARDs and biologics has led to side effects such as a 
reduction in circulating neutrophils and increased incidence of infection (Choy, 2011). 
Since the introduction of biologic treatments 15 years ago, at least 2-fold increased 
rates of infection in RA patients have been reported (Strangfeld, 2009; Thomas, 
2004). New biologics and the more recent biosimilars are the most advanced 
treatments for RA. TNF-α inhibitors are often prescribed and are used to reduce the 
effect of TNF-α, a major pro-inflammatory cytokine implicated in the disease 
pathogenesis of RA (Brenner, 2015). Infliximab and adalimumab are monoclonal anti-
TNF-α antibodies and etanercept is a TNF-α fusion protein (Strangfeld, 2009). The 
introduction of biologics and biosimilars has proven to be a good treatment option for 
RA sufferers, particularly those for whom conventional DMARDs do not sufficiently 
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control their disease. However, these benefits have also brought with them an apparent 
increased risk of infection compared to patients prescribed DMARDs alone (Listing, 
2005). In particular, increased risk and reactivation of HZV and TB have been 
documented (Keane, 2001; Mohan, 2004). 
Due to the inflammatory nature of RA and the immunosuppressive treatment, 
infection in RA is not uncommon. However, infection is not normally attributed to 
S.aureus, except in cases with congestive heart failure and following an indwelling 
catheter (Sams, 2015). Fewer studies have looked at the presence of S.aureus in RA, 
with research often focussing on the presence of pathogens perceived to be more life-
threatening (Sams, 2015; Carmona, 2003; Wolfe, 2006). Although S.aureus can be a 
member of the commensal flora, pathogenic strains can be opportunistic (Cohen, 
2016). This can result in severe bacteraemia, particularly in the immunocompromised 
(Richards, 2015). Bacteraemia caused by S.aureus is associated with higher morbidity 
and mortality than bacteraemia caused by other pathogens (Naber, 2009).  
Other bacteria possibly linked to RA include P.gingivalis and P.mirabilis. P.gingivalis 
is a periodontal pathogen with a unique ability to citrullinate proteins. Anti-CCP 
antibodies are a characteristic of RA, included in the 2010 RA classification criteria 
(Shipley, 2009; van Venrooij, 2011; Aletaha, 2010). However, it is possible to have 
anti-CCPs without having RA (Lima, 2010). P.gingivalis can be detected in 25% of 
healthy individuals but is not thought to be a normal inhabitant of a healthy 
periodontal dentition (Griffen, 1998). Results of a study by Wegner et al. suggest that 
the citrullination mediated by P.gingivalis occurs in both the bacterial proteins and 
host proteins, thus providing a potential molecular mechanism of generating the 
epitopes to which the body has no immunologic tolerance (Wegner, 2010). Anti-CCP 
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antibodies have been seen following various microbial infections, particularly 
following 37% of TB cases (Lima, 2010; Mori, 2009).  
P.mirabilis is a member of the commensal gut flora but, like S.aureus, can become 
pathogenic when given the opportunity to infect a wound or the urinary tract. UTIs are 
much more common in patients with RA (Tishler, 1992). Studies have shown that 
isolation of P.mirabilis in the urine of RA patients can be two-fold higher than 
controls. Levels of P.mirabilis are particularly increased in females with RA (63%) 
compared with males with RA (50%); and even more so than in healthy female (32%) 
and male (11%) controls (Ebringer, 1996). Furthermore, such antibodies were found 
to be in higher titres in the sera and urine of RA patients compared to controls 
(Rashid, 2007; Ebringer, 2010). It is likely that P.mirabilis infection is a consequence 
of RA, taking advantage of the compromised immune system.  
EBV has been linked to the pathogenesis of RA. Similar to S.aureus, EBV is 
abundantly present and is often first encountered early in life. In developing countries, 
most children have encountered the virus before the age of 5, whereas this is often 
delayed in developed countries (Haahr, 2004; Henle, 1967; de-The, 1975).  Haahr et 
al. looked at the prevalence of EBV in an area with a high incidence of MS, an 
autoimmune disease whose pathogenesis shows some similarities to that of RA. 
Interestingly, all of the MS patients were seropositive for EBV antibodies (Haahr, 
2004). 
A basic overview of the immunological response to an antigen and a simplified 
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Figure 6.7   A basic diagram to show the process of inflammation  - adapted from 
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Figure 6.8  A basic diagram to show the process of inflammation following a fracture - 
adapted from K.Wassung (Wassung, 2012). 
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Macrophages are derived from monocytes following monocytopoesis. Macrophages 
reside in almost all of the tissues in the body, in numerous forms, scavenging for 
potential pathogens by amoeboid movement (Ovchinnikov, 2008). Similarly, mast 
cells are also found in most tissues of the body, particularly in locations that are in 
close contact with the external environment; such as skin, airways, and intestines. 
Activation of mast cells results in the release of a variety of soluble factors including 
TNF-α (Urb, 2012).  
White blood cells such as monocytes and neutrophils reside in the blood, continuously 
circulating through the body. Monocytes are highly plastic and heterogeneous, and 
they are able to change their functional phenotype in response to an environmental 
stimulus; they also have the ability to differentiate into inflammatory or anti-
inflammatory subsets. Upon infection, monocytes are rapidly recruited to the affected 
tissue, where they differentiate into macrophages or dendritic cells (Yang, 
2014). Macrophages are present in almost all of the tissues in the body, scavenging for 
potential pathogens by amoeboid movement (Ovchinnikov, 2008). Mast cells are also 
found in most human tissues, particularly in locations that are in close contact with the 
external environment. Activation of mast cells results in the release of a variety of 
soluble factors including TNF-α (Urb, 2012).  
Inflammation is a major and important part of the healing process. Ordinarily, aside 
from the pain and restricted movement caused by inflammation, the process is 
beneficial and repairs the damage. However, the immune system of fracture patients is 
under a considerable burden due to the trauma-induced inflammation. Furthermore, an 
individual with a fracture needs to repeatedly visit the hospital, where the chance of 
bacterial cross-infection is high. These two factors together go some way to explain 
why staphylococcal enterotoxins can be detected in the urine of patients with closed 
fractures. Similarly, in those individuals suffering from RA, the inflammation is 
triggered repeatedly, causing irreparable damage and chronic pain. The immune 
system is compromised, as a consequence of both the chronic inflammation and 
immunosuppressive drugs. 
There is an apparent correlation between inflammation and a dysfunctional immune 
response within autoimmune disease. Vella et al. determined that inflammation in 
conjunction with the activation of other T cell stimulatory molecules can help T cell 
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growth and increase the number of helper T cells. In experiments, the researchers 
injected mice with an antigen that caused significant death of the antigen-responsive T 
cells; however, when inflammation was present, the death of these cells was 
prevented. In addition, some bacteria have a lipopolysaccharide (LPS). It appears that 
LPS can play a role in causing inflammation, and keeping activated T cells alive 
(Vella, 1998; Wassung, 2012). This mechanism could mean that T cells that have 
come into contact with, and mounted an immune response towards staphylococcal 
toxins could actually multiply and remain active; exerting their immunological effect 
repeatedly and long after the toxin is removed. 
The healing of fractures and broken bone is a well-orchestrated sequence of biological 
events (Bigham-Sadegh, 2015). Inflammation occurs immediately at the site of the 
fracture and persists for up to 5 days. This event is important as the damaged bone 
tissue dies back and is removed by osteoclasts. The dead cells stimulate the release of 
cytokines, initiating the healing process (Bigham-Sadegh, 2015). Fibroblasts in the 
blood lay down granulation tissues, leading to the early formation of cartilage and 
fibrocartilage. As time goes on, the inflammation subsides and soft callus formation 
commences (4 days to 3 weeks post fracture), followed by hard callus (6-12 weeks 
post fracture) and eventually bone remodelling (years post fracture) (Bigham-Sadegh, 
2015). 
Other than external factors, there may also be internal immunological factors in the 
fracture patients to consider. The increased presence of staphylococcal toxins in urine 
when suffering from a fracture compared to the general population can only be 
speculated. As discussed previously, when the body is under stress the kidneys may 
become leaky as a way of ridding the body of surplus pathogens and toxins, relieving 
the immune system of some of the burden (Chamberlain, 2003). The trauma causing 
the fractured bone(s) will no doubt have inflamed the tissue surrounding it. This acute 
inflammation may, like the chronic inflammation associated with RA, have an effect 
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on the kidneys, allowing them to permit larger proteins through the glomeruli and into 
the urine. The patients included in this study had closed fractures; therefore for the 
chance of the S.aureus bacterium entering the body through a break in the skin is 
highly unlikely and does not explain the increased number of patients with 
staphylococcal toxin in their urine. 
Alternatively, the inability to clear S.aureus in individuals with closed fractures may 
be due to the fact that such patients already have a demand on their immune system, 
due to acute inflammation. The WBCs may not be present in the quantities necessary 
to kill and phagocytose the toxin. As described previously, neutrophils circulate in the 
blood for approximately 10 hours, during which time all of on individuals blood 
passes through the capillary venules of the lungs numerous times. Here, the 
neutrophils move more slowly than the RBCs, meaning that an estimated 50% of all 
neutrophils are present in the lung; which is a very effective mechanism for clearing 
the lungs of pathogens (Morris, 2007). During inflammation or fever, neutrophils and 
RBCs appear to flow through the venules at the same speed, thus reducing the 
concentration of WBCs in the lung, leaving the lungs more vulnerable to invasion by 









Chapter 7  RESULTS: MASS SPECTROMETRY 
7.1  Theoretical Target Proteins 
 
Detection of SEB, SEC1 and TSST-1 in food and patient samples is typically 
performed using immunological techniques; however, commercial kits available for 
the detection of enterotoxins, SEA to SEE, suffer from serious limitations with respect 
to sensitivity, specificity and suitability for complex matrices.  A number of reports 
have been published on the detection of staphylococcal enterotoxins in food matrices 
using mass spectrometry as the detection method, with the aim of selective and 
sensitive identification and quantitation of such toxins (Andjelkovic, 2016; Callahan, 
2006; Sospedra, 2011).   
Herein we report the analysis of staphylococcal enterotoxins, SEB and SEC1, along 
with TSST-1 in patient samples via mass spectrometric detection using a Shimadzu 
ion-trap time-of-flight tandem mass spectrometer (LCMS-IT-TOF), to selectively 







7.1.1  Toxin Identification 
 
7.1.1.1 In silico digests 
 
Peptide sequences for SEB, SEC1 and TSST-1 were obtained from the UniProtKB 
online database, reference codes and links shown in Table 7.1.  Each UniProtKB 
sequence was used to generate peptide masses for tryptic digests via ExPASy peptide 
mass calculation tool.  PeptideMass calculations were performed with iodoacetamide 
treatment of cysteines, digested with trypsin enzyme allowing for up to 2 missed 
cleavage sites.  Monoisotopic mass-to-charge values were obtained for [M+H]+, 
[M+2H]2+ and [M+3H]3+ peptides between 500 – 1,000 Da.  Example data generated 
via UniProtKB and ExPASy is shown below, Figure 7.1.  
 
Table 7.1 UniProtKB protein database identification code for target proteins AH, SEB, SEC1 and 
TSST-1, full amino acid sequence presented in appendix. 
Toxin Uniprot Reference Code 
SEB P01552 http://www.uniprot.org/uniprot/P01552 
SEC1 P01553 http://www.uniprot.org/uniprot/P01553 
TSST-1 P06886 http://www.uniprot.org/uniprot/P06886 
AH P09616 http://www.uniprot.org/uniprot/P09616 
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Figure 7.1 ExPASy in silico theoretical tryptic digestion of SEB with iodoacetamide 
treatment and up to 2 missed cleavages.  Data displays amino acid sequences, cleavage sites and 
monoisotopic mass from [M + 3H]3+ peptides. 
 
7.1.1.2 Toxin Standards MS1 Screening 
 
Tryptic digests of standard compounds for SEB, SEC1 and TSST-1 were combined in 
a single sample and analysed via a generic 30 minute LCMS method using a C18 
column with a water/acetonitrile gradient with 0.1% (v/v) formic acid modifier.  
Resultant LCMS Total Ion Current (TIC) MS1 data was mined for extracted ion 
chromatograms (XIC) corresponding to the monoisotopic m/z values obtained from 
the in silico digestions, example shown in Figure 7.2. Mass spectra peaks that could 
be assigned within 5 ppm mass accuracy to a predicted monoisotopic peptide mass 
and which also displayed the correct isotopic distributions were considered for further 
confirmation via MS2 fragmentation experiments.  The monoisotopic masses observed 
in the MS1 of the peptides from toxin standard scans are reported below in in Table 
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7.2, Table 7.3 and Table 7.4, additional tryptic peptides are expected but were not 
observed. 
 
Figure 7.2  Extracted ion chromatogram of LCMS MS1 analysis of standard sample 
containing SEB, SEC1 and TSST-1 toxins.  Target peptides predicted, in order from top to 
bottom (423.25; 760.37; 564.77; 746.85; 789.40; 705.37; 552.30; 529.61; 485.25; 654.84; 774.91; 




Table 7.2 SEB peptides observed from LCMS analysis of peptide standard compounds; 
matched against predicted peptides generated in silico. 







Start Finish Missed 
Cleavages 
VLYDDNHVSAINVK 793.9123 2 53 66 0 
KTNDINSHQTDKR 778.8924 2 125 137 2 
TNDINSHQTDKRK 778.8924 2 126 138 2 
ESQPDPKPDELHK 760.3730 2 28 40 0 
SIDQFLYFDLIYSIKDTK 737.0524 3 67 84 1 
LGNYDNVRVEFK 727.3753 2 85 96 1 
DVKIEVYLTTKK 718.9216 2 254 265 2 
KVTAQELDYLTR 714.8449 2 181 192 1 
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VFEDGKNLLSFDVQTNKK 694.7004 3 163 180 2 
HYLVK 659.3875 1 193 197 0 
VTAQELDYLTR 654.8433 2 182 192 0 
VLYDDNHVSAINVK 529.6112 3 53 66 0 
LGNYDNVRVEFK 485.2532 3 85 96 1 
 
Table 7.3 SEC1 peptides observed from LCMS analysis of peptide standard compounds; 
matched against predicted peptides generated in silico. 







Start Finish Missed 
Cleavages 
FLAHDLIYNISDK 774.9064 2 71 83 0 
ESQPDPTPDELHK 746.8493 2 28 40 0 
NTISFEVQTDKK 705.3672 2 168 179 1 
SVTAQELDIKAR 665.8699 2 180 191 1 
SVTAQELDIK 552.3008 2 180 189 0 
DNVGK 532.2725 1 126 130 0 
DNVGKVTGGK 487.7669 2 126 135 1 
IEVHLTTK 470.7767 2 257 264 0 
NTISFEVQTDKK 470.5805 3 168 179 1 
SVTAQELDIKAR 444.2490 3 180 191 1 
NFLINKK 438.7687 2 192 198 1 
NYDKVK 383.7083 2 87 92 1 




Table 7.4 TSST-1 peptides observed from LCMS analysis of peptide standard compounds; 
matched against predicted peptides generated in silico. 







Start Finish Missed 
Cleavages 
TIEAEIN 789.3988 1 228 234 0 
KFEYNTEKPPINIDEIK 693.3650 3 211 227 1 
HQLTQIHGLYR 683.3729 2 175 185 0 
SSDKTGGYWK 564.7696 2 186 195 1 
LPTPIELPLK 560.8524 2 134 143 0 
VDLNTKR 423.2456 2 102 108 1 
 
 
7.1.1.3 MS2 Fragmentation Experiments 
 
For the initial MS1 scan the instrument method performed a single scanning event 
measuring m/z values between 300 – 1000 Da, Figure 7.2. Individual peaks were 
allocated retention time windows called “Segments”, each Segment was then 
expanded to include an MS2 fragmentation experiment which isolated a 3 Da wide ion 
packet which contained the tryptic peptide eluted in that Segment.  Fragmentation 
experiments were conducted on this ion packet to generate an MS2 product ion scan 
containing fragment ions of the isolated peptide precursor.  Peptide molecules 
fragment predictably and MS2 spectra were compared against a list of masses 
corresponding to calculated fragment ions generated in silico, Figure 7.3. Toxin 
compounds could be assigned unequivocally through matching MS2 ions with the 
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predicted fragments generated from the peptide sequences described in Table 7.2, 
Table 7.3 and Table 7.4. Table 7.5.contains a list of peptides that were identified 
through the observed product ions that correspond to predicted y/b fragments.  Figure 
7.4 shows an example MS1 scan with the peptide precursor selected for the 
MS2 experiment highlighted. Figure 7.5 shows the resultant MS2 spectrum obtained 
from the fragmentation of 552.3014 ± 3 Da, the assigned y/b fragment ions are also 
highlight.  Peaks found during the MS1 scan that did not generated predicted fragment 
product ions could not be assigned to have originated from the target toxins; it is 
likely that these peaks contain the same amino acid composition, but do not match the 
amino acid sequence of the target peptide. 
 
Figure 7.3 Screen shot of predicted y/b fragmentation ions along the peptide chain of 
LPTPIELPLK from TSST-1.  Only amino acids in this exact sequence will generate MS2 spectra 





Figure 7.4  MS1 full scan spectrum of SEB, SEC1, TSST-1 standard peptide mixture, data 
averaged across a peak position located within a XIC targeted at 552.30 Da, highlighted in red. 
 
Figure 7.5 MS2 fragmentation spectrum of precursor 552.80 ± 3.0 Da (isotopic envelope); 
target fragments 917.49, 617.35, 543.30, 459.25 Da, Table 7.5. 
 
 
Table 7.5 Tryptic peptides observed in LCMS analysis of combined SEB, SEC1 and TSST-
1 standards; fragment ions generated from selected precursors, matched against fragmentation 
position along the peptide chain. 
 









































































4 SEC1 ESQPDPTPDELHK 746.8499 2+ 936.4791 Y8 1+ No 


















341.1853 502.2955 617.3569 720.8173
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7.1.1.4 Protein BLAST Search 
 
Once target peptides and fragment markers were identified peptides were tested for 
uniqueness via an NCBI (National Center for Biotechnology Information) protein 
BLAST (Basic Local Alignment Search Tool) search referenced against the 
UniProt/SwissProt database, the results of which are shown in Table 7.5. Peptides are 
checked that the amino acid composition and sequence are unique to that protein and 
therefore the presence in samples cannot be attributed to other compounds.  Peptides 
which display a unique sequence are described as proteotypic; peptides that created 
more than one possible source, with the exception of SEC1, were excluded from the 
analytical method and not used as a detection marker for the presence of a given toxin.  
Proteotypic peptides were observed for both SEB and TSST-1, however, SEC1 
peptides share a large amount of their peptide sequence with other SEC toxins and 
therefore proteotypic peptides could not be assigned for this target. 
The use of combined tryptic peptides derived from standard protein toxins of SEB, 
SEC1 and TSST-1 in a combined sample generated four unique peptides with a 
minimum of three, and up to eleven, fragment product ions with accurate mass 
confirmation for the detection of the three described toxin compounds known to us as 
products of staphylococcus aureus. Figure 7.6 and Figure 7.7 show overlay spectra of 
XICs generated from both MS1 and MS2 scans of peptide and fragment ions that come 
from the same origin and were used to unequivocally confirm peptide structure and 




Figure 7.6 Extracted ion chromatograms of standard compound mixture containing SEB, 
SEC1 and TSST-1; targeted to Segment 12, TSST-1 peptide LPTPIELPLK (m/z 560.8524) MS1 
XIC and overlapping XICs of product ions from MS2 fragmentation experiment. 
 
Figure 7.7 Extracted ion chromatograms (XICs) of Segment 7 of the standard compound 
mixture containing SEB, SEC1 and TSST-1; the displayed Segment analyses SEC1 peptide 
SVTAQELDIK (m/z 552.3008); MS1 and MS2 XIC data. 
 
Figure 7.8  Extracted ion chromatograms (XICs) of Segment 7 of the standard compound 
mixture containing SEB, SEC1 and TSST-1; the displayed Segment analyses SEC1 peptide 
SVTAQELDIK (m/z 552.3008); MS1 and MS2 XIC data. 
 
 
7.2  Method Development 
 
The analytical method underwent further development to improve sensitivity and 
increase target peak resolution; this included increasing the length of the 
chromatographic run from 30 to 60 minutes total elution time.  Retention times, mass 
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assignment and fragmentation experiments were repeated to confirm correct 
instrument settings for toxin assignment.   The final analytical method used to analyse 
patient samples is fully described in Table 7.6.  Instrument settings are specific to 
software and operating protocols of the Shimadzu LCMS-IT-TOF although a number 
of common analytical parameters are transferable between similar instruments. 
 
7.3  Quantitation 
 
The main objective of this work was to detect the presence of SEB, SEC1 and TSST-1 
in patient samples both sensitively and selectively using mass spectrometry.  
Quantitation of the protein toxins was not a requirement; however, some quantitation 
was achieved via an external calibration curve generated from the SEB, SEC1 and 
TSST-1 combined external standard.  It is important to stress that whilst data is 
presented with concentration values obtained from the intensity of the XIC MS2 
product ions spectra, Table 7.7 and Table 7.8, a number of requirements were not 
undertaken that would enable quantitation of patient samples to be accurately 
reported.  Therefore, whilst concentration values are reported they are done so under 
the caveat that quantitation is beyond the scope of this study. 
The analytical method targeted four peptides from each toxin; each peptide was then 
fragmented to generate MS2 product ions that can be used to create XIC data targeting 
a MS/MS transition with an m/z tolerance of 0.005 Da.  XIC data was then integrated 
and quantitated using a calibration curve for that particular MS/MS transition.  The 
number of MS2 fragments per peptide were limited only by the number of matching 
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product ions observed consistently from the standard compounds during method 
development.  In some cases as many as 10 product ion peaks were targeted and 
integrated, the MS1 peptide precursors and corresponding MS2 product ions monitored 
during analysis are reported in Table 7.5. Figure 7.6 and Figure 7.7 show example 
spectra of multiple XICs from MS1 and corresponding MS2 scans.  All XICs overlap 
exactly as the MS2 scans originate solely from the fragmentation of the MS1 precursor.  
Again, the number of MS2 markers that confirm the presence of a specific toxin was 
limited only by the number of MS2 products assigned from the peptide fragment 
experiment; obviously a larger number of assigned fragments creates an increase in 
peptide assignment. 
All XICs were generated to an accuracy of 2 decimal places, data smoothing was not 
adjusted from the instrument default settings.  The automatic peak picking and 
integration parameters could not be optimised to fit all of the target peptide XICs in a 
single analytical run due to the large differences in instrument response for each 
target, therefore manual peak integration of MS2 XICs was performed in the majority 
of cases.  Furthermore, the patient samples proved to be very weak, sometimes beyond 
the detection limits of the instrument, which proved too difficult for the instrument 
software to perform peak integration reproducibly; therefore, some automatic peak 
integration had to be corrected manually to obtained linear response curves with a 
minimum R2 value of 0.99 or greater. 
 
Table 7.6 LCMS conditions in the analysis of patient samples for SEB, SEC1 and TSST-1. 
  
Column Shimpack XR-ODS (3.0 x 50 mm, 2.2 μm, 12.5 
nm) 
Oven Temperature 40°C 
Mobile Phase A water + 0.1% formic acid (v/v) 
Mobile Phase B Acetonitrile + 0.1% formic acid (v/v) 
Gradient Program 0.00 min 5%B; 5.00 min 5%B; 50.00 min 30%B; 
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50.01 100%B; 55.00 min 100%B; 55.01 min 
5%B; 60.00 5%B 
Flow Rate 0.5 mL/min 
Flow Rate Gradient Program 0.00 min 0.5 mL/min; 50.00 min 0.5 mL/min; 
50.01 1.0 mL/min; 55.00 min 1.0 mL/min; 55.01 
min 0.5 mL/min; 60.00 0.5 mL/min 
Injection Volume 10 μL 
Ionisation Mode ESI(+) 
Nebulising Gas 1.5 L/min 
Drying Gas Pressure 128 bar 
Probe Voltage +4.5 kV 
CDL Temperature 200°C 
Heat Block Temperature 200°C 
MS Acquisition Parameters  
Segment 1 
0.00 – 5.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 423.55 
Segment 2 
5.00 – 7.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 760.87 
Segment 3 
7.00 – 10.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 565.27 
Segment 4 
10.00 – 12.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 747.35 
Segment 5 
12.00 – 15.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 789.90 
Segment 6 
15.00 – 17.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 705.87 
Segment 7 
17.00 – 18.50 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 552.80 
Segment 8 
18.50 – 20.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 530.11 
Segment 9 
20.00 – 22.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 485.75 
Segment 10 
22.00 – 26.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 655.35 
Segment 11 
26.00 – 30.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 775.41 
Segment 12 
30.00 – 37.00 min 
Event 1 400 – 1200 10  
Event 2 300 – 1200 200 561.35 
Segment 13 
37.00 – 60.00 mins 
Event 1 400 – 1200 0.5  







Table 7.7 Patient samples analysed by proteomics based MS method generated a list of 
observed peptides with accompanying assignment of fragment ions.  The XIC for the product ion 
intensity in the MS2 scan is integrated against an external calibration standard.  Data field blank 



























LR014     LF008     
LR028 TSST-1 423.2456 746.4120 28.9 LF009 TSST-1 423.2456 746.4120 16.5 
   631.3820 36.6    631.3820 5.1 
    518.3030 31.2    518.3030 21.2 
    404.2560 32.6     404.2560 11.2 
      316.1940 41.7       316.1940 25.8 
  TSST-1 789.3988 657.3460 104.5   SEC1 746.8493 936.4791 36.0 
    575.2677 58.0     737.8447 100.8 
      544.2619 116.3     574.7830 11.3 
  TSST-1 560.8524 910.5614 125.0       468.7435 36.2 
    809.5137 143.0   TSST-1 789.3988   47.6 
    712.4609 77.9   SEC1 705.3672 847.4526 34.6 
    599.3769 111.9       718.4100 30.1 
    551.8478 793.1   SEC1 552.3008 917.4944 29.1 
    470.3343 111.6     816.4468 13.4 
    455.7846 149.9     745.4096 11.1 
    405.2608 138.9     617.3511 14.0 
      357.2502 111.6     543.2961 24.4 
LR038 SEC1 746.8493        459.2512 11.7 
  TSST-1 560.8524 910.5614 8.5       375.2244 17.6 
      809.5137 3.5   TSST-1  910.5614 23.2 
LR050 TSST-1   910.5614 7.3     809.5137 44.1 
    809.5137 9.7     712.4609 38.2 
      712.4609 6.3     599.3769 24.1 
LR052 TSST-1 560.8524 809.5137 26.9     470.3343 40.5 
    599.3769 27.9       405.2608 52.5 
      405.2608 40.0 LF010 TSST-1 423.2456 746.4120 20.6 
LR053 TSST-1 560.8524 910.5614 57.2     631.3820 52.4 
    809.5137 75.6     518.3030 45.9 
    712.4609 29.9     404.2560 62.8 
    599.3769 61.4       316.1940 61.2 
    551.8478 315.7   SEC1 746.8493 936.4791 26.9 
    470.3343 59.8     737.8447 100.4 
    405.2608 83.7     574.7830 23.8 
      357.2502 96.2     526.2990 19.2 
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LR061             468.7435 23.1 
LR073 TSST-1 423.2456 746.4120 38.2   TSST-1 789.3988 657.3460 94.4 
    631.3820 46.3       544.2619 63.6 
    518.3030 51.5   SEC1 705.3672 847.4526 15.9 
    404.2560 45.3     718.4100 9.8 
      316.1940 64.9       597.8225 27.2 
  SEC1 746.8493 936.4791 13.9   SEC1 552.3008 917.4944 11.9 
    737.8447 37.5     816.4468 12.5 
LR073     574.7830 13.7  LF010   617.3511 8.0 
  SEC1 552.3008 917.4944 16.6     543.2961 15.4 
    844.4053 3.7     459.2512 10.4 
    816.4468 7.2       375.2244 12.1 
    745.4096 12.4   SEB  744.3787 2.3 
    617.3511 7.3     687.8366 16.3 
    543.2961 8.4       548.7915 11.7 
    459.2512 7.1   TSST-1 560.8524 910.5614 13.4 
      375.2244 8.9     809.5137 58.9 
  TSST-1 560.8524 910.5614 94.2     712.4609 23.0 
    809.5137 118.8     599.3769 48.7 
    712.4609 107.6     551.8478 199.8 
    599.3769 88.0     470.3343 48.2 
    551.8478 631.4       405.2608 92.5 
    470.3343 112.5 LF011     
    455.7846 75.6 LF022       
    405.2608 143.2 LF023       
    357.2502 126.8 LF029       
      312.1924 119.2 LF030 TSST-1   631.3820  
LR079             316.1940 4.5 
LR083       LF031      2.9 
LR110       LF054 TSST-1   631.3820  
LR111           518.3030 8.9 
LR113             316.1940 6.6 
LR133       LF056 TSST-1   746.4120 17.9 
LR142           631.3820 6.1 
LR151           518.3030 12.8 
           316.1940 10.7 
       SEC1 746.8493 936.4791 11.3 
         737.8447 14.8 
         574.7830 46.4 
         468.7435 21.3 
       TSST-1 789.3988 657.3460 17.8 
       SEC1 552.3008 917.4944 56.6 
         816.4468 12.0 
         745.4096 10.0 
         617.3511 15.8 
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         543.2961 9.2 
         488.3085 17.2 
         459.2512 15.3 
           375.2244 8.9 
       SEB 654.8433 909.4682 9.2 
         780.4256 3.3 
         667.3416 3.7 
         552.3146 3.2 
           389.2513 4.4 
       TSST-1 560.8524 910.5614 2.6 
         809.5137 6.1 
         599.3769 36.6 
           405.2608 8.9 
     LF064       30.5 
 
7.4  Detection 
 
Four patient samples, including LR003, LR004 and LR008, which all displayed a 
positive response for at least one of SEB, SEC1 and TSST-1 via western blot, were 
analysed using the original 30 minute LCMS method described early.  Unfortunately, 
no signals were observed in any of the samples, neither MS1 peptides nor the 
corresponding MS2 fragment ions, Figure 7.8.  It was clear from the TIC data alone 
that sufficient biological material was present in the patient samples and in reasonably 
high concentrations.  However, MS2 scans gave no assignable fragment ions, and 
mining data for XICs of the peptide fragments described in Table 7.2, Table 7.3 and 
Table 7.4 gave no indication that the target peptides were eluting at an alternative 
retention time.  LR004 spiked with a concentration of combined standard within the 
known detection range of the instrument yielded peak detection as predicted from the 
analysis of the toxin standards, retention time matching was achieved as expected. 
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Assuming that the patient samples did indeed contain a reasonable quantity of the 
target peptide mixtures, instrument and method sensitivity was the likely candidate for 
lack of signal.  Ion suppression from matrix components is an understood issue for 
proteomics work in complex matrices (Callahan, 2006).  Improving separation of the 
sample mixture could reduce co-elution of target compounds with sample matrix 
components.  Further development of the method resulted, as described earlier; 
extension of the LC gradient time from 30 to 60 minutes was hypothetically chosen to 
improve method sensitivity.  However, whilst this hypothesis was not validated, 
further studies with more concentrated samples yielded useful results.   
The next batch of patient samples were selected because they gave the most 
concentrated positive response in the western blot analysis, coupled with a possible 
reduction in ion suppression; these next batch of samples, Table 7.7 and Table 7.8, 
returned positive confirmation for the presence of toxin peptides. 
TSST-1 was the most commonly observed toxin, LR028, LR038, LR050, LR052, 
LR053, LR073, LF009, LF010, LF054, LF056.  Peptides corresponding to SEC1 were 
observed in three patient samples LF009, LF010, and LF056; whilst SEB toxin was 
observed only twice at best, LF010 and LF056.  Observed peaks in MS1 and MS2 
scans with estimated quantitation, Table 7.7, and observed peaks with mass accuracy 
against theoretical values, Table 7.8, are reported.  However, partial reporting of data, 
see LF030 Table 7.7, or blank entries, see LR151, had limited either evidence of toxin 
peptides or no evidence respectively. 
The concentration of toxin peptides within the patient samples was low in all cases, 
which made detection difficult, and perhaps ambiguous in a few samples, see LF022, 
LF023 and LF029 in Table 7.8.  Sensitivity of the analysis was complicated further by 
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the presence of multiple co-eluting compounds from the sample matrix.  Figure 7.9 
and Figure 7.10 show typical TIC and XIC data obtained from some of the higher 
concentration batch of samples, the cluster of MS2 peaks from the XICs of target 
fragment ions shows the presence of tryptic peptide material indicative of a specific 
toxin compound.  Noise, or isobaric peaks in MS2 XIC data is not uncommon in 
proteomics based analysis; Figure 7.9 contains an intense MS1 peak in blue 
corresponding to a match with the measured 423.25 m/z, a targeted peptide mass.  
However, multiple co-eluting MS2 peaks with a retention time consistent with a 
peptide from a standard compound is observed to elute later at 1.5 min, the multiple 
points of confirmation gave certainty to the assignment of the detection of a given 
toxin in a patient sample.  Similar data are shown in Figure 7.10. Figure 7.11 shows 
the assignment of MS2 product ions that match in silico fragmentation products for the 
proteotypic peptide of TSST-1.  In this case, six points of confirmation are obtained, 
peak retention time matching against known standards, MS1 mass confirmation 
(typically sub 10 ppm, but more discussion is required, see Table 7.8), MS2 matching 
of multiple fragment ions each with accurate mass confirmation (sub-10 ppm would 
be ideal, see Table 7.8).  The complete method of assignment is observed in Figure 
7.12, Figure 7.13 and Figure 7.14.  
As mentioned above, an accurate mass measurement was used to assign elemental 
composition consistent with the peptides derived from toxins in patient samples.  It is 
common to apply a requirement of a sub-10 ppm measurement error to such an 
assignment (Webb, 2004).  The data shown in Table 7.8 occasionally assigns target 
peaks with a measurement error as high as 25 ppm, and whilst this is not ideal, a 
number of factors are known to affect the accuracy of mass measurements in time-of-
flight instruments.  In this instance both the temperature stability of the lab (a current 
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known issue) and the intensity of the measured ions play an important role in observed 
mass accuracy.  An excessively weak signal can yield poor ion statistics and can 
therefore be unreliable; low intensity peaks, such as those observed in some of the 
samples reported here, are known to suffer from poor mass accuracy (Webb, 2004).  
Signal-to-noise levels of ions are not always above the 3:1 level required to define 
lower limit of detection, but in most cases at least three diagnostic ions with 
reasonable mass accuracy are observed, reported in Table 7.8.  
 
Figure 7.9 LCMS chromatogram of LR004 patient sample; the black trace represents the 
TIC for the MS1 scans, whilst the pink trace represents the TIC for MS2 scans (Event 2 of each 
Segment only).  The sample contains a significant quantity of peptide like material, as shown in 
the intensity of Event 1 (MS1) TIC.  None of the detected material matched well with targeted 
method for detection of the toxins. 
 
 
Figure 7.10 LCMS chromatogram of LR053 Segment 1 showing the total ion chromatogram 
(TIC) for MS1 full scan (black), the TIC MS2 scan from precursor 423.75 ± 3 Da (tR = 1.56 min); 
all other colours represent XICs of targeted y/b fragment ions from MS2 of precursor mass.  XIC 
data enhanced x100.00 to improve visualisation, therefore a weak cluster of fragment peaks 




Figure 7.11 LCMS chromatogram of LR053 Segment 12 showing TIC for MS1 full scan 
(black); TIC MS2 scan for precursor mass 561.3524 ± 3 Da (tR = 31.4 min); all other colours 
represent XIC of targeted y/b fragment ions from MS2 of precursor.    XIC data enhanced 
x100.00 to improve visualisation, therefore a weak cluster of fragment peaks confirming the 
presence of TSST-1 proteotypic peptide LPTPIELPLK. 
 
 
Figure 7.12 LR053 Segment 12; MS2 full scan of product ions from fragmentation 
experiments of 561.35 ± 3 Da precursor.  Highlighted peaks represent ions matched with 
theoretical y/b fragment ions for the proteotypic peptide LPTPIELPLK of TSST-1.   
 
No attempt was made to calculate a lower limit of detection in this project.  The use of 
external standards and the calibration curve used to generate the approximations in 
concentration were less than ideal.  However, a lower limit of detection was applied 
with some basic assumptions and the understanding of likely inaccuracy.  Data 
presented in Table 7.7 and Table 7.8 contains various comments relating to 
observations made about the intensity of target peaks within these sample data; this 





















approach formed the basis of how the lower limit of detection was estimated.  For 
example, MS1 and MS2 XICs for LR050 displayed peaks capable of reasonable 
integration using the instrument software; however, it was not possible to locate the 
peak responsible in the averaged mass spectrum to assign mass accuracy.  On such 
occasions, signals were considered too weak to positively confirm the presence of a 
target compound.  Further complications to this approach were evident from the 
method of data collection used for MS1 and MS2 scans respectively.  On occasion MS1 
scans were too weak to assign an observed mass to the target, whereas the high ion 
accumulation times used in the MS2 scans, see Table 7.6, meant that ion intensity of 
MS2 fragments were much higher and thus provided target confirmation.  On such 
occasions, MS2 fragment detection and assignment was sufficient to consider the 
target peak as being above the limit of detection.   From this approach, the lower limit 
of detection (LLOD) of target peptides in the LCMS samples was 10ng/ml.  Quoted 
values in the literature use more stringent approaches to determine the LLOD and 
values such as 80-100ng (Callahan, 2006) have been reported; although much depends 
on the particulars of the experimental procedure including type and manufacturer of 
the analytical instrument, the extent of sample preparation and the accompanying 
sample loss, to a name only a few obvious variants. 
It is noteworthy, that whilst the LC gradient conditions were optimised to create 
maximum resolution between eluting target peptides, the method could not be further 
developed to remove co-elution of background matrix compounds from the patient 
samples prior to them being run.  As a consequence it is likely that the co-elution of 
multiple matrix components will influence the ionisation efficiency of the target 






Figure 7.13 LR073 Segment 12 XIC of MS1 and MS2 targets (top); MS1 scan of peptide mass 
560.85 Da (middle); MS2 precursor 561.35 + 3 Da, 10 separate product ions matched to predict 
y/b fragments (bottom).  Three separate data sets confirming the presence of TSST-1 proteotypic 
peptide LPTPIELPLK. 
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Figure 7.14 LF009 Segment 7 TIC (black line) with enhanced (x100) XIC of MS1 and MS2 
targets (top); MS1 scan of peptide mass 552.30 Da (middle); MS2 precursor 552.80 + 3 Da, 7 
separate product ions matched to predict y/b fragments (bottom).  Three separate data sets 
confirming the presence of SEC1 peptide SVTAQELDIK. 
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Figure 7.15 LF056 Segment 7 TIC (black line) with enhanced (x100) XIC of MS1 and MS2 
targets (top); MS1 scan of peptide mass 552.30 Da (middle); MS2 precursor 552.80 + 3 Da, 7 
separate product ions matched to predict y/b fragments (bottom).  Three separate data sets 
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7.5  Conclusion 
 
An LCMS method for the sensitive and selective detection of toxins SEB, SEC1 and 
TSST-1 has been developed using an ion-trap time-of-flight mass spectrometer.  The 
LCMS-IT-TOF allows the detection of target peptides with a high degree of certainty 
as a large number of fragment ions are unequivocally assigned simultaneously due to 
the time-of-flight detection.  This approach using similar instruments in often referred 
to as parallel reaction monitoring. 
The results directly confirm molecular identity of toxin peptides in samples where 
immune assay tests have already returned a positive result.  However, the detection of 
toxin peptides was not confirmed in all samples analysed creating some doubt as to 
whether the current analytical method is of sufficient sensitivity to detect the relatively 
lower concentrations of toxin peptides found in patient samples.  Whilst the limits of 
detection for the target peptides have not been calculated, standard compounds 
demonstrated a detection limit of approximately 5ng/ml in LCMS samples.  This 
appears to be consistent with MS examples in the literature where selected ion 
monitoring (SIM) and multiple reaction monitoring (MRM) has been used with triple 
quadrupole mass detection to achieve LLOD values of 5 – 10 ng/ml (Callahan, 2006), 
but are higher than detection limits already observed in biological based assays. 
Toxin standards used to investigate the instrument’s response were prepared from 
purified compounds and therefore not matrix matched with the patient samples which 
are the focus of this study.  The complex sample matrices observed in the patient 
samples was likely to have had a significant influence on the ionisation efficiency of 
the target peptide as they are eluted from the LC column, quantitative data derived 
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from this external calibration method will be inaccurate as a result.  Alternative 
approaches utilising internal standards have been reported (Adrait, 2012; Dupuis, 
2008; Dupre, 2015) that overcome this issue, but such an approach was beyond the 
capabilities of this project.  However, using isotopically labelled synthetic internal 
standards, literature examples have reported LLOD for toxin peptides ~0.4ng/ml 
(Adrait, 2012).   
Further improvements to the sensitivity of the analytical method can be made through 
judicial adjustments made to sample preparation and some of the LCMS parameters.  
The principle limitation of the current technique is likely to be the ion suppression 
effects induced by the high levels of background signals from the complicated matrix.  
Efficient sample preparation prior to mass spectrometric analysis is essential to 
counteract ion suppression/matrix effects observed for complex biological samples.  
Therefore, decomplexification of the patient samples coupled with improvements in 











Chapter 8  DISCUSSION & CONCLUSION 
8.1  Staphylococcal Toxins in Urine 
 
Chronic autoimmune diseases are the consequence of the immune system recognising 
self-antigens as foreign, leading to inflammation and destruction of specific tissues 
and organs (Abou-Raya, 2006; Cusick, 2012). 
 
Table 8.1  Summary of S.aureus presence in human samples. Comparison of general 
population, medical students, acute ischemic heart disease (AIHD) (on admission & 6 week 
follow-up), RA and closed fractures. 
























In the patient cohorts that we analysed, S.aureus was found to be present in 56.4% of 
RA patients and 27.1% of fracture patients. Similar work by Bull et al. looked for the 
presence of S.aureus toxin in medical students and patients suffering an episode of 
acute ischaemic heart disease (AIHD) (Bull, 2014). A urine sample was taken from 
the AIHD patients, in the same way as for the RA/fracture study, before any 
intervention in A+E (AIHD UA samples). A further sample was taken at an outpatient 
clinic appointment 6 weeks later (AIHD UB sample). The AIHD UB sample would 
represent a sample taken under similar conditions to the RA and fracture patients as all 
three populations have attended scheduled appointments as outpatients. The 
population of medical students consisted of 50 individuals between 20-25 years old. It 
was assumed that by this age and following a lot of time spent in the hospital 
environment due to their education and training, this population would most likely 
have been infected or colonised by S.aureus at some point.  
The positive results were as follows: medical students (18%); AIHD UA (29%); 
AIHD UB (19%) (Bull, 2014). The results for the medical students and AIHD UB 
samples were very similar, which is understandable as an AIHD patient 6 weeks post-
episode would probably be returning back towards the health of a healthy individual, 
which is the group that the medical students represent. Both of these populations 
would have attended hospital, giving them a similar amount of exposure. 
Similarly, 27.1% of fracture patients and 29% of AIHD patients (on admission) were 
shown to have S.aureus toxins in their urine. Although we do not have data for exactly 
how long after the fracture each and every sample was taken, most were asked to take 
part within a week of the initial trauma. It can be said that these two populations are 
also comparable as they are both at the initial contact stage with the hospital. 
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Although there is a substantial difference between the numbers of patients testing 
positive for staphylococcal enterotoxin in each of our populations (RA and fracture), 
the question must be asked; why does at least one quarter of the patients appear to 
have toxin present in their urine (RA, fracture and AIHD UA)? This observation 
suggests that an inflammation event – acute or chronic – increases the chance of an 
individual testing positive for staphylococcal enterotoxin(s) in their urine. Using 
current evidence, we can only speculate, however there are a couple of potentially 
credible explanations. 
The kidney filters small molecules such as glucose, urea, ions and water into the 
nephrons. However, larger molecules are too big to diffuse through the capillary 
membrane and therefore remain in the blood. We hypothesise that: (i) the 
opportunistic bacteria are more of a burden when under stress and/or; (ii) the immune 
cells are elsewhere in the body.  
Neutrophils originate in the bone marrow and circulate in the blood for approximately 
10 hours before exiting into the tissues and onto the body surface. During their time in 
the blood stream, the neutrophils travel more slowly in the post capillary venules than 
the RBCs. Therefore, the neutrophils become more concentrated in the post capillary 
venules than in the rest of the circulation. Since all blood goes through the lungs, this 
means that up to 50% of the neutrophils are in the post capillary venules of the lung at 
any one time (Morris, 2007). This system efficiently clears bacteria from the blood as 
the bacteria pass through the dense concentration of neutrophils in the lungs, giving 
the neutrophils the opportunity to phagocytose and destroy the bacteria. 
During a fever or an inflammation event (acute or chronic), there is more demand put 
on the immune system. Fever changes the dynamics of the circulation in some way so 
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that the neutrophils and the RBCs travel at the same rate and so the neutrophils are not 
concentrated in the post capillary venules but are more evenly spread within the blood 
(Morris, 2007). This is an explanation for why the white cell count rises during 
infection. However, this does mean that bacteria will not be cleared from the 
lungs/blood as efficiently. Thus, if bacteraemia is common then bacteria are likely to 
stay in the circulation longer in patients with fever. Furthermore, lung complaints and 
diseases and been linked as a major comorbidity in RA. In particular, interstitial lung 
disease (ILD). Bongartz et al. studied 1185 people with and without RA; 7.7% of the 
individuals with RA also had ILD, compared to 0.9% of the healthy controls 
(Bongartz, 2010).  
 
  
8.2  Infection  
 
8.2.1   Cause or Consequence? 
 
For decades, it has been known that there is an increased risk of serious infection in 
people with RA. Observational studies have shown at least a 2-fold increased risk of 
serious infection in RA, subsequently supported by numerous cohort studies (Doranb, 
2002; Franklin, 2007; Smitten, 2008). The heightened susceptibility of patients with 
RA can be explained by the pathobiology of the disease itself, the impact of chronic 
comorbid conditions and the nature of the immunosuppressive treatments used 
(Listing, 2013). It is considered that premature ageing of the immune system in RA 
209 
 
contributes to weakened protection against infectious organisms. Additional chronic 
comorbidities and lifestyle factors increase the risk in individual patients.  
Furthermore, there is an increased risk of infection in RA patients treated with drugs 
that inhibit TNF-α. For example, TNF inhibitors were already showing a strong 
association with an increased risk of TB in RA, soon after licensing (Keane, 2001; 
Mohan, 2004). However, there is relatively little known about the effect of TNF-α 
inhibitor therapy and the reactivation of latent infections (Strangfeld, 2009). 
The inhibition of TNF-α in patients with active RA, has proved to be an effective 
treatment, particularly as a vital alternative for patients whose disease is insufficiently 
controlled by DMARDs. Similarly, patients with alkylosing spondylitis, psoriatic 
arthritis and inflammatory bowel disease are also seeing the benefit of treatments 
using new biologics, including TNF-α inhibitors. Due to the relatively recent 
introduction of biologic treatments, little is known about the long term effects. In time, 
this will be overcome by the biologics registers that have been set up to keep track of 
all patients treated using biologic drugs; for example, BSRBR-RA in the UK and 
RABBIT in Germany. 
Immunosuppression and ageing both contribute to a decline in cellular immunity 
which has been linked to the reactivation of latent varicella zoster virus (VZV) 
(Thomas, 2004). Immunodeficiency in general has shown to have a strong link to an 
increase (Veenstra, 1995), recipients of bone transplants (Locksley, 1985) and 
children with leukaemia (Glynn, 1990; Kost, 1996). 
Treatment using monoclonal anti-TNF-α antibodies (infliximab and adalimumab), has 
shown to increase the incidence of herpes zoster (Strangfeld, 2009). However, 
etanercept, a fusion protein, does not appear to give an increased risk of herpes zoster. 
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Herpes zoster is a neurocutaneous disease caused by VZV, which can be reactivated 
after the initial infection. The disease is characterized by a painful vesicular 
dermatomal rash and is one of the most common adverse events reported in clinical 
trials of anti–TNF-α biologics. Subsequent complications include bacterial 
superinfection. 
The use of GCs as an immunosuppressant have been shown to increase the risk of 
infection 4-fold (in a dose dependent manner) (Listing, 2013). The use of GCs and 
TNF inhibitors together results in a significantly elevated risk of infection for the 
patient. This combination is discouraged, particularly in populations with additional 
risk factors such as age. 
Listing et al. compared the rates of infections in patients treated with biologic agents 
with the rates in patients receiving conventional DMARDs. It was observed that there 
were considerably more infections in patients treated with etanercept or infliximab. In 
the control group however, the incidence of serious infections was 2.7–2.8 times 
lower than in patients treated using biologic agents. Their data suggest, as in many 
other studies, that the major contributor to the increased incidence of infection is 
probably caused by TNF inhibitors. In particular, there was the most concern for 
lower respiratory tract infections (especially pneumonia), bacterial skin infections 
(erysipelas), and bone and joint infections (Listing, 2005). In relation to this study, 
S.aureus is known to cause infections in all of these sites, therefore indicating that 
infection is a consequence of RA. 
RA has been linked with a noticeable risk of infectious diseases, based on 
observational studies over the last 60 years (Cobb et al., 1953; Uddin et al., 1970). 
Controlled observational studies found that mortality in RA patients (age-adjusted) 
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was about 2-fold higher compared with the general population; where infectious 
disease proved to be one of the three leading causes of premature death - in the USA 
and in Europe (Wolfe, 1994; Perez-Sola, 2011; Mutru, 1985; Mikuls, 2002). 
Transient, usually asymptomatic bacteraemia occurs in a wide variety of procedures 
and manipulations, particularly those associated with mucous membrane trauma 
(Everett, 1970). Interventions such as tonsillectomy, tracheal intubation, 
bronchoscopy, sigmoidoscopy, barium enema and liver biopsy can lead to 
bacteraemia. It is most likely that S.aureus gets into the body via the lungs, 
genitourinary tract, a break in the skin or through the mucosa (Sullivan, 1973; Everett, 
1977; Aryee, 2016). 
 
8.2.2  TNF-α 
 
TNF plays a central role within a complicated network of cytokines. TNF is a pro-
inflammatory cytokine and is involved in cellular homeostasis including cellular 
communication, differentiation and apoptotic death.  Furthermore, TNF has been 
widely linked to the development of cancer and autoimmunity, due to its diverse 
functions and subsequent effects (Brenner, 2015). TNF was first associated with 
tumour regression and with cachexia accompanying chronic, invasive diseases 
(Keffer, 1991). TNF is mainly a product of macrophage activation and has been 
established as an immune regulator in both inflammatory and normal states (Beutler, 
1989). A number of other cell types are known to produce TNF but the quantities are 
much less. Examples include activated T cells (Steffen, 1988; Kinkhabwala, 1990), 
natural killer cells (Peters, 1986) and mast cells (Gordon, 1990). Conversely, almost 
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every cell type in the human body is found to express a TNF specific plasma 
membrane receptor (Schall, 1990; Loetscher, 1990). Deregulation of its receptor, 
TNFR, and changes to the signalling pathway have been attributed to a number of 
inflammatory illnesses, including various types of arthritis. Deregulated production of 
TNF itself in humans is known to contribute to the development of diseases such as 
cancer-associated cachexia (Oliff, 1987), endotoxic shock (Beutler, 1985), graft 
versus host disease (Piguet, 1987), autoimmunity (Held, 1990) and RA (Saxne, 1988; 
Yocum, 1989).  
TNF-α was first described, in relation to inflammatory disease, by George Kollias and 
colleagues at the Hellenic Pasteur Institute, Athens in 1991(Keffer, 1991). Using 
transgenic mouse models, it was demonstrated that TNF played a role in arthritis and 
that the blocking of TNF-associated signalling pathways using a monoclonal antibody 
to human TNF completely prevented disease development. 
Inflammation, characteristic of RA, is localised in the synovial lining, a monolayer of 
synovial cells that lines diarthroidal joints. In a diseased state, the synovial lining 
becomes thickened due to synovial cell proliferation and infiltration by inflammatory 
cells, such as macrophages (Lubberts, 2000). The pannus is the subsequent 
proliferative mass that invades and destroys articular cartilage and bone, leading to 
irreversible destruction of joint structure and function and ultimately a significant 
amount of pain (Lubberts, 2000). Several recent studies have implicated cytokines in 
the pathogenesis of this disease. Elevated levels of TNF (Saxne, 1988; Di Giovine, 
1988) as well as IL-1 (Nouri, 1984) and IL-6 (Hirano, 1988) are consistently found in 
the synovial fluid of RA patients. Additionally, in vitro models of human synovial 
fibroblast cell lines have been shown to proliferate when triggered by rTNF and rIL-1 
(Gitter, 1989; Butler, 1988).  
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8.2.3  ACPA and RF 
 
Mori et al. evaluated the utility of ACPA (second generation, anti-CCP2) as a 
diagnostic marker for RA in patients with active tuberculosis. Among patients with 
active tuberculosis, anti-CCP2 was detected in six (6.7%). The rate of anti-CCP2 in 
patients with newly diagnosed RA was 82.1% versus 0.4% in healthy controls. 
Additionally, IgM RF was detected in 18% of the tuberculosis group and 72.6% of the 
RA group (Mori, 2009).  
 
8.2.4  Molecular Mimicry 
 
There are a number of suggested mechanisms which infer that infections can initiate 
and/or exacerbate autoimmune diseases. One of the most discussed mechanisms is 
molecular mimicry. This hypothesis describes when a foreign protein/antigen shares 
sequence homology or structural similarities to the human self-antigens, thus 
mimicking the native protein (Fujinami, 1985).   
It has been indicated that at most, there are 30,000 protein coding genes in the human 
genome (Baltimore, 2001); but they are thought to code for in excess of 250,000 
proteins (Morris, 2012). By comparison, bacteria have 3000 to 5000 genes coding for 
approximately 3000 to 5000 proteins (Tlaskalova-Hogenova, 2011). There are 
approximately 400 different species of bacteria that can make up the commensal gut 
flora and any individual can carry about 40 at any one time (Moore, 1974; Moore, 
1978). Therefore, the complexity of the proteome of the microbial flora is of the same 
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order of magnitude as that of the human body. Additionally, proteins that perform 
essential functions are conserved in evolution and since all forms of life are related, 
there will be considerable mimicry between human and bacterial proteins (Morris, 
2007). Therefore, it may be assumed that for every protein within a human cell 
membrane, there will be a bacterial product capable of combining with it and 
switching the function it controls, on or off (Morris, 2004). 
Molecular mimicry has typically been characterised by the cross-reaction of 
autoreactive B cells and/or T cells. However, it has been found that structural 
relatedness between pathogen and self-protein, does not account for T cell activation 
in a number of autoimmune diseases (Cusick, 2012).  
Another proposed mechanism, possibly misinterpreted for molecular mimicry, is the 
expression of dual TCRs on a single T cell. Such T cells have dual reactivity to both 
foreign and self-antigens leaving the host vulnerable to foreign insults capable of 
triggering an autoimmune response (Cusick, 2012). 
Morris et al. discussed molecular mimicry in irritable bowel syndrome (IBS), chronic 
fatigue syndrome (CFS) and anorexia nervosa (AN), which have a number of features 
in common, with not only each other but RA (Morris, 2016). 
1. They are much more common in women than in men.  
2. The onset of the disorder is most likely to occur in the middle years. The age 
incidence rises to a peak in the second, third or fourth decades, depending on the 
specific condition. The incidence then declines and onset in old age is uncommon.  
3. There is some evidence that they are becoming more common with technological, 
social and economic progress in society.  
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4. There are suggestions that infection can precipitate and exacerbate the conditions 
but the links remain somewhat tenuous.  
The immune system’s job is complex. 20 amino acids can combine in ten trillion ways 
to form a polypeptide chain ten amino acids long (2010 = 1013) (Morris, 2016). From 
the human and bacterial proteomes, there is probably fewer than 1 million proteins, 
which are on average, 300 amino acids in length. Therefore, the total number of 
polypeptides of length 10 amino acids is less than 109. T cell receptors are the main 
APCs and it is their job to efficiently differentiate similar to self from different than 
self (Morris, 2016). 
 
8.2.5  Evasion of the Immune System 
 
The evasion of pathogens from the immune system is not a new concept (Finlay, 
2006). This phenomenon has been described in relation to viruses, bacteria and 
parasites; for example, HIV, TB and malaria (Morens, 2004; Fauci, 2005). S.aureus 
has also been described as having developed novel immune evasion phenotypes 
(Richards, 2015). 
 
 8.3  Questionnaires 
 
There is no doubt that increased age plays a role in the increased incidence of 
infection (Strangfeld, 2011; Galloway, 2011; Laube, 2004).This is further exacerbated 
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by comorbidities which significantly increase the risk; for example, chronic 
obstructive pulmonary disease and other chronic lung diseases (Strangfeld, 2011; 
Dixon, 2006; Curtis, 2007; Greenberg, 2010), chronic kidney diseases (Strangfeld, 
2011; Curtis, 2007) and diabetes mellitus (Curtis, 2007; Greenberg, 2010).  
Smoking is the most potent lifestyle risk factor. It is linked to the pathogenesis of RA 
(Symmons, 1997; Klareskog, 2006) and at the same time is a risk factor for infectious 
diseases, not only in RA but in the general population (Stampfli, 2009). A complex 
immune defence system protects us against harmful agents and pathogens. Exposure 
to cigarette smoke directly or indirectly, distinctly affects the immune system; this 
compromises the host's ability to mount the appropriate immune and inflammatory 
response. These adverse effects on the human immune system not only occur in active 
smokers, but also in passive smokers. Such effects can persist for decades after 
exposure has ended (Stampfli, 2009). Quirke et al. have described bronchiectasis (BR) 
as a potent model for autoimmunity induced by chronic bacterial infection (Quirke, 
2015). Subsequent periodontis and smoking-induced lung inflammation gives rise to 
increased levels of antibodies to un-citrullinated RA antigens and citrullinated 
proteins. The study authors suggest that the ACPA response is not citrulline specific 
throughout the initial stages of tolerance breakdown but that it becomes more specific 






8.4  Conclusion 
 
Overall, the presence of S.aureus in the urine of patients with RA or closed fractures, 
without any active infection, is clearly raised. The RA patients in particular showed an 
overwhelming presence of staphylococcal enterotoxins in their urine. The immune 
system of RA patients is known to be considerably suppressed by the current 
treatments available (Murphy, 2008),  however both populations can be affected by 
the immunosuppressive effects of staphylococcal SAgs (Ferens, 1998). There is 
evidence that suggests that toxins produced by S.aureus are capable of initiating and 
maintaining an inflammatory event. Furthermore there is opportunity for the immune 
system to deregulate and lead to the development of autoimmune disease. An immune 
response instigated by staphylococcal toxins causes the release of a range of pro-
inflammatory cytokines and their effects can be systemic. Additionally, inflammation 
may play a role in controlling the amount of toxin that enters the urine; especially if 
the toxins are part of larger immune complexes. Such immune complexes may be too 
large to be filtered into the urine by the kidneys under normal conditions. 
The strength of this study lies in the novel techniques developed and the new, original 
datasets produced. Using a well-defined western blot protocol, it was possible to 
design a process that could screen each patient urine sample for all four 
staphylococcal enterotoxins. Subsequently, building on a protocol for the preparation 
of urine samples for analysis by mass spectrometry, a complex technique was 




This is the first time that high levels of S.aureus toxins have been detected in RA 
patients. It is also the first time that the increased presence of S.aureus in RA patients 
has been described using a technique to analyse their urine. Additionally, the data 
collected from the fracture patient cohort has given us novel findings on the presence 
of S.aureus toxins in the urine of an out-patient population with closed fractures. 
Furthermore, a LCMS technique was developed that was able to detect proteotypic 
staphylococcal peptides in urine. 
However, there were some limitations within this study: 
• Samples were collected on different days and at varying times of the day. 
• The fracture patients were, on average, slightly younger so may have more 
bacterial exposure. 
• Similarly, the fracture patients, depending on what bone they had fractured, are 
probably more mobile than the RA patients – giving them the ability to be 
exposed to more pathogens. 
• ‘No infection’ was based on the lack of symptoms confirmed by each 
individual’s opinion of their own health status. We would only be able to 
confirm no infection for sure if we screened each patient but this would take a 
lot of time and be very expensive. 
It is unlikely that S.aureus alone can be the cause of RA but there is sufficient 
evidence that suggests that it could be a contributor. The bacterium may be a factor 
alongside the other pathogens discussed: EBV, P. gingivalis or P.mirabilis; genetics 




8.5  Future Work 
 
Given more time, the MS method should be developed further. The initial work 
carried out, and data collected, has shown that the methodology works. With more 
tests and further changes of the parameters, the method could become automated and 
more sensitive. 
It remains unclear as to whether S.aureus is a cause or consequence of RA but there is 
considerable evidence so far to support either. There needs to be substantially more 
research concerning the primary data produced by this study. In relation to the aspect 
of infection, it would be interesting if the positive/negative S.aureus results were 
compared with each patient’s treatment at the time of sample collection. This would 
show if there is any increased incidence of infection in the individuals being treated 
using new biologics or biosimilars. Furthermore, comparison of the S.aureus 
presence/absence with RF positivity and the presence of anti-CCPs also may or may 
not show an association with infection. We used the father’s occupation of each 
patient to try and anticipate the SES of their childhood. This may not have been very 
accurate and it may be useful to include the patient’s work/career history to see if 
what they do day-to-day has any bearing on their RA status. 
Now that there is a well-defined western blot protocol to look for these toxins in urine, 
samples from other cohorts could be analysed to produce a large dataset, to compare 
the presence of S.aureus amongst controlled populations. With more data will come 





Table A1 Table to show the corresponding three and one letter codes for each amino acid. 
Amino Acid Name Three Letter Code One Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ilu I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F  
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
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Appendix  C 
C1  ExPASy: BSA & Trypsin 





























































C2 ExPASy: HA & Trypsin 
 
Position Peptide Cleavage 
311-337 SHCIAEVENDEMPADLPSLA ADFVESK 
139-160 LVRPEVDVMCTAFHDNEETF LK 
45-65 ALVLIAFAQYLQQCPFEDHV K 
























































• To which of the following ethnic groups do you belong? 
White British Irish Other  
Black or 
black British 
Caribbean African Other  
Asian or 
Asian British 
Indian Pakistani Bangladeshi  Other  
Mixed White and black 
Caribbean 




 Other  
Chinese 
Other ethnic group 























Appendix D1 - RA Patient Questionnaire 
‘Identification of the foreign protein component of immune complexes in 
rheumatological disease’ 
Any information given in this in this questionnaire will only be used for purposes related to 
this research project. Questionnaires are anonymous and will not be traced back to you. 
The aim of this questionnaire is to collect supplementary data on participants of this study. 
Current literature includes numerous theories and statistics. We would like to use the data 
from these questionnaires to corroborate or disprove previous studies. 
• Please select your gender: Male Female 










• What is your disease activity score (DAS28)? 
• At what age did your Rheumatoid Arthritis -related symptoms begin?  
• At what age were you formally diagnosed with Rheumatoid Arthritis? 

























• Do you smoke? 
Never have 











• Has there been/are there any other cases of Rheumatoid Arthritis in your 
(blood-related) family? 
• Where were you born? 



















5th + Born 
• Amongst your siblings (if any), were you: 
• As a child, did you share a bedroom? 
No Yes 
If Yes: 
• At what age? 
• For how many years? 










































• Do you currently have any active infections?  
• Are you currently taking antibiotics? 
• In what type of area did you live for the majority of your early childhood? 
• In what type of area do you currently live? 
Urban Suburban Rural 
Urban Suburban Rural 
• Did you live or spend a lot of time on a farm during your early childhood? 
No Yes 







• Does your Rheumatoid Arthritis appear to be worse in a particular season? 






• What was your mother’s occupation during your childhood? 
• What was your father’s occupation during your childhood? 
For Internal Use Only 
Unique Identifier Number: 
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• To which of the following ethnic groups do you belong? 
White British Irish Other  
Black or 
black British 
Caribbean African Other  
Asian or 
Asian British 
Indian Pakistani Bangladeshi  Other  
Mixed White and black 
Caribbean 




 Other  
Chinese 
Other ethnic group 

























Appendix D2 - Control Patient Questionnaire 
‘Identification of the foreign protein component of immune complexes in 
rheumatological disease’ 
Any information given in this in this questionnaire will only be used for purposes 
related to this research project. Questionnaires are anonymous and will not be traced 
back to you. 
The aim of this questionnaire is to collect supplementary data on participants of this 
study. Current literature includes numerous theories and statistics. We would like to use 
the data from these questionnaires to corroborate or disprove previous studies. 
• Please select your gender: Male Female 



































• Do you smoke? 
Never have 











• Has there been/are there any cases of Rheumatoid Arthritis in your 
(blood-related) family? 
• Where were you born? 



















5th + Born 











































• Do you currently have any active infections?  
• Are you currently taking antibiotics? 
• As a child, did you share a bedroom? 
No Yes 
If Yes: 
• At what age? 
• For how many years? 
• With how many people? 
• In what type of area did you live for the majority of your early childhood? 
• In what type of area do you currently live? 
Urban Suburban Rural 
Urban Suburban Rural 
• Did you live or spend a lot of time on a farm during your early 
childhood? 
No Yes 







• What was your mother’s occupation during your childhood? 
• What was your father’s occupation during your childhood? 
For Internal Use Only 
Unique Identifier Number: 
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Figure E1  Western blot membrane incubated with αAH primary antibody (1:1000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 






Figure E2  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E3  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E4  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E5  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E6  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E7  Western blot membrane incubated with αAH primary antibody (1:1000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 






Figure E8  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E9  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E10  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E11  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E12  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure E13  Western blot membrane incubated with αAH primary antibody 
(1:1000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and 







Figure E14  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E15  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E16  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 

































Figure E17  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 
(Lane 2-4) and neat samples of urine from patients LR145-152 (28µl) (Lane 5-13). 
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Figure E18  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E19  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E20  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E21  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 





























Figure E22  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E23  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






























Figure E24  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E25  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure E26  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E27  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 



































Figure E28  Western blot membrane incubated with αSEB primary antibody 
(1:2000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC 






Figure E29  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure E30  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E31  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 



































Figure E32  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E33  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 























Figure E34  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 
(Lane 2-4) and neat samples of urine from patients LR145-152 (28µl) (Lane 5-13). 
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Figure E35  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E36  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure E37  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E38  Western blot membrane incubated with αSEC primary antibody (1:2000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 



































Figure E39  Western blot membrane incubated with αSEC primary antibody 
(1:2000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and 







Figure E40  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E41  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E42  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure E43  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E44  Western blot membrane incubated with αSEC primary antibody (1:2000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 



































Figure E45  Western blot membrane incubated with αSEC primary antibody 
(1:2000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and 







Figure E46  Western blot membrane incubated with αSEC primary antibody (1:2000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 



































Figure E47  Western blot membrane incubated with αSEC primary antibody 
(1:2000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and 






Figure E48  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 
































Figure E49  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure E50  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure E51  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 
(Lane 2-4) and neat samples of urine from patients LR145-152 (28µl) (Lane 5-13). 
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Figure E52  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E53  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 




































Figure E54  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E55  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 








































Figure E56  Western blot membrane incubated with αTSST-1 primary antibody 
(1:1000). Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) 






Figure E57  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 




































Figure E58  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E59  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and neat 































Figure E60  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and neat 






Figure E61  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 









































Figure E62  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E63  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and neat 



































Figure E64  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E65  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and neat 




































Figure E66  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure E67  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 




































Figure E68  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 
neat samples of urine from patients LR145-152 (28µl) (Lane 5-13). 
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Figure F1  Western blot membrane incubated with αAH primary antibody (1:1000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 






Figure F2  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F3  Western blot membrane incubated with αAH primary antibody (1:1000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 






Figure F4  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F5  Western blot membrane incubated with αAH primary antibody (1:1000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 






Figure F6  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F7  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F8  Western blot membrane incubated with αAH primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 


































Figure F9  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F10  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F11  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F12 Western blot membrane incubated with αSEB primary antibody (1:2000). Low 
molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) (Lane 2-4) 



































Figure F13  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F14  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 

































Figure F15  Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F16 Western blot membrane incubated with αSEB primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F17  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F18  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F19  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F20  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F21  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F22  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F23  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 






Figure F24  Western blot membrane incubated with αSEC primary antibody (1:2000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control AH, SEB and SEC (1µg/ml) 



































Figure F25  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure F26  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 


































Figure F27  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure F28  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 



































Figure F29  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure F30  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 



































Figure F31  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 






Figure F32  Western blot membrane incubated with αTSST-1 primary antibody (1:1000). 
Low molecular weight ladder (kDa) (20µl) (Lane 1), Control TSST-1 (1µg/ml) (Lane 3) and 










Table G1 LCMS data for the most concentrated patient samples, as observed by Western 
Blot analysis.  Observed masses for precursor and product ions are reported against the 























LR014         
LR028 1 TSST-1 423.2532 423.2456 18.0 746.4261 746.4120 18.9 
       631.3881 631.3820 9.7 
       518.2990 518.3030 -7.7 
       404.2601 404.2560 10.1 
            316.1935 316.1940 -1.6 
  5 TSST-1 789.3879 789.3988 -13.8 657.3407 657.3460 -8.1 
       575.2603 575.2677 -12.9 
            544.2590 544.2619 -5.3 
  12 TSST-1 560.8444 560.8524 -14.3 910.5548 910.5614 -7.2 
       809.5060 809.5137 -9.5 
       712.4524 712.4609 -11.9 
       599.3706 599.3769 -10.5 
       551.8444 551.8478 -6.2 
       470.3298 470.3343 -9.6 
       455.7787 455.7846 -12.9 
       405.2552 405.2608 -13.8 
            357.2450 357.2502 -14.6 
LR038 4 SEC1 746.8589 746.8493 12.9 Too 
Weak 
    
  12 TSST-1 560.8386 560.8524 -24.6 910.5390 910.5614 -24.6 
            809.5036 809.5137 -12.5 
LR050 12 TSST-1 Too Weak     910.5560 910.5614 -5.9 
       809.5094 809.5137 -5.3 
            712.4631 712.4609 3.1 
LR052 12 TSST-1 560.8637 560.8524 20.1 809.5069 809.5137 -8.4 
       599.3744 599.3769 -4.2 
            405.2588 405.2608 -4.9 
LR053 12 TSST-1 560.8425 560.8524 -17.7 910.5511 910.5614 -11.3 
       809.5076 809.5137 -7.5 
       712.4694 712.4609 11.9 
       599.3742 599.3769 -4.5 
       551.8356 551.8478 -22.1 
       470.3264 470.3343 -16.8 
       405.2574 405.2608 -8.4 
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            357.2468 357.2502 -9.5 
LR061   None Detected             
LR073 1 TSST-1 423.2433 423.2456 -5.4 746.3989 746.4120 -17.6 
       631.3864 631.3820 7.0 
       518.2955 518.3030 -14.5 
       404.2524 404.2560 -8.9 
            316.1951 316.1940 3.5 
  4 SEC1 746.8442 746.8493 -6.8 936.4681 936.4791 -11.7 
       737.8385 737.8447 -8.4 
            574.7752 574.7830 -13.6 
  7 SEC1 552.2898 552.3008 -19.9 917.4899 917.4944 -4.9 
       844.3956 844.4053 -11.5 
       816.4355 816.4468 -13.8 
       745.4160 745.4096 8.6 
       617.3480 617.3511 -5.0 
       543.2915 543.2961 -8.5 
       459.2439 459.2512 -15.9 
            375.2207 375.2244 -9.9 
  12 TSST-1 560.8440 560.8524 -15.0 910.5646 910.5614 3.5 
       809.5099 809.5137 -4.7 
       712.4591 712.4609 -2.5 
       599.3737 599.3769 -5.3 
       551.8383 551.8478 -17.2 
       470.3271 470.3343 -15.3 
       455.7774 455.7846 -15.8 
       405.2549 405.2608 -14.6 
       357.2475 357.2502 -7.6 
            312.1891 312.1924 -10.6 
LR079   None Detected             
LR083   None Detected             
LR110   None Detected             
LR111   None Detected             
LR113   None Detected             
LR133   Signals Too 
Weak 
            
LR142   None Detected             
LR151   None Detected             
LF008   None Detected             
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LF009 1 TSST-1   423.2456   746.4365 746.4120 32.8 
       631.3639 631.3820 -28.7 
       518.3013 518.3030 -3.3 
       404.2692 404.2560 32.7 
            316.1933 316.1940 -2.2 
  4 SEC1 746.8394 746.8493 -13.3 936.4695 936.4791 -10.3 
       737.8357 737.8447 -12.2 
       574.7756 574.7830 -12.9 
            468.7324 468.7435 -23.7 
  5 TSST-1 789.3954 789.3988 -4.3       
  6 SEC1 705.3501 705.3672 -24.2 847.4348 847.4526 -21.0 
            718.3975 718.4100 -17.4 
  7 SEC1 552.2981 552.3008 -4.9 917.4911 917.4944 -3.6 
       816.4410 816.4468 -7.1 
       745.4055 745.4096 -5.5 
       617.3444 617.3511 -10.9 
       543.2873 543.2961 -16.2 
       459.2457 459.2512 -12.0 
            375.2178 375.2244 -17.6 
  12 TSST-1 obscured   910.5495 910.5614 -13.1 
       809.5137 809.5137 0.0 
       712.4548 712.4609 -8.6 
       599.3761 599.3769 -1.3 
       470.3293 470.3343 -10.6 
            405.2529 405.2608 -19.5 
LF010 1 TSST-1 423.2364 423.2456 -21.7 746.4030 746.4120 -12.1 
       631.3812 631.3820 -1.3 
       518.3018 518.3030 -2.3 
       404.2569 404.2560 2.2 
            316.1935 316.1940 -1.6 
  4 SEC1 746.8378 746.8493 -15.4 936.4733 936.4791 -6.2 
       737.8367 737.8447 -10.8 
       574.7748 574.7830 -14.3 
       526.2881 526.2990 -20.7 
            468.7349 468.7435 -18.3 
  5 TSST-1 789.3825 789.3988 -20.6 657.3418 657.3460 -6.4 
            544.2597 544.2619 -4.0 
  6 SEC1 705.3585 705.3672 -12.3 847.4429 847.4526 -11.4 
       718.4027 718.4100 -10.2 
            597.8115 597.8225 -18.4 
  7 SEC1 552.2954 552.3008 -9.8 917.4859 917.4944 -9.3 
       816.4393 816.4468 -9.2 
       617.3520 617.3511 1.5 
       543.2944 543.2961 -3.1 
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       459.2470 459.2512 -9.1 
            375.2187 375.2244 -15.2 
  8 SEB too weak   744.3764 744.3787 -3.1 
       687.8303 687.8366 -9.2 
            548.7933 548.7915 3.3 
  12 TSST-1 560.8503 560.8524 -3.7 910.5534 910.5614 -8.8 
       809.5026 809.5137 -13.7 
       712.4535 712.4609 -10.4 
       599.3660 599.3769 -18.2 
       551.8270 551.8478 -37.7 
       470.3288 470.3343 -11.7 
            405.2566 405.2608 -10.4 
LF011  None Detected       
LF022 1 TSST-1 too weak           
LF023 1 TSST-1 too weak           
LF029 1 TSST-1 too weak           
  7 SEC1 too weak           
LF030 1 TSST-1 too weak     631.3833 631.3820 2.1 
            316.1917 316.1940 -7.3 
LF031 1 TSST-1 too weak           
LF054 1 TSST-1 too weak     631.3926 631.3820 16.8 
       518.2922 518.3030 -20.8 
            316.1931 316.1940 -2.8 
LF056 1 TSST-1 too weak     746.4208 746.4120 11.8 
       631.3736 631.3820 -13.3 
       518.2910 518.3030 -23.2 
            316.1915 316.1940 -7.9 
  4 SEC1 746.8380 746.8493 -15.1 936.4728 936.4791 -6.7 
       737.8390 737.8447 -7.7 
       574.7788 574.7830 -7.3 
       468.7333 468.7435 -21.8 
  5 TSST-1   789.3988   657.3390 657.3460 -10.6 
  7 SEC1 552.2996 552.3008 -2.2 917.4909 917.4944 -3.8 
       816.4468 816.4468 0.0 
       745.4012 745.4096 -11.3 
       617.3401 617.3511 -17.8 
       543.2882 543.2961 -14.5 
       488.3031 488.3085 -11.1 
       459.2501 459.2512 -2.4 
            375.2231 375.2244 -3.5 
  10 SEB 654.8424 654.8433 -1.4 909.4537 909.4682 -15.9 
       780.4164 780.4256 -11.8 
       667.3367 667.3416 -7.3 
       552.3111 552.3146 -6.3 
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            389.2379 389.2513 -34.4 
  12 TSST-1 560.8402 560.8524 -21.8 910.5628 910.5614 1.5 
       809.5091 809.5137 -5.7 
       599.3621 599.3769 -24.7 
            405.2596 405.2608 -3.0 
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